

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau










































INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : C12N 15/12, 15/62, 5/10, 5/20, C07K 14/705, 16/18, G01N 33/68, 33/50, A01K 67/027	A1	(11) International Publication Number: <b>WO 98/46749</b> (43) International Publication Date: 22 October 1998 (22.10.98)
----------------------------------------------------------------------------------------------------------------------------------------------------	----	------------------------------------------------------------------------------------------------------------------------------

(21) International Application Number: PCT/US98/07283 (22) International Filing Date: 10 April 1998 (10.04.98) (30) Priority Data: 08/838,845 11 April 1997 (11.04.97) US 09/058,389 9 April 1998 (09.04.98) US (71) Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL [US/US]; 332 North Lauderdale Street, Memphis, TN 38105-2794 (US). (72) Inventors: BELT, Judith, A.; 817 Pecan Gardens Circle, West, Memphis, TN 38122 (US). CRAWFORD, Charles, R.; 1040 Cabana Circle, East #7, Memphis, TN 38107 (US). PATEL, Divyen, H.; 1861 Jefferson Avenue, Memphis, TN 38104 (US). (74) Agents: DAVIS, Michael, D. et al.; Klauber & Jackson, 411 Hackensack Avenue, Hackensack, NJ 07601 (US).	(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

(54) Title: A NITROBENZYL MERCAPTOPYRIMIDINE NUCLEOSIDE (NBMPR)-INSENSITIVE, EQUILIBRATIVE, NUCLEOSIDE TRANSPORT PROTEIN, NUCLEIC ACIDS ENCODING THE SAME AND METHODS OF USE

MBMT2 :  : 39 MBMT3 :  : 39 MBMT1 :  : 39	MBMT2 :  : 337 MBMT3 :  : 337 MBMT1 :  : 337
MBMT2 :  : 46 MBMT3 :  : 46 MBMT1 :  : 46	MBMT2 :  : 374 MBMT3 :  : 374 MBMT1 :  : 374
MBMT2 :  : 104 MBMT3 :  : 104 MBMT1 :  : 104	MBMT2 :  : 410 MBMT3 :  : 410 MBMT1 :  : 410
MBMT2 :  : 143 MBMT3 :  : 143 MBMT1 :  : 143	MBMT2 :  : 454 MBMT3 :  : 454 MBMT1 :  : 454
MBMT2 :  : 183 MBMT3 :  : 183 MBMT1 :  : 183	MBMT2 :  : 456 MBMT3 :  : 456 MBMT1 :  : 456
MBMT2 :  : 221 MBMT3 :  : 221 MBMT1 :  : 221	
MBMT2 :  : 269 MBMT3 :  : 269 MBMT1 :  : 269	
MBMT2 :  : 299 MBMT3 :  : 299 MBMT1 :  : 299	

A

B

(57) Abstract

An isolated NBMPR-insensitive equilibrative nucleoside transport protein (iENTP) and the nucleic acid encoding it is disclosed. The iENTP can be used in screening assays to identify both natural nucleoside permeants and/or inhibitors and analogs thereof. In addition, transfected or transduced cell lines are disclosed which use the iENTP as the sole nucleoside transport protein. Methods of employing such cell lines for drug screening are also included. Furthermore methods of using hematopoietic stem cells transduced with an iENTP in a chemotherapy protocol is also described. In addition, methods of using these cells to selectively express a heterologous gene for gene therapy is disclosed.

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**A NITROBENZYL MERCAPTOPURINERIBOSIDE (NBMPR)-INSENSITIVE,  
EQUILBRATIVE, NUCLEOSIDE TRANSPORT PROTEIN, NUCLEIC ACIDS  
ENCODING THE SAME AND METHODS OF USE**

**RESEARCH SUPPORT**

- 5 The research leading to the present invention was supported in part by R01-CA55056 and Cancer Center CORE Support grant P30-CA21765 from the National Cancer Institute. The government may have certain rights in the present invention. Support for this invention was also provided by the AMERICAN LEBANESE SYRIAN ASSOCIATED CHARITIES.

**FIELD OF THE INVENTION**

- 10 The invention relates generally to the equilibrative transport of nucleosides into cells, and more particularly to nitrobenzylmercaptapurineriboside (NBMPR)-insensitive, equilibrative, nucleoside transport proteins (*i*ENTPs), to nucleic acids which encode the proteins, methods of use of the proteins and nucleic acids, and antibodies to the proteins.

**BACKGROUND OF THE INVENTION**

- 15 Aside from being potential precursors to the building blocks of nucleic acids, the natural nucleosides are important metabolites having many physiological effects in assorted organs. For example, adenosine and its corresponding nucleotides are local signaling molecules that act through purinergic receptors to affect such varied physiological functions as lipolysis, neurotransmitter release, coronary vasodilation, cardiac contractility, renal vasoconstriction, and bronchial constriction; and thus extracellular adenosine concentrations can have  
20 significant effects on cardiac and vascular functions as well as play a role in neuromodulation [reviewed by Griffith *et al. Biochim. Biophys. Acta Rev. Biomembr.*, **1286**:153-181 (1996); Cass, in *Drug Transport in Antimicrobial Therapy and Anticancer Therapy* (N.H. Georgopapadakou, ed.(Marcel Dekker)), 403-451 (1995)]. In addition,  
25 nucleoside analogs are presently employed as anti-retroviral drugs, and as anticancer drugs. Although some extracellular nucleosides can passively permeate the plasma membrane, most participate in some form of protein mediated transport performed by nucleoside transport proteins. Nucleoside transport proteins play an important role in the uptake and efflux of physiological nucleosides used in DNA and RNA synthesis, lipid and glycogen metabolism,  
30 and glycoprotein and glycolipid synthesis. Furthermore nucleoside transport proteins mediate the uptake and efflux of a number of antitumor and antiviral nucleoside analogs in

cells [Cass, 1995, *supra*]. Nucleoside transport inhibitors are currently being investigated as modulators of adenosine action in cerebral and cardiac ischemia to provide protection from reperfusion injury [Rongen *et al.*, *J. Clin. Invest.* **95**:658-668 (1995); Parkinson *et al.*, *Gen. Pharmacol.* **25**:1053-1058 (1994)].

- 5 The first nucleoside transporters studied functioned as facilitated diffusion systems. Such equilibrative nucleoside transport proteins were initially classified solely by their sensitivity to nitrobenzylmercaptapurineriboside (NBMPR). As the study of these proteins progressed, additional characteristics such as permeant selectivity and tissue distribution have been used to further distinguish these proteins [Griffith and Jarvis, *Biochim. Biophys. Acta Rev. Biomembr.*, **1286**:153-181 (1996)].
- 10 More recently, sodium-dependent concentrative nucleoside transport proteins have also been identified.

- At least five distinct nucleoside transport activities have been identified that differ in their permeant selectivity, sensitivity to inhibitors and distribution in normal tissues and tumors [Griffith and Jarvis, 1996, *supra*]. Two of these activities exhibit equilibrative mechanisms
- 15 that mediate both the influx and efflux of nucleosides across the plasma membrane, while the other three activities exhibit concentrative, sodium-dependent mechanisms that under physiological conditions mediate only the influx of nucleosides.

- The major equilibrative carrier in most cells, *es* (equilibrative, sensitive) is highly sensitive to the inhibitor NBMPR, having  $IC_{50}$  values of 0.1 to 1 nM. A human homolog of this protein
- 20 (hENT1) has recently been cloned (Griffiths *et al.*, *Nature Med.* **3**:89-93 (1997)). It has 10 to 11 predicted membrane spanning regions and has some structural similarities to the equilibrative glucose carriers. It does not however, share sequence homology with the glucose transporter family and appears to represent a new family of membrane transport proteins designated ENT for equilibrative nucleoside transporter.

- 25 Many cells also contain a second equilibrative transporter *ei* (equilibrative, insensitive) that is insensitive to nanomolar concentrations of NBMPR, but can be inhibited by higher ( $\mu$ M) concentrations [Belt, *Mol. Pharmacol.*, **24**:479-484 (1983); Plagemann and Wohlheuter, *Biochim. Biophys. Acta*, **773**:39-52 (1984)]. This protein, an NBMPR-insensitive equilibrative nucleoside transport protein (*i*ENTP) has remained elusive. Both of the
- 30 equilibrative transporters accept a broad range of physiological nucleosides and their

cytotoxic and antiviral analogs as permeants, although there appear to be differences in their affinity for some nucleosides [Griffith and Jarvis, 1996, *supra*].

*i*ENTPs also are present in most tumor cells, although the level of *i*ENTP appears to be variable. The concentration of *i*ENTP in a particular tumor cell is likely to be a major  
5 determinant in the ability of that cell to grow following the administration of an *es* transport inhibitor to block the nucleoside salvage pathway, together with an inhibitor of *de novo* nucleoside synthesis, such as trimetrexate, methotrexate, and tomudex. The level of *i*ENTP in a tumor cell is also likely to be a determinant of the success of using *es* inhibitors to block the efflux of cytotoxic and antiviral nucleoside analogs from cells. Under such  
10 circumstances, cells with higher concentrations of *i*ENTP will have a higher efflux of cytotoxic and antiviral nucleoside analogs, unless an inhibitor of the *i*ENTP is also administered.

NBMPR and its congeners are the most specific and potent inhibitors of the *es* transporter currently available. The *es* transporter has a high-affinity binding site for NBMPR that  
15 overlaps at least in part with the substrate binding site [Jarvis, in *Adenosine Receptors*, D.M.F. Cooper and C. Londos, eds., (New York: Alan R. Liss, Inc.), pp. 113-123 (1988)]. NBMPR binds to this site with a dissociation constant of 0.1 to 1 nM and completely inhibits nucleoside uptake via *es* at concentrations in the nanomolar range [Paterson and Cass, in  
20 *Membrane Transport of Antineoplastic Agents*, I.D. Goldman, ed., (New York: Pergamon Press), pp. 309-329 (1986); Gati and Paterson, in *The red cell membrane: structure, function, and clinical implications*, P. Agre and J.C. Parker, eds., (New York: Marcel Decker), pp. 635-661 (1989); Jarvis, 1988, *supra*; Plagemann *et al.*, *Biochim. Biophys. Acta.*, **969**:1-8 (1988)]. At high concentrations (>1  $\mu$ M), however, NBMPR also inhibits the *ei* transporter [Paterson *et al.*, *Mol. Pharmacol.*, **18**:40-44 (1980); Belt, *Mol. Pharmacol.*, **24**:479-484  
25 (1983); Plagemann and Wohlheuter, *Biochim. Biophys. Acta.*, **773**:39-52 (1984)].

Dipyridamole also binds to the NBMPR-binding site of *es* [Jarvis, *Mol. Pharmacol.*, **30**:659-665 (1986)], but is a less potent inhibitor of *es* than NBMPR [Plagemann and Wohlheuter, *Curr. Topics Membr. Trans.*, **14**:225-330 (1980); Paterson and Cass, 1986, *supra*; Plagemann and Woffedin, *Biochim. Biophys. Acta.*, **969**:1-8 (1988)].

Dipyridamole also inhibits the ei transporter, but its potency against this transporter has been unclear. It has been suggested that the es transporter and the ei transporter are equally sensitive to dipyridamole since the curves for inhibition of nucleoside transport are monophasic in cells that possess both transporters [Jarvis, 1988, *supra*; Plagemann *et al.*, 1988, *supra*]. However, recent studies with Ehrlich ascites tumor cells in which the es transporter was blocked by addition of low concentrations of NBMPR, suggest that the ei transporter is significantly less sensitive to dipyridamole than es [Hammond, *J. Pharmacol. Exp. Ther.*, 259:799-807 (1991)].

In addition to the two equilibrative nucleoside transporters there are at least three Na<sup>+</sup>-dependent, concentrative nucleoside transport activities that differ from each other, and from the equilibrative transporters, in their substrate specificity. Two of these, cif and cit (also called N1 and N2), exhibit selectivity for purine and pyrimidine nucleosides respectively [Vijayalakshmi *et al.*, *J. Biol. Chem.*, 263:19419-19423 (1988) and Williams *et al.*, *Biochem. J.*, 264:223-231 (1991)]; while the third, cib (also called N3), has a broader selectivity accepting both purine and pyrimidine nucleosides [Wu *et al.*, *J. Biol. Chem.*, 267:8813-8818 (1992); Huang *et al.*, *J. Biol. Chem.*, 268:20613-20620 (1993)]. All three of the concentrative nucleoside transporters are insensitive to NBMPR and dipyridamole at concentrations up to 10  $\mu$ M; and under physiological conditions mediate only the influx of nucleoside into cells. These concentrative transport activities have been observed predominantly in normal tissues such as kidney [Le Hir and Dubach *et al.*, *Pflugers Arch.*, 401:58-63 (1984); Williams *et al.*, *Biochem. J.*, 264:223-231 (1989); Williams *et al.*, *Biochem. J.*, 274:27-33 (1991); Le Hir *et al.*, *Pflugers Arch.*, 401:58-63 (1990)] and intestine [Schwenk *et al.*, *Biochim. Biophys. Acta.*, 805:370-374 (1984); Vijayalakshmi *et al.*, *J. Biol. Chem.*, 263:19419-19423 (1988); Williams *et al.*, *Biochem. J.*, 274:27-33 (1991)], and appear to be the major nucleoside transport activity in the specialized epithelial cells of these tissues [Williams *et al.*, *Biochem. J.*, 274:27-33 (1989); Vijayalakshmi *et al.*, *J. Biol. Chem.*, 263:19419-19423 (1988)]. However, low levels of Na<sup>+</sup>-dependent nucleoside transport have been observed in some tumor cells lines (Lee *et al.*, *Biochem. J.*, 274:85-90 (1991); Belt *et al.*, *Mol. Pharmacol.*, 24:479-484 (1993); Crawford *et al.*, *J. Biol. Chem.*, 265:13730-13734 (1990b); Dagnino *et al.*, *Cancer Res.*, 50:6549-6553 (1990)].

cDNA clones have recently been obtained for two of the concentrative nucleoside transporters. Cass and co-workers have cloned rCNT1 from rat intestine. This cDNA

- encodes a 71 Kd protein with cit-type transport activity in transient expression studies in *Xenopus* oocytes [Huang *et al.*, *J. Biol. Chem.*, 269:17757-17760 (1994)] and COS cells [Fang *et al.*, *Biochem. J.*, 317:457-465 (1996)]. The second transporter, rSPNT (rCNT2) was cloned from rat liver and encodes a 72 Kd protein that has cif-type transport activity in expression studies in *Xenopus* oocytes. The CNT1 and SPNT transporters are 64% identical in their deduced amino acid sequences, and have significant homology with the bacterial nupC nucleoside transporters. They do not, however, have significant homology with any known mammalian proteins, and thus represent a new family of mammalian membrane transporters. It should be noted that rCNT1 and rSPNT do not share homology with SNS1 [Pajor *et al.*, *J. Biol. Chem.*, 267:3557-3560 (1992)], a member of the sodium-dependent glucose transporter family that has weak nucleoside transport activity when expressed in *Xenopus* oocytes. It is not yet known whether SNS1 represents a significant nucleoside transport activity in mammalian cells. The human homolog of CNT1 has recently been cloned [Ritzel *et al. Am. J. Physiol.* (1997)].
- 15 The isolation and cloning of nucleoside transport proteins allows the biochemical characteristics of these transport proteins to be individually investigated and exploited. Such analysis is important for drug development, for example, in which drugs can be more readily designed to inhibit specific transport mechanisms. Unfortunately, heretofore, no NBMPR-insensitive equilibrative transport protein has been isolated or cloned, which has severely hampered analogous studies with this major class of nucleoside transporters.
- 20

The citation of any reference herein should not be deemed as an admission that such reference is available as prior art to the instant invention.

#### SUMMARY OF THE INVENTION

- Nucleosides play a central role in cellular metabolism. The nucleoside salvage pathway is an important means employed by cells to maintain the requisite amount of these important metabolites. The initial step in the nucleoside salvage pathway is their transport across the plasma membrane. The key mode of transport of nucleosides into the cell is performed by nucleoside transport proteins contained in the plasma membranes. The present disclosure reports the first isolation and cloning of a cDNA encoding an NBMPR-insensitive equilibrative nucleoside transporter.
- 25
- 30

The present invention provides a purified transmembrane protein with nucleoside transport activity and the active fragments thereof. The transmembrane protein transports nucleosides across the plasma membrane through a facilitated diffusion process. More specifically, the transmembrane protein is an equilibrative nucleoside transport protein which is insensitive to  
5 nitrobenzylmercaptapurineriboside (NBMPR). In one embodiment the NBMPR insensitive, equilibrative nucleoside transport protein (*i*ENTP) contains approximately 450 amino acid residues, and 8 to 12 putative transmembrane domains. In one such embodiment the *i*ENTP is a vertebrate protein. In a preferred embodiment the *i*ENTP is a mammalian protein. In a more preferred embodiment the *i*ENTP is a human protein containing 456 amino acids and  
10 has 10 to 11 putative transmembrane domains.

One aspect of the present invention provides an isolated nucleic acid which encodes an *i*ENTP of the present invention that includes exons and introns as shown in Figure 6. In a preferred embodiment of this type, the isolated nucleic acid contains the nucleotide sequences of SEQ ID NO:5 and SEQ ID NO:10. The introns of the gene are individually part  
15 of the present invention, having nucleotide sequences of SEQ ID NOs:11, 12, 13, 14, 15, 16, 17, 18, and 19 for introns 1-9 respectively. The 5' portion of intron 10 has the nucleotide sequence of SEQ ID NO:20 whereas the 3' portion of intron 10 has the nucleotide sequence of SEQ ID NO:21. Intron 11 has the nucleotide sequence of SEQ ID NO:22. Nucleic acid probes which hybridize to the isolated nucleic acid are also included in the present invention.  
20 In a preferred embodiment of this type, the nucleic acid probes hybridize to the untranslated portion of the nucleic acid.

The present invention further provides an isolated nucleic acid that contains a nucleotide sequence of the genomic 5' flanking region of a gene encoding an *i*ENTP. In a preferred embodiment of this type, the isolated nucleic acid has the nucleotide sequence of SEQ ID  
25 NO:6. The present invention also includes nucleic acid probes which hybridize to the nucleic acid sequence of SEQ ID NO:6.

Another aspect of the present invention includes isolated nucleic acids encoding the *i*ENTPs and active fragments thereof. One such isolated nucleic acid encodes an amino acid sequence of a transmembrane protein that functions as an equilibrative nucleoside transport  
30 protein that is insensitive to NBMPR. In a particular embodiment the nucleic acid encodes an *i*ENTP that contains approximately 450 amino acid residues. In one embodiment of this



type, the isolated nucleic acid has a nucleotide sequence with at least 80% similarity with the coding sequence of the human *i*ENTP (hENT2), SEQ ID NO:1. In another embodiment of this type, the isolated nucleic acid has a nucleotide sequence with at least 80% identity with the coding sequence of the human *i*ENTP (hENT2), SEQ ID NO:1. In still another  
5 embodiment the isolated nucleic acid has the nucleotide sequence of nucleotides 238-1605 of SEQ ID NO:1. In yet another embodiment of this aspect of the invention, an isolated nucleic acid encodes an *i*ENTP having the amino acid sequence of hENT2, SEQ ID NO:2. In a related embodiment an isolated nucleic acid encodes SEQ ID NO:2 comprising one or more conservative substitutions thereof.

- 10 The *i*ENTPs of the present invention, as well as the corresponding nucleic acids which encode them can be obtained from any natural source preferably from a vertebrate cell, more preferably from a mammalian cell, and most preferably from a human cell.

The present invention also includes oligonucleotides that hybridize to the nucleic acids encoding the *i*ENTPs of the present invention. In one embodiment the oligonucleotide  
15 consists of at least 18 nucleotides. In a preferred embodiment, the oligonucleotide consists of at least 27 nucleotides. In a more preferred embodiment, the oligonucleotide consists of at least 36 nucleotides. Oligonucleotides of the present invention can be used as nucleic acid probes, PCR primers, antisense nucleic acids, and the like, including for diagnostic and therapeutic purposes.

- 20 In one such embodiment the oligonucleotide hybridizes to SEQ ID NO:1, or more particularly hybridizes to the coding sequence of SEQ ID NO:1. In a related embodiment the oligonucleotide hybridizes to the nucleotides 512-579 of SEQ ID NO:1. In one embodiment, the hybridization is performed under moderate stringency. In another embodiment, the hybridization is performed under standard hybridization conditions. In yet a third  
25 embodiment, the hybridization is performed under stringent hybridization conditions.

Isolated DNAs that encode the *i*ENTPs of the present invention and active fragments thereof are also part of the present invention. In one embodiment, the nucleotide sequence of the DNA has at least 80% similarity with the coding sequence of SEQ ID NO:1. In another  
30 embodiment, the nucleotide sequence of the DNA has at least 80% identity with the coding sequence of SEQ ID NO:1. In still another embodiment the DNA has the nucleotide

sequence of nucleotides 238-1605 of SEQ ID NO:1. In yet another embodiment the DNA encodes an *i*ENTP having the amino acid sequence of SEQ ID NO:2. In a related embodiment the DNA encodes an amino acid sequence of SEQ ID NO:2 comprising one or more conservative substitutions thereof. In a particular embodiment the DNA is a  
5 recombinant DNA (cDNA).

In another embodiment, an isolated or recombinant nucleic acid (including a DNA) has at least 80% similarity with the coding sequence of SEQ ID NO:7. In another embodiment, the nucleotide sequence of the nucleic acid has at least 80% identity with the coding sequence of SEQ ID NO:7. In still another embodiment the nucleic acid contains the nucleotide sequence  
10 of SEQ ID NO:7. In yet another embodiment the nucleic acid encodes a protein containing the amino acid sequence of SEQ ID NO:8. In a related embodiment the nucleic acid encodes an amino acid sequence of SEQ ID NO:8 comprising one or more conservative substitutions thereof. In a particular embodiment the DNA is recombinant (cDNA).

All of the isolated nucleic acids and recombinant DNAs of the present invention can further  
15 comprise a heterologous nucleotide sequence. Such heterologous nucleotide sequences can encode, for example, a fusion peptide (*e.g.*, a FLAG-tag) or a chimeric protein partner such as a fusion protein.

The present invention also includes DNA constructs comprising the isolated DNAs encoding the *i*ENTPs of the present invention. In one such embodiment the DNA is operatively linked  
20 to an expression control sequence. In one embodiment the DNA is operatively linked to an expression control sequence and encodes the amino acid sequence of SEQ ID NO:2. In another embodiment the DNA is operatively linked to an expression control sequence and encodes the amino acid sequence of SEQ ID NO:2 comprising one or more conservative substitutions thereof. In a particular embodiment the DNA is a recombinant DNA (cDNA).

25 Also included in the present invention are transfected or transduced cells which are transfected or transduced with the recombinant DNA constructs of the present invention. The transfected or transduced cells can be either a prokaryotic cell, or a eukaryotic cell. In one such embodiment, the transfected cell is a COS cell. In another embodiment, the transduced cell is a hematopoietic stem cell. In a particular embodiment, the transfected cell  
30 is a human T-cell leukemia CEM cell. In a preferred embodiment the transfected or

transduced cell is transfected or transduced with a DNA construct containing a DNA that is operatively linked to an expression control sequence and encodes the amino acid sequence of SEQ ID NO:2. In a related embodiment the transfected or transduced cell is transfected or transduced with a DNA construct containing a DNA that is operatively linked to an  
5 expression control sequence and encodes the amino acid sequence of SEQ ID NO:2 comprising one or more conservative substitutions thereof.

Another aspect of the present invention includes the isolated *i*ENTPs of the present invention and active fragments thereof. In its broadest embodiment the isolated *i*ENTP is a transmembrane protein that is NBMPR insensitive, and functions as an equilibrative  
10 nucleoside transport protein. In a particular embodiment, the *i*ENTP has approximately 450 amino acids. In one embodiment the *i*ENTP is encoded by a nucleotide sequence having at least 80% similarity with the coding sequence of SEQ ID NO:1. In another embodiment the *i*ENTP is encoded by a nucleotide sequence having at least 80% identity with the coding sequence of SEQ ID NO:1. In still another embodiment the *i*ENTP has an amino acid  
15 sequence of SEQ ID NO:2 comprising one or more conservative substitutions thereof. In a preferred embodiment the isolated *i*ENTP has an amino acid sequence of SEQ ID NO:2.

In another embodiment the *i*ENTP is encoded by a nucleotide sequence having at least 80% similarity with the coding sequence of SEQ ID NO:7. In another embodiment the *i*ENTP is encoded by a nucleotide sequence having at least 80% identity with the coding sequence of  
20 SEQ ID NO:7. In still another embodiment the *i*ENTP has an amino acid sequence of SEQ ID NO:8 comprising one or more conservative substitutions thereof. In a preferred embodiment the isolated *i*ENTP has an amino acid sequence of SEQ ID NO:8.

The present invention also includes modified *i*ENTPs of the present invention, such as tagged proteins, labeled proteins, fusion proteins and the like. Such modified *i*ENTPs may be used  
25 for example as antigens or for marker purposes. In a particular embodiment of this type, the fusion protein comprises an *i*ENTP protein or active fragment thereof having an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:2 comprising a conservative substitution thereof. In preferred embodiments the modified *i*ENTP retains its activity as an NBMPR insensitive equilibrative nucleoside transport protein.

In a specific embodiment, an *i*ENTP fusion protein can be expressed. An *i*ENTP fusion protein comprises at least a functionally active portion of a non-*i*ENTP protein joined via a peptide bond to at least a functionally active portion of an *i*ENTP polypeptide. In a particular embodiment, an *i*ENTP fusion protein or peptide contains an *i*ENTP or fragment thereof and a FLAG-tag. In an alternative embodiment, an *i*ENTP fusion protein or peptide contains an *i*ENTP or fragment thereof and green fluorescent protein or derivatives thereof, as exemplified in U.S. Patent 5,625,048 Issued 4/29/97 and International Publication No: WO 97/26333, hereby incorporated by reference in their entireties, can also be used.

The non-*i*ENTP sequences of the *i*ENTP fusion protein can be amino- or carboxy-terminal to the *i*ENTP sequences. More preferably, for stable expression of an *i*ENTP fusion protein (including a proteolytically inactive *i*ENTP fusion protein), the portion of the non-*i*ENTP fusion protein is joined via a peptide bond to the amino terminus of the *i*ENTP protein. A recombinant DNA molecule encoding such a fusion protein comprises a sequence encoding at least a functionally active portion of a non-*i*ENTP protein joined in-frame to the *i*ENTP coding sequence. In one such embodiment the DNA molecule encodes a cleavage site for a specific protease, *e.g.*, thrombin or Factor Xa, preferably at the *i*ENTP-non-*i*ENTP juncture. In a specific embodiment, the fusion protein is expressed in *Escherichia coli*.

Antibodies to the *i*ENTPs of the present invention are also part of the present invention. In a particular embodiment the antibody is raised against an *i*ENTP having an amino acid sequence of SEQ ID NO:2. In another such embodiment the antibody is raised against an *i*ENTP having an amino acid sequence of SEQ ID NO:2 comprising one or more conservative substitutions thereof. In still another embodiment the antibody is raised against a portion of, or alternatively all of the N-terminal 92 amino acids of SEQ ID NO:2, *i.e.*, amino acids 1-92 of SEQ ID NO:2.

In one embodiment the antibody is a polyclonal antibody. In another embodiment the antibody is a monoclonal antibody. In yet another embodiment the monoclonal antibody is a chimeric antibody. The present invention also includes an immortal cell line that produces a monoclonal antibody of the present invention.

Still another aspect of the present invention includes a transfected or transduced cell in which all detectable nucleoside transport activity is performed by the nucleoside transport protein

encoded by a nucleic acid of the present invention. In one embodiment of this type, the transfected or transduced cell is a vertebrate cell. In a preferred embodiment the transfected or transduced cell is a mammalian cell. In a more preferred embodiment the transfected or transduced cell is a human cell. In one such embodiment, the transfected cell is a human T-cell leukemia CEM cell. In a more particular embodiment of this type the transfected human  
5 cell is a CEM/N1-7 cell. In a preferred embodiment of this aspect of the present invention, all detectable nucleoside transport activity is performed by an *i*ENTP having the amino acid sequence of SEQ ID NO:2, or an active fragment of that *i*ENTP. In a related embodiment the *i*ENTP has the amino acid sequence of SEQ ID NO:2 comprising a conservative substitution  
10 thereof, or an active fragment of that *i*ENTP.

The present invention also includes a nucleoside transport deficient subline of a human T-cell leukemia cell line CEM, transfected with an Epstein-Barr Nuclear Antigen 1 expression cassette, in which the cell line is capable of supporting the episomal replication of an Epstein-Barr virus-based mammalian expression vector. In one particular embodiment of  
15 this type the expression vector is pDR2. In a preferred embodiment of this type the cell line has a stable transfection frequency with pDR2 of approximately  $10^{-2}$ . In one particular embodiment the nucleoside transport deficient subline is CEM/C19.

Ribozymes specifically designed to modify the nucleic acids of the present invention are also contemplated as part of the present invention. Similarly antisense nucleic acids that  
20 hybridize under physiological conditions to an mRNA encoding an *i*ENTP of the present invention is also included in the present invention. In one such embodiment, the antisense nucleic acid hybridizes to the mRNA that corresponds to the sense strand of nucleotides 238-1605 of the nucleotide sequence of SEQ ID NO:1.

A related aspect of the invention is a knockout mouse for the *i*ENTPs of the present  
25 invention. One such embodiment comprises a first and a second allele which naturally encode and express the nucleoside transport protein having the amino acid sequence of SEQ ID NO:2. Both the first allele and the second allele each contain a defect which prevents the knockout mouse from expressing a nucleoside transport protein that is both insensitive to NBMPR and can function as an equilibrative nucleoside transport protein. Such a knockout  
30 mouse is particularly susceptible to drugs such as NBMPR.

The present invention also includes methods of making and using the *i*ENTPs, antibodies to the *i*ENTPs, the nucleic acids encoding the *i*ENTPs, oligonucleotides that hybridize to these nucleic acids, DNA constructs containing these nucleic acids, cells containing these constructs, as well as to the other compositions and processes of the present invention.

- 5 Accordingly, one aspect of the present invention includes a method of isolating a cDNA encoding a nucleoside transport protein. This process comprises transfecting a nucleoside transport protein deficient cell with an expression vector from an expression vector library, wherein the expression vector library contains a vector comprising a cDNA encoding a nucleoside transport protein. The cDNA encoding the nucleoside transport protein is  
10 expressed in the transfected cell. An expression vector containing the cDNA encoding a nucleoside transport protein is selected by culturing the transfected cell under conditions in which the cell growth is dependent on the expression of the nucleoside transport protein. Therefore the selected expression vector contains the cDNA encoding a nucleoside transport protein. The selected expression vector is extracted from the transfected cell. A host cell is  
15 transfected with the selected expression vector, and the cDNA encoding the nucleoside transport protein is isolated.

- In a specific embodiment of this type includes a method of isolating a cDNA encoding an NBMPR insensitive, equilibrative nucleoside transport protein (*iENTP* cDNA). This process comprises transfecting a nucleoside transport protein deficient cell with an expression vector  
20 from an expression vector library, wherein a cDNA library containing an *iENTP* cDNA has been subcloned into the expression vector library, and wherein the *iENTP* cDNA is expressed in the transfected cell. An expression vector containing the *iENTP* cDNA is selected by culturing the transfected cell under conditions in which the cell growth is dependent on the expression of the *iENTP* and its corresponding transport activity, and wherein the selected  
25 expression vector contains the *iENTP* cDNA. The selected expression vector is extracted from the transfected cell. A host cell is transfected with the selected expression vector, and the cDNA encoding the NBMPR insensitive, equilibrative nucleoside transport protein is isolated. In a preferred embodiment of this type the transfected cell is a human cell that expresses EBNA-1 and the human cell is CEM/C19.

- 30 Another aspect of the present invention includes a method of making an NBMPR insensitive, equilibrative nucleoside transport protein of the present invention through introducing an

expression vector comprising a nucleic acid encoding the *i*ENTP or an active fragment thereof into a host cell, and expressing the nucleic acid in the host cell. In one embodiment the host cell is a prokaryotic cell. In another embodiment the host cell is a eukaryotic cell. In one specific embodiment, the eukaryotic cell is an insect cell. In a particular embodiment  
5 the *i*ENTP has an amino acid sequence of SEQ ID NO:2. In another particular embodiment the *i*ENTP has an amino acid sequence of SEQ ID NO:2 comprising a conservative substitution thereof. In one embodiment, the method further comprises purifying the *i*ENTP.

The present invention includes methods for obtaining a purified NBMPR insensitive,  
10 equilibrative nucleoside transport protein (*i*ENTP) or an active fragment thereof, from a cell that expresses the *i*ENTP which comprises lysing the cell, and purifying the NBMPR insensitive, equilibrative nucleoside transport protein. In one embodiment the purifying step includes extracting the *i*ENTP from the plasma membrane of the cell. In another such embodiment the purifying step also includes fractionating the proteins contained in the cell.  
15 In a particular embodiment, the *i*ENTP is obtained from a natural source. In a preferred embodiment the natural source is a mammalian cell. In another particular embodiment the *i*ENTP is a recombinant protein obtained from a prokaryotic cell. In still another embodiment the *i*ENTP is a recombinant protein obtained from a eukaryotic cell. In one preferred embodiment the *i*ENTP has an amino acid sequence of SEQ ID NO:2. In another  
20 preferred embodiment the *i*ENTP has an amino acid sequence of SEQ ID NO:2 comprising a conservative substitution thereof.

Yet another aspect of the invention includes a method of identifying a ligand of an *i*ENTP of the present invention which comprises contacting a potential ligand with the isolated *i*ENTP under physiological conditions (*e.g.*, neutral pH, buffered solution with approximately 150  
25 mM salt) and detecting whether the potential ligand binds to the *i*ENTP wherein a potential ligand is selected as a ligand if it binds to the *i*ENTP. The ligand and/or the *i*ENTP can be labeled such as with a label defined below. Similarly, either the *i*ENTP or ligand can be attached to a solid support. The binding can be detected with any of the standard protein-ligand binding assays known in the art as exemplified below. Once a ligand is identified its  
30 dissociation constant can be determined. Alternatively, the detecting step may be performed by determining the dissociation constant initially. In either case a potential ligand is selected as a ligand when the dissociation constant is less than  $10^{-5}$  M. In one such embodiment the

ligand is a permeant of the *i*ENTP. In another embodiment, the ligand is an inhibitor of the *i*ENTP. In yet another embodiment, the ligand is both a permeant and an inhibitor of the *i*ENTP. In one preferred embodiment the *i*ENTP has an amino acid sequence of SEQ ID NO:2. In another preferred embodiment the *i*ENTP has an amino acid sequence of SEQ ID  
5 NO:2 comprising a conservative substitution thereof.

The present invention also includes specific methods of identifying a permeant of an NBMPR insensitive, equilibrative nucleoside transport protein (*i*ENTP). In one such embodiment a nucleoside or nucleoside analog is contacted with a transfected or transduced cell of the present invention in which all detectable nucleoside transport activity is performed  
10 by an *i*ENTP of the present invention. The nucleoside transport of the nucleoside or nucleoside analog by the transfected or transduced cell is evaluated, wherein the nucleoside or nucleoside analog is identified as a permeant when the transport of the nucleoside or nucleoside analog into the transfected or transduced cell is determined to follow a facilitated diffusion process. In one such embodiment the nucleoside or nucleoside analog is an  
15 antiviral nucleoside analog. In another embodiment the nucleoside or nucleoside analog is an antitumor nucleoside analog. In one particular embodiment of this type the transfected or transduced cell is a transfected or transduced human cell. In one preferred embodiment the *i*ENTP has an amino acid sequence of SEQ ID NO:2. In another preferred embodiment the *i*ENTP has an amino acid sequence of SEQ ID NO:2 comprising a conservative substitution  
20 thereof.

The present invention further includes specific methods of selecting drugs that inhibit an NBMPR insensitive, equilibrative nucleoside transport protein. One such embodiment comprises contacting a potential drug with a transfected or transduced cell of the present invention in which all detectable nucleoside transport activity is performed by an *i*ENTP of  
25 the present invention. The nucleoside transport activity of the cell is evaluated. A potential drug is selected as a drug when a decrease in the nucleoside transport activity is determined relative to that determined when the evaluating was performed in the absence of the potential drug.

In one embodiment of this type the nucleoside transport activity of the transfected or  
30 transduced cell is evaluated as a function of the determination of the trans-stimulation of a permeant. In another embodiment the nucleoside transport activity of the transfected or



transduce cell is evaluated as a function of the determination of the direct transport of a permeant. In still another embodiment the nucleoside transport activity of the transfected or transduced cell is evaluated as a function of the determination of the countertransport of a permeant. In one specific embodiment, the nucleoside transport activity of the transfected or transduced cell is evaluated as a function of the toxicity of a nucleoside analog which is a permeant of the *i*ENTP, such as tubercidin, 2-chloro-2'-deoxyadenosine, or Ara-C. In yet another embodiment, the nucleoside transport activity of the transfected or transduced cell is evaluated as a function of toxicity in the presence of an antimetabolite. In yet another embodiment the nucleoside transport activity of the transfected or transduced cell is evaluated as a function of two of these determinations. In still another embodiment the nucleoside transport activity of the transfected or transduced cell is evaluated as a function of all of these determinations.

Another embodiment of a method of selecting a drug that inhibits an NBMPR insensitive, equilibrative nucleoside transport protein (*i*ENTP) comprises detecting the mutual inhibition (*i.e.* mutual competition) of a potential drug with a permeant, such as uridine for the *i*ENTP in a transfected or transduced cell of the present invention in which all detectable nucleoside transport activity is performed by an *i*ENTP of the present invention. A potential drug is selected as a drug when mutual inhibition is detected. This embodiment may be used alone or in conjunction with the other determinations described above.

For any of the drug assays of the present invention the *i*ENTP functions as an equilibrative nucleoside transport protein, is insensitive to NBMPR, and contains approximately 450 amino acid residues. In one particular embodiment the *i*ENTP has an amino acid sequence of SEQ ID NO:2. In another embodiment the *i*ENTP has an amino acid sequence of SEQ ID NO:2 comprising a conservative substitution thereof. In a preferred embodiment the transfected or transduced cell is a human transfected or transduced cell.

Accordingly, it is a principal object of the present invention to provide a purified NBMPR-insensitive, equilibrative nucleoside transport protein (*i*ENTP).

It is a further object of the present invention to provide an isolated nucleic acid encoding a *i*ENTP.

It is a further object of the present invention to provide a DNA construct containing a nucleic acid encoding a *i*ENTP.

It is a further object of the present invention to provide an antibody specific for a purified *i*ENTP.

- 5 It is a further object of the present invention to provide a method of producing an *i*ENTP, including through modification of a *i*ENTP, and through recombinant technology.

It is a further object of the present invention to provide a method of selecting a drug that preferentially inhibits an *i*ENTP-dependent nucleoside transport pathway.

- 10 It is a further object of the present invention to provide a method of screening drug libraries for drugs that preferentially inhibit an *i*ENTP.

It is a further object of the present invention to provide a cell in which the only detectable facilitated diffusion pathway for nucleosides includes an *i*ENTP.

- 15 It is a further object of the present invention to provide a cell where the NBMPR-insensitive facilitated diffusion pathway for nucleosides includes a modified *i*ENTP.

It is a further object of the present invention to provide a method of cancer chemotherapy by transducing hematopoietic stem cells *ex vivo* with a cDNA encoding an *i*ENTP, introducing the transduced cells into an animal subject, and then treating the animal subject with an antimetabolite and NBMPR.

- 20 It is a further object of the present invention to provide a novel method of hematopoietic cell-directed gene therapy using an expression vector encoding the *i*ENTP.

These and other aspects of the present invention will be better appreciated by reference to the following drawings and Detailed Description.

### BRIEF DESCRIPTION OF THE DRAWINGS

- Figure 1 shows uridine uptake in N1-7 and C19 cells. Figure 1A depicts  $^3\text{H}$ -uridine uptake (10  $\mu\text{M}$  at 2.5  $\mu\text{Ci/ml}$ ) by CEM/N1-7 (●, □, ◆) and CEM/C19 (▲, ▼) cells which was determined at 22°C in  $\text{Na}^+$  (filled symbols) or  $\text{Na}^+$ -free (□) in the presence (◆, ▼) or absence (●, □, ▲) of a large excess (4 mM) unlabeled uridine as described in the methods. The values shown are means of duplicate assays and have been corrected for extracellular water space. Figures 1B-1C depict the uptake of 10  $\mu\text{M}$   $^3\text{H}$ -uridine determined at 22°C in  $\text{Na}^+$  buffer using a 7.5 second uptake interval in the presence of nucleoside transport inhibitors. The uptake interval was initiated by simultaneous addition of the label and inhibitory nucleobase, nucleoside or nucleotide. In the case of NBMPR and dipyridamole, the cells were incubated for 5 minutes at 22°C in the appropriate concentration of inhibitor prior to starting the assay. Uridine uptake was also determined in the presence of a large excess (4 mM) of unlabeled uridine to determine the radioactivity associated with the extracellular water space and simple diffusion. This value was subtracted from the total uridine uptake values. The results are from triplicate assays and are expressed as percent of uridine uptake in the absence of inhibitor.
- Figures 2A and 2B depict the comparison of the amino acid sequences of proteins related to hENT2. Two related sequences found in the Genbank database were aligned with hENT2 using the Pileup program in the GCG suite of sequence analysis software. Residues that are identical or have conservative substitutions in at least 8 of the 10 sequences are shown on a black background, and conservative substitutions in at least 5 of the 10 sequences are shown on a grey background. Putative transmembrane domains are shown by dashed lines (====), the N-glycosylation consensus sequence \*\*\*\*, and the start site for mouse and human HNP36 by #.
- Figure 3 shows uridine uptake by COS-1 cells transiently transfected with pcDNA3/N1-71 constructs. COS-1 cells were transfected with pcDNA3/N1-71orf1 (■) or pcDNA3/N1-71orf2 (○) as described in the methods. Control cells (●) were transfected with the pcDNA3 plasmid without an insert. Uptake of 10  $\mu\text{M}$   $^3\text{H}$ -uridine (2  $\mu\text{Ci/ml}$ ) was determined in sodium-free buffer 72 hours after transfection. 0.1  $\mu\text{M}$  NBMPR was present

in all assays to block the endogenous *es* transporter in COS-1 cells {4539}. The values shown are the average of triplicate determination.

Figure 4 demonstrates the expression of hENT2 in human cell lines and tissues. Northern blots of polyA+ RNA from the indicated cell lines (Figure 4A) and tissues (Figure 4B) were  
5 hybridized with a BamHI/NheI fragment of hENT2 (1.8kb, nucleotides 393-2183 of SEQ ID NO:1) and washed at high stringency as described in the methods.

Figure 5 is a schematic drawing showing the results of challenging CD34 positive hematopoietic stem cells with an antimetabolite and a nucleoside transport inhibitor, after the cells have been transduced, *ex vivo*, with a viral vector comprising a nucleic acid encoding  
10 hENT2. The antimetabolite (*e.g.*, methotrexate, trimetrexate, 5-FU or PALA) *plus* the nucleoside transport inhibitor NBMPR or draflazine are administered to the cells thereby selectively enriching for cells that have been successfully transduced with hENT2. The enrichment is achieved because the antimetabolite prevents *de novo* synthesis of the nucleosides required for cell growth, and the transduced cells are uniquely resistant to  
15 NBMPR and draflazine and thereby retaining a functional salvage pathway for purine and pyrimidine nucleosides present in exogenous nucleoside pools. Although not shown, the *ex vivo* transduced cells may be transplanted into the animal subject and the antimetabolite and nucleoside transport inhibitor may be administered parenterally.

Figure 6 shows the exon structure of an *i*ENTP of the present invention. As shown, each  
20 exon approximately defines a different functional domain. TM is short for transmembrane.

Figure 7 shows the 3.5 KB message isolated from Thymus which is apparently a splice variant of an *i*ENTP.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention in its broadest embodiment provides an equilibrative nucleoside  
25 transport protein which is insensitive to nitrobenzylmercaptapurineriboside, NBMPR, [6-[(4-nitrobenzyl)thio-9- $\beta$ -D-ribofuranosyl purine]. The NBMPR-insensitive nucleoside transport protein (*i*ENTP) is a transmembrane protein that serves to transport nucleosides across the plasma membrane through a facilitated diffusion process. The present invention also

provides nucleic acids encoding the *i*ENTPs of the present invention which can be used to transfect or transduce mammalian cells for various medical purposes. For example, such a transfected or transduced cell can be used as a screening tool for identifying antitumor and antiviral nucleoside analogs that can be preferentially transported into cells by this specific nucleoside transport protein. In addition, hematopoietic cells transduced with an *i*ENTP of the present invention can be used in cancer chemotherapy protocols in which both the *de novo* nucleoside biosynthesis and the major nucleoside salvage pathway of the hematopoietic cells are purposely disabled. In such instances the expression of the *i*ENTP uniquely provides the transduced cells with an alternative means of obtaining the required nucleosides.

10

Therefore, if appearing herein, the following terms shall have the definitions set out below.

As used herein "*i*ENTP" and "*ei*" transporter are interchangeable names for an NBMPR-insensitive equilibrative nucleoside transport protein, which is a transmembrane protein that functions in the facilitated diffusion of nucleosides across cell membranes. As disclosed herein, "hENT2" is a human *i*ENTP that has an amino acid sequence of SEQ ID NO:2. The natural nucleic acid sequence encoding hENT2 consists of nucleotides 238-1605 of SEQ ID NO:1.

A nucleoside transporter may be classified as being either "NBMPR-insensitive" or "NBMPR-sensitive." This classification system is widely accepted in the field [See Griffith *et al.*, *Biochim. Biophys. Acta* **1286**:153-181 (1996)] to distinguish two major classes of nucleoside transport proteins. "NBMPR-sensitive" indicates that the nucleoside transporter has a high sensitivity to the inhibitor NBMPR *i.e.*,  $IC_{50}$  values of 0.1 to 1 nanomolar. "NBMPR-insensitive" indicates that the nucleoside transporter is insensitive to nanomolar concentrations of NBMPR, but can be inhibited by higher (e.g., micromolar) concentrations.

20

As used herein an "active fragment" of an *i*ENTP is a polypeptide or glycopolypeptide that has an amino acid sequence that corresponds to that of a full-length *i*ENTP except the active fragment has at least one less amino acid than the corresponding full-length *i*ENTP; further an "active fragment" of an *i*ENTP is NBMPR-insensitive, and has at least 20% of the

nucleoside transport activity of the corresponding full-length *i*ENTP, (determined under conditions in which the full-length *i*ENTP has nucleoside transport activity.)

As used herein a "functional *i*ENTP" is a *i*ENTP that is NBMPR-insensitive and has at least 20% of the nucleoside transport activity of the corresponding native *i*ENTP.

- 5 As used herein, an "antimetabolite" is a compound that interferes with the synthesis and/or metabolism of nucleotides or nucleosides. In one instance an antimetabolite can inhibit *de novo* nucleotide synthesis. In another instance an antimetabolite can be a nucleoside analog that interferes with a nucleoside and/or nucleotide-dependent process. Antimetabolites include trimetrexate, methotrexate (MTX), N-(phosphonacetyl)-L-aspartic acid (PALA), and  
10 5-fluorouracil (5-FU).

- As used herein "facilitated diffusion" is a carrier-mediated transport system that operates along a concentration gradient of the permeating solute. At equilibrium, the solute will attain the same concentration on either side of the membrane, as in simple diffusion. The transport of a permeant "is determined to follow a facilitated diffusion process" when the kinetic  
15 determinations for the transport process are consistent with that predicted for a facilitated diffusion process [See Stein, *Transport and Diffusion Across Cell Membranes*, Academic Press, London (1986)].

- As used herein the term "approximately" is used to signify that a value is within ten percent  
20 of the indicated value *i.e.*, a protein containing "approximately" 450 amino acid residues can contain between 405 and 495 amino acid residues.

- As used herein the term "binds to" is meant to include all such specific interactions that result in two or more molecules showing a preference for one another relative to some third molecule. This includes processes such as covalent, ionic, hydrophobic and hydrogen  
25 bonding but does not include non-specific associations such solvent preferences.

As used herein a "ligand" of an *i*ENTP can be either a natural or artificial binding partner for the *i*ENTP which binds to the *i*ENTP under physiological conditions forming a binding complex. In preferred embodiments the *i*ENTP-ligand binding complex has a dissociation

constant of less than  $10^{-5}$  M. Ligands include permeants, and/or inhibitors and activators of the iENTP-dependent nucleoside salvage pathway.

As used herein a "permeant" is a nucleoside or nucleoside analog that binds to an iENTP and is transported by the iENTP across a membrane by a facilitated diffusion process.

- 5 As used herein the "iENTP-dependent nucleoside salvage pathway" is used to denote an iENTP-dependent transport of nucleosides across the plasma membrane of a cell.

- As used herein a cell has "detectable nucleoside transport activity" when the rate of nucleoside uptake of the cell is greater than that determined for simple diffusion. The rate of diffusion is measured by the uptake of  $^3\text{H}$ -uridine ( $1-10 \mu\text{M}$ ) over a thirty second time
- 10 course, at  $22^\circ\text{C}$  in the presence of a large excess ( $1-10\text{mM}$ ) of unlabeled uridine, or a competing nucleoside. For example, see Figure 1, where the uptake of  $^3\text{H}$ -uridine by CEM/C19 cells is not significantly different in the presence or absence of a large excess of unlabeled uridine. Similarly, a cell has "no detectable nucleoside transport activity" when the rate of nucleoside uptake of the cell is not significantly different than that determined for
- 15 a simple diffusion process, as determined by the method above.

A "vector" is a replicon, such as plasmid, phage or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment. A "replicon" is any genetic element (e.g., plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication *in vivo*, i.e., capable of replication under its own control.

- 20 A "cassette" refers to a segment of DNA that can be inserted into a vector at specific restriction sites. The segment of DNA encodes a polypeptide of interest, and the cassette and restriction sites are designed to ensure insertion of the cassette in the proper reading frame for transcription and translation.

- A cell has been "transfected" by exogenous or heterologous DNA when such DNA has been
- 25 introduced inside the cell. The transfecting DNA can be maintained in an episome as exemplified in the transfection studies using the CEM/N1-7 cell described herein. A cell has been "transduced" by exogenous or heterologous DNA when the exogenous or heterologous DNA is introduced by a viral vector.

A "heterologous nucleotide sequence" as used herein is a nucleotide sequence that is added to a nucleotide sequence of the present invention by recombinant methods to form a nucleic acid which is not naturally formed in nature. Such nucleic acids can encode chimeric and/or fusion proteins. Thus the heterologous nucleotide sequence can encode peptides and/or  
5 proteins which contain regulatory and/or structural properties. In another such embodiment the heterologous nucleotide can encode a protein or peptide that functions as a means of detecting the protein or peptide encoded by the nucleotide sequence of the present invention after the recombinant nucleic acid is expressed. In still another embodiment the heterologous nucleotide can function as a means of detecting a nucleotide sequence of the present  
10 invention. A heterologous nucleotide sequence can comprise non-coding sequences including restriction sites, regulatory sites, promoters and the like.

A "heterologous" region of the DNA construct is an identifiable segment of DNA within a larger DNA molecule that is not found in association with the larger molecule in nature. Thus, when the heterologous region encodes a mammalian gene, the gene will usually be  
15 flanked by DNA that does not flank the mammalian genomic DNA in the genome of the source organism. Another example of a heterologous coding sequence is a construct where the coding sequence itself is not found in nature (*e.g.*, a cDNA where the genomic coding sequence contains introns, or synthetic sequences having codons different than the negative gene). Allelic variations or naturally-occurring mutational events do not give rise to a  
20 heterologous region of DNA as defined herein.

A "nucleic acid molecule" refers to the phosphate ester polymeric form of ribonucleosides (adenosine, guanosine, uridine or cytidine; "RNA molecules") or deoxyribonucleosides (deoxyadenosine, deoxyguanosine, deoxythymidine, or deoxycytidine; "DNA molecules"), or any phosphoester analogs thereof, such as phosphorothioates and thioesters, in either single  
25 stranded form, or a double-stranded helix. Double stranded DNA-DNA, DNA-RNA and RNA-RNA helices are possible. The term nucleic acid molecule, and in particular DNA or RNA molecule, refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, *inter alia*, in linear or circular DNA molecules (*e.g.*, restriction fragments), plasmids,  
30 and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (*i.e.*, the strand



having a sequence homologous to the mRNA). A "recombinant DNA molecule" is a DNA molecule that has undergone a molecular biological manipulation.

A nucleic acid molecule is "hybridizable" to another nucleic acid molecule, such as a cDNA, genomic DNA, or RNA, when a single stranded form of the nucleic acid molecule can anneal  
5 to the other nucleic acid molecule under the appropriate conditions of temperature and solution ionic strength (*see Sambrook et al., supra*). The conditions of temperature and ionic strength determine the "stringency" of the hybridization. For preliminary screening for homologous nucleic acids, low stringency hybridization conditions, corresponding to a  $T_m$  of 55°, can be used, *e.g.*, 5x SSC, 0.1% SDS, 0.25% milk, and no formamide; or 30%  
10 formamide, 5x SSC, 0.5% SDS). Moderate stringency hybridization conditions correspond to a higher  $T_m$ , *e.g.*, 40% formamide, with 5x or 6x SCC. High stringency hybridization conditions correspond to the highest  $T_m$ , *e.g.*, 50% formamide, 5x or 6x SCC. Hybridization requires that the two nucleic acids contain complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible. The appropriate  
15 stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of similarity or homology between two nucleotide sequences, the greater the value of  $T_m$  for hybrids of nucleic acids having those sequences. The relative stability (corresponding to higher  $T_m$ ) of nucleic acid hybridizations decreases in the following order: RNA:RNA,  
20 DNA:RNA, DNA:DNA. For hybrids of greater than 100 nucleotides in length, equations for calculating  $T_m$  have been derived (*see Sambrook et al., supra*, 9.50-0.51). For hybridization with shorter nucleic acids, *i.e.*, oligonucleotides, the position of mismatches becomes more important, and the length of the oligonucleotide determines its specificity (*see Sambrook et al., supra*, 11.7-11.8). Preferably a minimum length for a hybridizable nucleic acid is at least  
25 about 12 nucleotides; preferably at least about 18 nucleotides; and more preferably the length is at least about 27 nucleotides; and most preferably 36 nucleotides.

In a specific embodiment, the term "standard hybridization conditions" refers to a  $T_m$  of 55°C, and utilizes conditions as set forth above. In a preferred embodiment, the  $T_m$  is 60°C; in a more preferred embodiment, the  $T_m$  is 65°C.

30 "Homologous recombination" refers to the insertion of a foreign DNA sequence of a vector in a chromosome. Preferably, the vector targets a specific chromosomal site for homologous

recombination. For specific homologous recombination, the vector will contain sufficiently long regions of homology to sequences of the chromosome to allow complementary binding and incorporation of the vector into the chromosome. Longer regions of homology, and greater degrees of sequence similarity, may increase the efficiency of homologous recombination.

A DNA "coding sequence" is a double-stranded DNA sequence which is transcribed and translated into a polypeptide in a cell *in vitro* or *in vivo* when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (*e.g.*, mammalian) DNA, and even synthetic DNA sequences. If the coding sequence is intended for expression in a eukaryotic cell, a polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence.

"Transcriptional and translational control sequences" are DNA regulatory sequences, such as promoters, enhancers, terminators, and the like, that provide for the expression of a coding sequence in a host cell. In eukaryotic cells, polyadenylation signals are control sequences.

A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site (conveniently defined for example, by mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase.

A coding sequence is "under the control" of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then trans-RNA spliced and translated into the protein encoded by the coding sequence.

A "signal sequence" is included at the beginning of the coding sequence of a protein to be expressed on the surface of a cell. This sequence encodes a signal peptide, N-terminal to the mature polypeptide, that directs the host cell to translocate the polypeptide. The term "translocation signal sequence" is used herein to refer to this sort of signal sequence.

5 Translocation signal sequences can be found associated with a variety of proteins native to eukaryotes and prokaryotes, and are often functional in both types of organisms.

As used herein, the term "sequence homology" in all its grammatical forms refers to the relationship between proteins that possess a "common evolutionary origin," including proteins from superfamilies (e.g., the immunoglobulin superfamily) and homologous proteins  
10 from different species (e.g., myosin light chain, etc.) (Reeck *et al.*, 1987, Cell 50:667).

Accordingly, the term "sequence similarity" in all its grammatical forms refers to the degree of identity or correspondence between nucleic acid or amino acid sequences of proteins that do not share a common evolutionary origin (*see* Reeck *et al.*, *supra*). However, in common usage and in the instant application, the term "homologous," when modified with an adverb  
15 such as "highly," may refer to sequence similarity and not a common evolutionary origin.

In a specific embodiment, two DNA sequences are "substantially homologous" or "substantially similar" when at least about 50% (preferably at least about 75%, and most preferably at least about 90 or 95%) of the nucleotides match over the defined length of the DNA sequences. Sequences that are substantially homologous can be identified by  
20 comparing the sequences using standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Maniatis *et al.*, *supra*; DNA Cloning, Vols. I & II, *supra*; Nucleic Acid Hybridization, *supra*.

25 Similarly, in a particular embodiment, two amino acid sequences are "substantially homologous" or "substantially similar" when greater than 30% of the amino acids are identical, or greater than about 60% are similar (functionally identical). Preferably, the similar or homologous sequences are identified by alignment using, for example, the GCG (Genetics Computer Group, Program Manual for the GCG Package, Version 7, Madison,  
30 Wisconsin) pileup program.

The term "corresponding to" is used herein to refer similar or homologous sequences, whether the exact position is identical or different from the molecule to which the similarity or homology is measured. Thus, the term "corresponding to" refers to the sequence similarity, and not the numbering of the amino acid residues or nucleotide bases.

5

iENTPs: Proteins and Polypeptides

- The present invention provides isolated iENTPs and active fragments thereof. An iENTP is a transmembrane protein that contains approximately 450 amino acid residues, 8 to 12 putative transmembrane domains, is NBMPR insensitive, and functions as an equilibrative nucleoside transport protein. iENTPs represent one class of five, or more, classes of nucleoside
- 10 transporters found in mammalian cells (Griffith *et al.*, 1996, *supra*; Cass, 1995, *supra*). In preferred embodiments the iENTP is a mammalian protein. In one embodiment the iENTP is encoded by a nucleotide sequence having at least 80% similarity with the coding sequence of SEQ ID NO:1. In another embodiment the iENTP is encoded by a nucleotide sequence having at least 80% identity with the coding sequence of SEQ ID NO:1. In still another
- 15 embodiment the iENTP has an amino acid sequence of SEQ ID NO:2 comprising one or more conservative substitutions thereof. In a preferred embodiment the isolated iENTP is the human homolog (hENT2) having an amino acid sequence of SEQ ID NO:2. The iENTPs of the present invention may be used in assays to identify novel drugs, and the like, and in protein structure and mechanistic studies.
- 20 The hENT2 protein is 50% identical (having 69% similarity) to the hENT1 protein, the human homologue of the NBMPR-sensitive equilibrative nucleoside transport protein. As found for the concentrative transporters, hENT1 and hENT2 do not share significant homology with other known membrane transport proteins, and appear to represent a new family of transport proteins.
- 25 Surprisingly, the carboxy-terminal portion of the hENT2 protein is nearly identical to a 326 residue predicted peptide (hHNP36) in the Genbank database that has been identified as growth factor-induced "delayed early response" gene of unknown function [Williams *et al. Biochem.Biophys.Res.Comm.* 213:325-333 (1995)]. Inspection of the hHNP36 nucleotide sequence revealed two potential open reading frames with hHNP36 translated from the

second start codon. While hENT2 also has two potential start codons, they are within the same open reading frame. The full length cDNA of hHNP36 (2281 bp) is nearly identical to hENT2, but contains a 68 bp deletion beginning at position 338. This deletion shifts the initial reading frame relative to hENT2 and would result in a truncated 22 Kd peptide with only 51% identity to the hENT2 protein. Transient transfection studies with full length hENT2 and a 5'-truncated construct that lacks the first start codon (predicted protein 99% identical to hHNP36) demonstrated that a functional nucleoside transport protein is not produced from the second start codon. These data indicate that the hHNP36 peptide appears to be a truncated, non-functional form of hENT2.

- 10 The high degree of homology between hENT2 and hHNP36 was completely unexpected, and could not have been predicted from the earlier work of Williams *et al.* [Williams *et al.*, 1995, *supra*]. HNP36 had been identified as a 36 Kd peptide by *in vitro* translation of both the human and mouse mRNA homologs, but no data was provided regarding its function. It was only reported that HNP36 was localized in the nucleolus, as determined by immunostaining studies in mouse cells [Williams *et al.*, 1995, *supra*]. Therefore, knowledge of the 36 Kd peptide in the absence of the teachings provided by the present invention, could not have led to the iENTPs of the present invention.

- 20 The possible identity of hENT2 with a full-length, in frame natural analog of hHNP36 is consistent with the iENTP being a "delayed early response" gene. When quiescent cells are stimulated to proliferate there is a sequential expression of cellular genes whose products are thought to mediate the long-term responses to the growth factors. Therefore iENTPs are likely to play an important role in the proliferative response, when quiescent cells are stimulated into cycle by growth factors.

- 25 *Modified iENTPs:* The present invention also provides active fragments of the iENTPs and modified iENTPs of the present invention, such as tagged proteins, labeled proteins, fusion proteins and the like. Such modified iENTPs may be used for example as antigens or for marker purposes. In a particular embodiment of this type, the fusion protein comprises an iENTP protein or active fragment thereof having an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:2 comprising a conservative substitution thereof. Modified iENTPs of the present invention retain their activity as NBMPR insensitive equilibrative nucleoside
- 30

transport proteins. One particular use of the *i*ENTP fusion proteins of the present invention is for the production of the *i*ENTP-antibodies of the present invention.

An *i*ENTP fusion protein comprises at least a portion of a non-*i*ENTP protein joined via a peptide bond to at least a portion of an *i*ENTP polypeptide. In preferred embodiments the portion of the *i*ENTP is functional. The non-*i*ENTP sequences can be amino- or carboxy-terminal to the *i*ENTP sequences. More preferably, for stable expression of a proteolytically inactive *i*ENTP fusion protein, the portion of the non-*i*ENTP fusion protein is joined via a peptide bond to the amino terminus of the *i*ENTP protein. A recombinant DNA molecule encoding such a fusion protein comprises a sequence encoding at least a portion of a non-*i*ENTP protein joined in-frame to the *i*ENTP coding sequence, and preferably encodes a cleavage site for a specific protease, *e.g.*, thrombin or Factor Xa, preferably at the *i*ENTP-non-*i*ENTP juncture. In a specific embodiment, the fusion protein is expressed in *Escherichia coli*. Such a fusion protein can be used to isolate the *i*ENTPs of the present invention, through the use of an affinity column which is specific for the protein fused to the *i*ENTP. The purified *i*ENTP may then be released from the fusion protein through the use of a proteolytic enzyme and the cleavage site such as has been referred to above.

In one such embodiment, a chimeric *i*ENTP can be prepared, *e.g.*, a glutathione-S-transferase (GST) fusion protein, a maltose-binding (MBP) protein fusion protein, or a poly-histidine-tagged fusion protein, for expression in a eukaryotic cell. Expression of an *i*ENTP as a fusion protein can facilitate stable expression, or allow for purification based on the properties of the fusion partner. For example, GST binds glutathione conjugated to a solid support matrix, MBP binds to a maltose matrix, and poly-histidine chelates to a Ni-chelation support matrix. The fusion protein can be eluted from the specific matrix with appropriate buffers, or by treating with a protease specific for a cleavage site usually engineered between the *i*ENTP and the fusion partner (*e.g.*, GST, MBP, or poly-His) as described above. Alternatively the chimeric *i*ENTP protein may contain the green fluorescent protein, and be used to determine the intracellular localization of the *i*ENTP in the cell.

#### Genes Encoding *i*ENTPs

The present invention contemplates isolation of a gene encoding an *i*ENTP of the present invention, including a full length, or naturally occurring form of *i*ENTP, and antigenic

fragments thereof from any animal, particularly mammalian, and more particularly human, source. Such nucleic acids may be used for designing primers for RT-PCR, and for making probes that are useful for determining the expression of *iENTP* messenger RNA in tissues and tumors. Similarly such nucleic acids can be used to determine the expression of *iENTP* messenger RNA in normal tissues and tumors by Northern Blot analysis. RNA protection assays and the like. As used herein, the term "gene" refers to an assembly of nucleotides that encode a polypeptide, and includes cDNA and genomic DNA nucleic acids.

The present invention provides the primary structure of genes encoding *iENTPs* as exemplified in Figure 6 and Figure 7. Furthermore, the present invention provides the genetic information that allows the determination of tissue specific regulatory elements of genes encoding the *iENTPs* of the present invention. Such regulatory elements may be contained in SEQ ID NO:6.

In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, *Molecular Cloning: A Laboratory Manual*, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (herein "Sambrook *et al.*, 1989"); *DNA Cloning: A Practical Approach*, Volumes I and II (D.N. Glover ed. 1985); *Oligonucleotide Synthesis* (M.J. Gait ed. 1984); *Nucleic Acid Hybridization* [B.D. Hames & S.J. Higgins eds. (1985)]; *Transcription And Translation* [B.D. Hames & S.J. Higgins, eds. (1984)]; *Animal Cell Culture* [R.I. Freshney, ed. (1986)]; *Immobilized Cells And Enzymes* [IRL Press, (1986)]; B. Perbal, *A Practical Guide To Molecular Cloning* (1984); F.M. Ausubel *et al.* (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc. (1994).

A gene encoding *iENTP*, whether genomic DNA or cDNA, can be isolated from any source, particularly from a human cDNA or genomic library. In view and in conjunction with the present teachings, methods well known in the art. as described above can be used for obtaining *iENTP* genes from any source (*see, e.g.,* Sambrook *et al.*, 1989, *supra*).

Accordingly, any animal cell or transformed animal cell line potentially can serve as the nucleic acid source for the molecular cloning of a *iENTP* gene. The DNA may be obtained by standard procedures known in the art from cloned DNA (*e.g.,* a DNA "library"), and

preferably is obtained from a cDNA library prepared from tissues with high level expression of the protein, by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired cell (See, for example, Sambrook *et al.*, 1989, *supra*; Glover, D.M. (ed.), 1985, DNA Cloning: A Practical Approach, MRL Press, Ltd., Oxford, U.K. Vol. I, II). Clones derived from genomic DNA may contain regulatory and intron DNA regions in addition to coding regions; clones derived from cDNA will not contain intron sequences. Whatever the source, the gene should be molecularly cloned into a suitable vector for propagation of the gene.

In the molecular cloning of the gene from genomic DNA, DNA fragments are generated, some of which will encode the desired gene. The DNA may be cleaved at specific sites using various restriction enzymes. Alternatively, one may use DNase in the presence of manganese to fragment the DNA, or the DNA can be physically sheared, as for example, by sonication. The linear DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography.

Once the DNA fragments are generated, identification of the specific DNA fragment containing the desired *iENTP* gene may be accomplished in a number of ways. For example, the generated DNA fragments may be screened by nucleic acid hybridization to a labeled probe of the present invention (Benton and Davis, 1977, Science 196:180; Grunstein and Hogness, 1975, Proc. Natl. Acad. Sci. U.S.A. 72:3961). For example, a set of oligonucleotides corresponding to the sequence information provided by the present invention can be prepared and used as probes for DNA encoding *iENTP* (*e.g.*, in combination with a poly-T primer for RT-PCR). Preferably, a probe is selected that is highly unique to *iENTP* of the invention. Those DNA fragments with substantial homology to the probe will hybridize. As noted above, the greater the degree of homology, the more stringent hybridization conditions can be used.

Further selection can be carried out on the basis of the properties of the gene, *e.g.*, if the gene encodes a protein product having the isoelectric, electrophoretic, amino acid composition, or partial amino acid sequence of the *iENTP* as disclosed herein. Thus, the presence of the gene may be detected by assays based on the physical, chemical, or immunological properties of its expressed product. For example, cDNA clones, or DNA clones which hybrid-select the



proper mRNAs, can be selected which produce a protein that, *e.g.*, has similar or identical electrophoretic migration, isoelectric focusing or non-equilibrium pH gel electrophoresis behavior, proteolytic digestion maps or antigenic properties as known for *iENTP*.

5 An *iENTP* gene of the invention can also be identified by mRNA selection, *i.e.*, by nucleic acid hybridization followed by *in vitro* translation. In this procedure, nucleotide fragments are used to isolate complementary mRNAs by hybridization. Such DNA fragments may represent available, purified *iENTP* DNA, or may be synthetic oligonucleotides designed from the partial amino acid sequence information. Immunoprecipitation analysis or functional assays (*e.g.*, nucleoside transport activity) of the *in vitro* translation products of  
10 the products of the isolated mRNAs identifies the mRNA and, therefore, the complementary DNA fragments, that contain the desired sequences. In addition, specific mRNAs may be selected by adsorption of polysomes isolated from cells to immobilized antibodies specifically directed against *iENTP*.

15 A radiolabeled *iENTP* cDNA can be synthesized using the selected mRNA (from the adsorbed polysomes) as a template. The radiolabeled mRNA or cDNA may then be used as a probe to identify homologous *iENTP* DNA fragments from among other genomic DNA fragments.

The present invention also relates to cloning vectors containing genes encoding analogs and derivatives of *iENTP* of the invention, that have the same or homologous functional activity  
20 as *iENTP*, and homologs thereof from other species. The production and use of derivatives and analogs related to *iENTP* are within the scope of the present invention. In a specific embodiment, the derivative or analog is functionally active, *i.e.*, capable of exhibiting nucleoside transport activity.

*iENTP* derivatives can be made by altering encoding nucleic acid sequences by substitutions,  
25 additions or deletions that provide for functionally equivalent molecules. Preferably, derivatives are made that have enhanced or increased functional activity or greater specificity with regard to a particular permeant relative to native *iENTP*. Alternatively, such derivatives may encode soluble fragments of *iENTP* extracellular domain that have the same or greater affinity for the natural permeants of the *iENTPs* of the present invention. Such soluble  
30 derivatives also may be potent inhibitors of the nucleoside transport activity of the *iENTP*.

Due to the degeneracy of nucleotide coding sequences, other DNA sequences which encode substantially the same amino acid sequence as a *iENTP* gene may be used in the practice of the present invention. These include but are not limited to allelic genes, homologous genes from other species, and nucleotide sequences comprising all or portions of *iENTP* genes which are altered by the substitution of different codons that encode the same amino acid residue within the sequence, thus producing a silent change. Likewise, the *iENTP* derivatives of the invention include, but are not limited to, those containing, as a primary amino acid sequence, all or part of the amino acid sequence of a *iENTP* protein including altered sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence resulting in a conservative amino acid substitution. Such alterations define the term "a conservative substitution" as used herein. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity, which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. Amino acids containing aromatic ring structures are phenylalanine, tryptophan, and tyrosine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Such alterations will not be expected to affect apparent molecular weight as determined by polyacrylamide gel electrophoresis, or isoelectric point.

Particularly preferred substitutions are:

- Lys for Arg and vice versa such that a positive charge may be maintained;
- Glu for Asp and vice versa such that a negative charge may be maintained;
- Ser for Thr such that a free -OH can be maintained; and
- Gln for Asn such that a free NH<sub>2</sub> can be maintained.

Amino acid substitutions may also be introduced to substitute an amino acid with a particularly preferable property. For example, a Cys may be introduced at a potential site for disulfide bridges with another Cys. Pro may be introduced because of its particularly planar structure, which induces  $\beta$ -turns in the protein's structure.

The genes encoding *iENTP* derivatives and analogs of the invention can be produced by various methods known in the art. The manipulations which result in their production can occur at the gene or protein level. For example, the cloned *iENTP* gene sequence can be modified by any of numerous strategies known in the art (Sambrook *et al.*, 1989, *supra*). The sequence can be cleaved at appropriate sites with restriction endonuclease(s), followed by further enzymatic modification if desired, isolated, and ligated *in vitro*. In the production of the gene encoding a derivative or analog of *iENTP*, care should be taken to ensure that the modified gene remains within the same translational reading frame as the *iENTP* gene, uninterrupted by translational stop signals, in the gene region where the desired activity is encoded.

Additionally, the *iENTP*-encoding nucleic acid sequence can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further *in vitro* modification. Preferably, such mutations enhance the functional activity or specificity for a particular permeant, of the mutated *iENTP* gene product. Any technique for mutagenesis known in the art can be used, including but not limited to, *in vitro* site-directed mutagenesis (Hutchinson, C., *et al.*, 1978, J. Biol. Chem. 253:6551; Zoller and Smith, 1984, DNA 3:479-488; Oliphant *et al.*, 1986, Gene 44:177; Hutchinson *et al.*, 1986, Proc. Natl. Acad. Sci. U.S.A. 83:710), use of TAB® linkers (Pharmacia), etc. PCR techniques are preferred for site directed mutagenesis (see Higuchi, 1989, "Using PCR to Engineer DNA", in *PCR Technology: Principles and Applications for DNA Amplification*, H. Erlich, ed., Stockton Press, Chapter 6, pp. 61-70).

The identified and isolated gene can then be inserted into an appropriate cloning vector. A large number of vector-host systems known in the art may be used. Possible vectors include, but are not limited to, plasmids or modified viruses, but the vector system must be compatible with the host cell used. Examples of vectors include, but are not limited to, *E. coli*, bacteriophages such as lambda derivatives, or plasmids such as pBR322 derivatives or pUC plasmid derivatives, *e.g.*, pGEX vectors, pmal-c, pFLAG, etc. The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site desired may be

produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. Recombinant molecules can be introduced into host cells via transduction, transformation, transfection, infection, electroporation, etc., so that many copies of the gene sequence are generated. Preferably, the cloned gene is contained on a shuttle vector plasmid, which provides for expansion in a cloning cell, *e.g.*, *E. coli*, and facile purification for subsequent insertion into an appropriate expression cell line, if such is desired. For example, a shuttle vector, which is a vector that can replicate in more than one type of organism, can be prepared for replication in both *E. coli* and *Saccharomyces cerevisiae* by linking sequences from an *E. coli* plasmid with sequences from the yeast 2 $\mu$  plasmid.

In an alternative method, the desired gene may be identified and isolated after insertion into a suitable cloning vector in a "shot gun" approach. Enrichment for the desired gene, for example, by size fractionation, can be done before insertion into the cloning vector.

15

#### Expression of *i*ENTP

The present invention provides for expressing the nucleic acids which encode the *i*ENTPs active fragments thereof, derivatives or analog thereof, or a functionally active derivative, including a chimeric protein, thereof, that has been inserted into an appropriate expression vector, *i.e.*, a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. Such elements are termed herein a "promoter." Thus, the nucleic acid encoding an *i*ENTP of the invention is operationally associated with a promoter in an expression vector of the invention. Both cDNA and genomic sequences can be cloned and expressed under control of such regulatory sequences. An expression vector also preferably includes a replication origin. One particular use for such expression vectors is to express an *i*ENTP in large quantities that can be used for functional and structural studies of the purified transport protein.

The necessary transcriptional and translational signals can be provided on a recombinant expression vector, or they may be supplied by the native gene encoding *i*ENTP and/or its flanking regions.

Potential chimeric partners for the *iENTP* of the present invention include substitute lectin domains, either from naturally occurring multivalent lectin receptors, such as mannose receptor of macrophages, natural lectins, or other sources.

Potential host-vector systems include but are not limited to mammalian cell systems, infected  
5 with virus (*e.g.*, vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (*e.g.*, baculovirus); microorganisms such as yeast containing yeast vectors; or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used.

10 A recombinant *iENTP* protein of the invention, or functional fragment, derivative, chimeric construct, or analog thereof, may be expressed chromosomally, after integration of the coding sequence by recombination. In this regard, any of a number of amplification systems may be used to achieve high levels of stable gene expression (*See* Sambrook *et al.*, 1989, *supra*).

15 The cell containing the recombinant vector comprising the nucleic acid encoding *iENTP* is cultured in an appropriate cell culture medium under conditions that provide for expression of *iENTP* by the cell.

Any of the methods previously described for the insertion of DNA fragments into a cloning vector may be used to construct expression vectors containing a gene consisting of  
20 appropriate transcriptional/translational control signals and the protein coding sequences. These methods may include *in vitro* recombinant DNA and synthetic techniques and *in vivo* recombination (genetic recombination).

Expression of *iENTP* may be controlled by any promoter/enhancer element known in the art, but these regulatory elements must be functional in the host selected for expression.  
25 Promoters which may be used to control *iENTP* gene expression include, those described in Example 1 below, as well as the SV40 early promoter region (Benoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, *et al.*, 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner *et al.*, 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445), the regulatory sequences

- of the metallothionein gene (Brinster *et al.*, 1982, Nature 296:39-42); prokaryotic expression vectors such as the  $\beta$ -lactamase promoter (Villa-Komaroff, *et al.*, 1978, Proc. Natl. Acad. Sci. U.S.A. 75:3727-3731), or the *tac* promoter (DeBoer, *et al.*, 1983, Proc. Natl. Acad. Sci. U.S.A. 80:21-25); see also "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94; promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter; and the animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift *et al.*, 1984, Cell 38:639-646; Ornitz *et al.*, 1986, Cold Spring Harbor Symp. Quant. Biol. 50:399-409; MacDonald, 1987, Hepatology 7:425-515); insulin gene control region which is active in pancreatic beta cells (Hanahan, 1985, Nature 315:115-122), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl *et al.*, 1984, Cell 38:647-658; Adames *et al.*, 1985, Nature 318:533-538; Alexander *et al.*, 1987, Mol. Cell. Biol. 7:1436-1444), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder *et al.*, 1986, Cell 45:485-495), albumin gene control region which is active in liver (Pinkert *et al.*, 1987, Genes and Devel. 1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf *et al.*, 1985, Mol. Cell. Biol. 5:1639-1648; Hammer *et al.*, 1987, Science 235:53-58), alpha 1-antitrypsin gene control region which is active in the liver (Kelsey *et al.*, 1987, Genes and Devel. 1:161-171), beta-globin gene control region which is active in myeloid cells (Mogam *et al.*, 1985, Nature 315:338-340; Kollias *et al.*, 1986, Cell 46:89-94), myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead *et al.*, 1987, Cell 48:703-712), myosin light chain-2 gene control region which is active in skeletal muscle (Sani, 1985, Nature 314:283-286), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason *et al.*, 1986, Science 234:1372-1378).

- Expression vectors containing a nucleic acid encoding an iENTP of the invention can be identified by four general approaches: (a) PCR amplification of the desired plasmid DNA or specific mRNA, (b) nucleic acid hybridization, (c) presence or absence of selection marker gene functions, and (d) expression of inserted sequences. In the first approach, the nucleic acids can be amplified by PCR to provide for detection of the amplified product. In the second approach, the presence of a foreign gene inserted in an expression vector can be detected by nucleic acid hybridization using probes comprising sequences that are

homologous to an inserted marker gene. In the third approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "selection marker" gene functions (e.g.,  $\beta$ -galactosidase activity, thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes in the vector. In another example, if the nucleic acid encoding *iENTP* is inserted within the "selection marker" gene sequence of the vector, recombinants containing the *iENTP* insert can be identified by the absence of the *iENTP* gene function. In the fourth approach, recombinant expression vectors can be identified by assaying for the activity, biochemical, or immunological characteristics of the gene product expressed by the recombinant, provided that the expressed protein assumes a functionally active conformation. This last approach has been used in Example 1, below.

A wide variety of host/expression vector combinations may be employed in expressing the DNA sequences of this invention. Useful expression vectors, for example, may consist of segments of chromosomal, non-chromosomal and synthetic DNA sequences. Suitable vectors include derivatives of SV40 and known bacterial plasmids, e.g., *E. coli* plasmids col El, pCR1, pBR322, pMal-C2, pET, pGEX (Smith *et al.*, 1988, Gene 67:31-40), pMB9 and their derivatives, plasmids such as RP4; phage DNAs, e.g., the numerous derivatives of phage  $\lambda$ , e.g., NM989, and other phage DNA, e.g., M13 and filamentous single stranded phage DNA; yeast plasmids such as the 2 $\mu$  plasmid or derivatives thereof; vectors useful in eukaryotic cells, such as vectors useful in insect or mammalian cells; vectors derived from combinations of plasmids and phage DNAs, such as plasmids that have been modified to employ phage DNA or other expression control sequences; and the like.

For example, in a baculovirus expression systems, both non-fusion transfer vectors, such as but not limited to pVL941 (*Bam*H1 cloning site; Summers), pVL1393 (*Bam*H1, *Sma*I, *Xba*I, *Eco*R1, *Not*I, *Xma*III, *Bgl*II, and *Pst*I cloning site; Invitrogen), pVL1392 (*Bgl*II, *Pst*I, *Not*I, *Xma*III, *Eco*RI, *Xba*I, *Sma*I, and *Bam*H1 cloning site; Summers and Invitrogen), and pBlueBacIII (*Bam*H1, *Bgl*II, *Pst*I, *Nco*I, and *Hind*III cloning site, with blue/white recombinant screening possible; Invitrogen), and fusion transfer vectors, such as but not limited to pAc700 (*Bam*H1 and *Kpn*I cloning site, in which the *Bam*H1 recognition site begins with the initiation codon; Summers), pAc701 and pAc702 (same as pAc700, with different reading frames), pAc360 (*Bam*H1 cloning site 36 base pairs downstream of a polyhedrin initiation codon; Invitrogen(195)), and pBlueBacHisA, B, C (three different

reading frames, with *Bam*HI, *Bgl*II, *Pst*II, *Nco*I, and *Hind*III cloning site, an N-terminal peptide for ProBond purification, and blue/white recombinant screening of plaques; Invitrogen (220)) can be used.

- Mammalian expression vectors contemplated for use in the invention include vectors with
- 5 inducible promoters, such as the dihydrofolate reductase (DHFR) promoter, *e.g.* any expression vector with a *DHFR* expression vector, or a *DHFR*/methotrexate co-amplification vector, such as pED (*Pst*II, *Sal*I, *Sba*I, *Sma*I, and *Eco*RI cloning site, with the vector expressing both the cloned gene and *DHFR*; *see* Kaufman, *Current Protocols in Molecular Biology*, 16.12 (1991). Alternatively, a glutamine synthetase/methionine sulfoximine co-
- 10 amplification vector, such as pEE14 (*Hind*III, *Xba*I, *Sma*I, *Sba*I, *Eco*RI, and *Bcl*I cloning site, in which the vector expresses glutamine synthase and the cloned gene; Celltech). In another embodiment, a vector that directs episomal expression under control of Epstein Barr Virus (EBV) can be used, such as pREP4 (*Bam*HI, *Sfi*I, *Xho*I, *Not*I, *Nhe*I, *Hind*III, *Nhe*I, *Pvu*II, and *Kpn*I cloning site, constitutive RSV-LTR promoter, hygromycin selectable marker;
- 15 Invitrogen), pCEP4 (*Bam*HI, *Sfi*I, *Xho*I, *Not*I, *Nhe*I, *Hind*III, *Nhe*I, *Pvu*II, and *Kpn*I cloning site, constitutive hCMV immediate early gene, hygromycin selectable marker; Invitrogen), pMEP4 (*Kpn*I, *Pvu*I, *Nhe*I, *Hind*III, *Not*I, *Xho*I, *Sfi*I, *Bam*HI cloning site, inducible methallothionein IIa gene promoter, hygromycin selectable marker; Invitrogen), pREP8 (*Bam*HI, *Xho*I, *Not*I, *Hind*III, *Nhe*I, and *Kpn*I cloning site, RSV-LTR promoter, histidinol
- 20 selectable marker; Invitrogen), pREP9 (*Kpn*I, *Nhe*I, *Hind*III, *Not*I, *Xho*I, *Sfi*I, and *Bam*HI cloning site, RSV-LTR promoter, G418 selectable marker; Invitrogen), and pEBVHis (RSV-LTR promoter, hygromycin selectable marker, N-terminal peptide purifiable via ProBond resin and cleaved by enterokinase; Invitrogen). Selectable mammalian expression vectors for use in the invention include pRc/CMV (*Hind*III, *Bst*XI, *Not*I, *Sba*I, and *Apa*I cloning site,
- 25 G418 selection; Invitrogen), pRc/RSV (*Hind*III, *Spe*I, *Bst*XI, *Not*I, *Xba*I cloning site, G418 selection; Invitrogen), and others. Vaccinia virus mammalian expression vectors (*see*, Kaufman, 1991, *supra*) for use according to the invention include but are not limited to pSC11 (*Sma*I cloning site, TK- and  $\beta$ -gal selection), pMJ601 (*Sal*I, *Sma*I, *Afl*I, *Nar*I, *Bsp*MI, *Bam*HI, *Apa*I, *Nhe*I, *Sac*II, *Kpn*I, and *Hind*III cloning site; TK- and  $\beta$ -gal selection), and
- 30 pTKgptF1S (*Eco*RI, *Pst*II, *Sal*I, *Acc*I, *Hind*II, *Sba*I, *Bam*HI, and *Hpa*I cloning site, TK or XPRT selection).



Yeast expression systems can also be used according to the invention to express the *i*ENTP protein. For example, the non-fusion pYES2 vector (*Xba*I, *Sph*I, *Sho*I, *Not*I, *Gst*XI, *Eco*RI, *Bst*XI, *Bam*HI, *Sac*I, *Kpn*I, and *Hind*III cloning sit; Invitrogen) or the fusion pYESHisA, B, C (*Xba*I, *Sph*I, *Sho*I, *Not*I, *Bst*XI, *Eco*RI, *Bam*HI, *Sac*I, *Kpn*I, and *Hind*III cloning site, N-terminal peptide purified with ProBond resin and cleaved with enterokinase; Invitrogen), to  
5 mention just two, can be employed according to the invention.

In a preferred embodiment the expression vector is pDR2 (Clontech). In another preferred embodiment the expression vector is pcDNA3 (Invitrogen).

Once a particular recombinant DNA molecule is identified and isolated, several methods  
10 known in the art may be used to propagate it. Once a suitable host system and growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. As previously explained, the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as baculovirus; yeast vectors;  
15 bacteriophage vectors (*e.g.*, lambda), and plasmid and cosmid DNA vectors, to name but a few.

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Different host cells have characteristic and specific mechanisms for the translational and  
20 post-translational processing and modification (*e.g.*, glycosylation, cleavage [*e.g.*, of signal sequence]) of proteins. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed. For example, expression in a bacterial system can be used to produce an nonglycosylated core protein product. However, the transmembrane *i*ENTP expressed in bacteria may not be properly  
25 folded. Expression in yeast can produce a glycosylated product. Expression in eukaryotic cells can increase the likelihood of "native" glycosylation and folding of a heterologous protein. Moreover, expression in mammalian cells can provide a tool for reconstituting, or constituting, *i*ENTP activity. Furthermore, different vector/host expression systems may affect processing reactions, such as proteolytic cleavages, to a different extent.

Vectors are introduced into the desired host cells by methods known in the art, *e.g.*, transfection, transduction, electroporation, microinjection, cell fusion, DEAE dextran, calcium phosphate precipitation, lipofection (lysosome fusion), use of a gene gun, or a DNA vector transporter (see, *e.g.*, Wu *et al.*, 1992, J. Biol. Chem. 267:963-967; Wu and Wu, 1988, J. Biol. Chem. 263:14621-14624; Hartmut *et al.*, Canadian Patent Application No. 2,012,311, filed March 15, 1990).

The present invention also provides cell lines made from cells transfected or transduced with the *i*ENTPs of the present invention. In preferred embodiments of this type the cells are mammalian cells. In one such embodiment the *i*ENTP is introduced into a COS-1 cell with a pcDNA3 expression vector, as exemplified below. The *i*ENTP expressed in a human cell line is preferentially hENT2. In one such embodiment, the human cell expresses hENT2 as its only detectable nucleoside transport protein. In a particular embodiment of this type, the human cell is the T-cell leukemia cell line CEM, transfected with an Epstein-Barr Nuclear Antigen 1 expression cassette with a pDR2 expression vector capable of supporting the episomal replication of an Epstein-Barr virus-based mammalian expression vector encoding the hENT2. Such a transfected cell expresses the *i*ENTP as its only nucleoside transport protein and is therefore a valuable tool for further characterization of the *i*ENTPs of the present invention. Heretofore, such characterization appeared to be an impossible task, as all known cell lines expressing an *i*ENTP had also been shown to have one or more additional nucleoside transport activities. Such a cell line also is a valuable tool for determining whether antiviral and antitumor nucleoside analogs can enter cells *via* the *ei* transporter and/or for identifying specific inhibitors of *i*ENTPs as discussed below. In one particular embodiment of this type, the cell is an CEM/N1-7 cell exemplified below.

Such a cell line also can be used in expression cloning of proteins using an episomally replicating Epstein-Barr virus based vector that requires the expression of EBNA-1 in *trans*, and requires nucleoside transport in the selection process (*e.g.* HAT selection (with adenine substituted for hypoxanthine since the line is HPRT deficient)). Such procedures and cell lines are especially useful for proteins that are expressed in larger quantities in a T-cell background.

30

#### General Protein Purification Procedures:

The initial step for purifying the *i*ENTPs of the present invention, active fragments thereof, and related tagged or fusion proteins generally consists of lysing the cells containing the *i*ENTPs. Cell lysis can be achieved by a number of methods including through the use of a physical means such as a French press, a sonicator, or a blender; or through chemical means including enzymatic extractions (with for example, lysozyme or pancreatin), and/or organic  
5 extractions or solubilizations with detergents, such as sodium dodecyl sulfate (SDS), Triton X-100, nonidet P-40 (NP-40), digoxin, sodium deoxycholate, and the like, including mixtures thereof; or through a combination of chemical and physical means. For example, solubilization can be enhanced by sonication of the suspension. Subsequent steps of  
10 purification include salting in or salting out, such as in ammonium sulfate fractionations; solvent exclusion fractionations, *e.g.*, an ethanol precipitation; detergent extractions to free the membrane bound *i*ENTPs of the present invention using such detergents as Triton X-100, Tween-20 etc.; or high salt extractions. Solubilization of proteins may also be achieved using aprotic solvents such as dimethyl sulfoxide and hexamethylphosphoramide. In  
15 addition, high speed ultracentrifugation may be used either alone or in conjunction with other extraction techniques.

Generally good secondary isolation or purification steps include solid phase absorption using calcium phosphate gel or hydroxyapatite; or solid phase binding. Solid phase binding may be performed through ionic bonding, with either an anion exchanger, such as  
20 diethylaminoethyl (DEAE), or diethyl [2-hydroxypropyl] aminoethyl (QAE) SEPHADEX or cellulose; or with a cation exchanger such as carboxymethyl (CM) or sulfopropyl (SP) SEPHADEX or cellulose. Alternative means of solid phase binding includes the exploitation of hydrophobic interactions *e.g.*, the using of a solid support such as PHENYLSEPHAROSE and a high salt buffer; affinity-binding, using, *e.g.*, placing a nucleoside or nucleoside analog  
25 on to an activated support; immuno-binding, using *e.g.*, an antibody to an *i*ENTP of the present invention bound to an activated support; as well as other solid phase supports including those that contain specific dyes or lectins etc. A further solid phase support technique that is often used at the end of the purification procedure relies on size exclusion, such as SEPHADEX and SEPHAROSE gels, or pressurized or centrifugal membrane  
30 techniques, using size exclusion membrane filters.

Solid phase support separations are generally performed batch-wise with low-speed centrifugations or by column chromatography. High performance liquid chromatography

(HPLC), including such related techniques as FPLC, is presently the most common means of performing liquid chromatography. Size exclusion techniques may also be accomplished with the aid of low speed centrifugation.

In addition size permeation techniques such as gel electrophoretic techniques may be employed. These techniques are generally performed in tubes, slabs or by capillary electrophoresis.

Almost all steps involving protein purification employ a buffered solution. Unless otherwise specified, generally 25-100 mM concentrations are used. Low concentration buffers generally infer 5-25 mM concentrations. High concentration buffers generally infer concentrations of the buffering agent of between 0.1-2M concentrations. Typical buffers can be purchased from most biochemical catalogues and include the classical buffers such as Tris, pyrophosphate, monophosphate and diphosphate. The Good buffers [Good, *et al.*, *Biochemistry*, 5:467 (1966); Good *et al. Meth. Enzymol.*, 24: Part B, 53 (1972) ; and Ferguson, *et. al Anal. Biochem.* 104:300,(1980)] such as Mcs, Hepes, Mops, tricine and Ches.

Materials to perform all of these techniques are available from a variety of sources such as Sigma Chemical Company in St. Louis, Missouri.

#### Antibodies to *i*ENTPs

According to the invention, an *i*ENTP obtained from a natural source or produced recombinantly or by chemical synthesis, and fragments or other derivatives or analogs thereof, including fusion proteins, may be used as an immunogen to generate antibodies that recognize the *i*ENTP polypeptide. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library. The anti-*i*ENTP antibodies of the invention may be cross reactive, *e.g.*, they may recognize an *i*ENTP from different species. Polyclonal antibodies have greater likelihood of cross reactivity. Alternatively, an antibody of the invention may be specific for a single form of the *i*ENTP, such as murine *i*ENTP. Preferably, such an antibody is specific for human *i*ENTP.

Various procedures known in the art may be used for the production of polyclonal antibodies to an *i*ENTP of the present invention or derivative or analog thereof. For the production of

antibody, various host animals can be immunized by injection with an *i*ENTP or a derivative (e.g., fragment or fusion protein) thereof, including but not limited to rabbits, mice, rats, sheep, goats, etc. In one embodiment, an *i*ENTP or fragment thereof can be conjugated to an immunogenic carrier, e.g., bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH). Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (*bacille Calmette-Guerin*) and *Corynebacterium parvum*.

For preparation of monoclonal antibodies directed toward an *i*ENTP of the present invention, or fragment, analog, or derivative thereof, any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used. These include but are not limited to the hybridoma technique originally developed by Kohler and Milstein [*Nature* 256:495-497 (1975)], as well as the trioma technique, the human B-cell hybridoma technique [Kozbor *et al.*, *Immunology Today* 4:72 (1983); Cote *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 80:2026-2030 (1983)], and the EBV-hybridoma technique to produce human monoclonal antibodies [Cole *et al.*, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96 (1985)]. In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals utilizing recent technology [PCT/US90/02545]. In fact, according to the invention, techniques developed for the production of "chimeric antibodies" [Morrison *et al.*, *J. Bacteriol.* 159:870 (1984); Neuberger *et al.*, *Nature* 312:604-608 (1984); Takeda *et al.*, *Nature* 314:452-454 (1985)] by splicing the genes from a mouse antibody molecule specific for an *i*ENTP, for example, together with genes from a human antibody molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention. Such human or humanized chimeric antibodies are preferred for use in therapy of human diseases or disorders (described *infra*), since the human or humanized antibodies are much less likely than xenogenic antibodies to induce an immune response, in particular an allergic response, themselves.

According to the invention, techniques described for the production of single chain antibodies [U.S. Patent Nos. 5,476,786 and 5,132,405 to Huston; U.S. Patent 4,946,778] can be adapted to produce *i*ENTP-specific single chain antibodies. An additional embodiment of

the invention utilizes the techniques described for the construction of Fab expression libraries [Huse *et al.*, *Science* 246:1275-1281 (1989)] to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for an *i*ENTP or its derivatives, or analogs.

- 5 Antibody fragments which contain the idiotype of the antibody molecule can be generated by known techniques. For example, such fragments include but are not limited to: the  $F(ab')_2$  fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the  $F(ab')_2$  fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain  
10 and a reducing agent.

- In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, *e.g.*, radioimmunoassay, ELISA (enzyme-linked immunosorbant assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, *in situ* immunoassays (using colloidal gold, enzyme or  
15 radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (*e.g.*, gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary  
20 antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention. For example, to select antibodies which recognize a specific epitope of an *i*ENTP, for example the predicted extracellular loop, amino acids 35-64 of SEQ ID NO:2, one may assay generated hybridomas  
25 for a product which binds to an *i*ENTP fragment containing such epitope. For selection of an antibody specific to an *i*ENTP from a particular species of animal, one can select on the basis of positive binding with an *i*ENTP expressed by or isolated from cells of that species of animal.

- The foregoing antibodies can be used in methods known in the art relating to the localization  
30 and activity of the *i*ENTP, *e.g.*, for Western blotting, imaging *i*ENTP *in situ*, measuring levels thereof in appropriate physiological samples, etc. using any of the detection techniques

mentioned above or known in the art. More particularly, the antibodies of the present invention can be used in flow cytometry studies, in immunohistochemical staining, and in immunoprecipitation which serves to aid the determination of the level of expression of an iENTP in a tumor or normal cell or tissue.

- 5 In a specific embodiment, antibodies that agonize or antagonize the activity of an iENTP can be generated. Such antibodies can be tested using the assays described *infra* for identifying ligands.

### Labels

- Suitable labels include enzymes and proteins such as green fluorescent protein, fluorophores (e.g., fluoresceine isothiocyanate (FITC), phycoerythrin (PE), Texas red (TR), rhodamine, free or chelated lanthanide series salts, especially  $\text{Eu}^{3+}$ , to name a few fluorophores), chromophores, radioisotopes, chelating agents, dyes, colloidal gold, latex particles, ligands (e.g., biotin), and chemiluminescent agents. When a control marker is employed, the same or different labels may be used for the receptor and control marker.
- 10 (e.g., fluoresceine isothiocyanate (FITC), phycoerythrin (PE), Texas red (TR), rhodamine, free or chelated lanthanide series salts, especially  $\text{Eu}^{3+}$ , to name a few fluorophores), chromophores, radioisotopes, chelating agents, dyes, colloidal gold, latex particles, ligands (e.g., biotin), and chemiluminescent agents. When a control marker is employed, the same or different labels may be used for the receptor and control marker.
- 15 In the instance where a radioactive label, such as the isotopes  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^{36}\text{Cl}$ ,  $^{51}\text{Cr}$ ,  $^{57}\text{Co}$ ,  $^{58}\text{Co}$ ,  $^{59}\text{Fe}$ ,  $^{90}\text{Y}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ , and  $^{186}\text{Re}$  are used, known currently available counting procedures may be utilized. In the instance where the label is an enzyme, detection may be accomplished by any of the presently utilized colorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques known in the art.
- 20 Direct labels are one example of labels which can be used according to the present invention. A direct label has been defined as an entity, which in its natural state, is readily visible, either to the naked eye, or with the aid of an optical filter and/or applied stimulation, e.g. U.V. light to promote fluorescence. Among examples of colored labels, which can be used according to the present invention, include metallic sol particles, for example, gold sol particles such as those described by Leuving (U.S. Patent 4,313,734); dye sole particles such as described by Gribnau *et al.* (U.S. Patent 4,373,932) and May *et al.* (WO 88/08534); dyed latex such as described by May, *supra*, Snyder (EP-A 0 280 559 and 0 281 327); or dyes encapsulated in liposomes as described by Campbell *et al.* (U.S. Patent 4,703,017). Other direct labels include a radionucleotide, a fluorescent moiety or a luminescent moiety. In addition to these
- 25 those described by Leuving (U.S. Patent 4,313,734); dye sole particles such as described by Gribnau *et al.* (U.S. Patent 4,373,932) and May *et al.* (WO 88/08534); dyed latex such as described by May, *supra*, Snyder (EP-A 0 280 559 and 0 281 327); or dyes encapsulated in liposomes as described by Campbell *et al.* (U.S. Patent 4,703,017). Other direct labels include a radionucleotide, a fluorescent moiety or a luminescent moiety. In addition to these

direct labelling devices, indirect labels comprising enzymes can also be used according to the present invention. Various types of enzyme linked immunoassays are well known in the art, for example, alkaline phosphatase and horseradish peroxidase, lysozyme, glucose-6-phosphate dehydrogenase, lactate dehydrogenase, urease, these and others have been  
5 discussed in detail by Eva Engvall in Enzyme Immunoassay ELISA and EMIT in *Methods in Enzymology*, 70. 419-439, 1980 and in U.S. Patent 4,857,453.

Suitable enzymes include, but are not limited to, alkaline phosphatase and horseradish peroxidase.

Other labels for use in the invention include magnetic beads or magnetic resonance imaging  
10 labels.

In another embodiment, a phosphorylation site can be created on an antibody of the invention for labeling with  $^{32}\text{P}$ , e.g., as described in European Patent No. 0372707 (application No. 89311108.8) by Sidney Pestka, or U.S. Patent No. 5,459,240, issued October 17, 1995 to Foxwell *et al.*

15 As exemplified herein, proteins, including the *i*ENTPs of the present invention and antibodies thereto, can be labeled by metabolic labeling. Metabolic labeling occurs during *in vitro* incubation of the cells that express the protein in the presence of culture medium supplemented with a metabolic label, such as [ $^{35}\text{S}$ ]-methionine or [ $^{32}\text{P}$ ]-orthophosphate. In addition to metabolic (or biosynthetic) labeling with [ $^{35}\text{S}$ ]-methionine, the invention further  
20 contemplates labeling with [ $^{14}\text{C}$ ]-amino acids and [ $^3\text{H}$ ]-amino acids (with the tritium substituted at non-labile positions).

#### Solid Supports

A solid phase support for use in the present invention will be inert to the reaction conditions for binding. A solid phase support for use in the present invention must have reactive groups  
25 in order to attach a binding partner, such as an oligonucleotide encoding an *i*ENTP, an *i*ENTP, or an antibody to an *i*ENTP, or for attaching a linker or handle which can serve as the initial binding point for any of the foregoing. In another embodiment, the solid phase support may be a useful chromatographic support, such as the carbohydrate polymers



Identification and isolation of a gene encoding an *i*ENTP of the present invention provides for expression of *i*ENTP in quantities greater than can be isolated from natural sources, or in indicator cells that are specially engineered to indicate the activity of *i*ENTP expressed after transfection or transduction of the cells. Accordingly, in addition to rational design of permeants and/or inhibitors based on the structure of *i*ENTP, the present invention contemplates an alternative method for identifying specific ligands (including permeants and/or inhibitors and the like) of an *i*ENTP using various screening assays known in the art.

Any screening technique known in the art can be used to screen for ligands to an iENTP. The present invention contemplates screens for small molecule ligands or ligand analogs and mimics, as well as screens for natural ligands that bind to iENTP and its activity. Inhibitors can include analogues of lidoflazine, mioflazine, and draflazine and the like [Griffith *et al.*, *Biochem. Pharmacol.*, **40**:2297-2303 (1990); Baer *et al.*, *Naunyn Schmiedebergs Arch. Pharmacol.* **343**:365-369 (1991); Pirovano *et al.*, *Eur. J. Pharmacol. Mol. Pharmacol.*, **189**:419-422 (1990); Pirovano *et al.*, *Nucleosides Nucleotides*, **10**:1177-1179 (1991); Kruidering *et al.*, *Nucleosides Nucleotides*, **10**:1223-1224 (1991); Hammond, *J. Pharmacol. Exp. Ther.* **259**:799-807 (1991); Van Belle *et al.*, *Nucleosides Nucleotides*, **10**:975-982 (1991)]. Natural products libraries also can be screened using assays of the invention for

potential ligands to *i*ENTP. In addition, a large number of nucleoside analogues have been identified in the art and can be used in such screens.

Knowledge of the primary sequence of the *i*ENTPs of the present invention, and the similarity of that sequence with proteins of known function, can provide an initial clue as to  
5 new ligands of the protein. Identification and screening of ligands is further facilitated by determining structural features of the *i*ENTP, *e.g.*, using X-ray crystallography, neutron diffraction, nuclear magnetic resonance spectrometry, and other techniques for structure determination. These techniques provide for the rational design or identification of ligands.

Another approach uses recombinant bacteriophage to produce large libraries. Using the  
10 "phage method" [Scott and Smith, 1990, *Science* 249:386-390 (1990); Cwirla, *et al.*, *Proc. Natl. Acad. Sci.*, 87:6378-6382 (1990); Devlin *et al.*, *Science*, 249:404-406 (1990)], very large libraries can be constructed ( $10^6$ - $10^8$  chemical entities). A second approach uses primarily chemical methods, of which the Geysen method [Geysen *et al.*, *Molecular Immunology* 23:709-715 (1986); Geysen *et al.* *J. Immunologic Method* 102:259-274 (1987)]  
15 and the method of Fodor *et al.* [*Science* 251:767-773 (1991)] are examples. Furka *et al.* [*14th International Congress of Biochemistry, Volume 5*, Abstract FR:013 (1988); Furka, *Int. J. Peptide Protein Res.* 37:487-493 (1991)], Houghton [U.S. Patent No. 4,631,211, issued December 1986] and Rutter *et al.* [U.S. Patent No. 5,010,175, issued April 23, 1991] describe methods to produce a mixture of peptides that can be tested as agonists or antagonists.

20 In another aspect, synthetic libraries [Needels *et al.*, *Proc. Natl. Acad. Sci. USA* 90:10700-4 (1993); Ohlmeyer *et al.*, *Proc. Natl. Acad. Sci. USA* 90:10922-10926 (1993); Lam *et al.*, International Patent Publication No. WO 92/00252; Kocis *et al.*, International Patent Publication No. WO 9428028, each of which is incorporated herein by reference in its entirety], and the like can be used to screen for *i*ENTP ligands according to the present  
25 invention.

The screening can be performed with recombinant cells that express the *i*ENTP, or alternatively, using purified protein, *e.g.*, produced recombinantly, as described above or from natural sources. For example, the ability of labeled, soluble or solubilized *i*ENTP or fragment thereof that includes the permeant-binding portion of the molecule, to bind the

permeant or inhibitor thereto, can be used to screen libraries, as described in the foregoing references.

One such procedure comprises contacting a potential ligand with the isolated *i*ENTP under physiological conditions and detecting whether the potential ligand binds to the *i*ENTP. A  
5 potential ligand is selected as a ligand if it binds to the *i*ENTP. The binding can be detected with any of the standard protein-ligand binding assays known in the art as exemplified below. Either the *i*ENTP or the ligand can be appropriately labeled as described above. Similarly, either the *i*ENTP or ligand can be attached to a solid support. Once a ligand is identified, its dissociation constant can be determined. The ligand is selected when the  
10 dissociation constant is less than  $10^{-5}$  M.

The present invention also provides specific methods of identifying a permeant of an *i*ENTP using a recombinant cell that expresses the *i*ENTP, *i.e.*, a cell transfected or transduced with *i*ENTP. In one such method, a potential permeant is contacted with a transfected or transduced cell in which all detectable nucleoside transport activity is performed by the  
15 *i*ENTP. The nucleoside transport of the potential permeant is evaluated in the transfected or transduced cell. The potential permeant is identified as a permeant when the transport of the potential permeant in the transfected or transduced cell is determined to follow a facilitated diffusion process. Potential permeants can include antiviral nucleoside analogs, antitumor nucleoside analogs, or natural nucleosides. In preferred embodiments of this type, the  
20 transfected or transduced cell is a transfected or transduced human cell.

The present invention further provides specific methods for selecting a drug that inhibits an *i*ENTP using a recombinant cell that expresses the *i*ENTP as described above. In one such method, a potential drug is contacted with a transfected or transduced cell in which all detectable nucleoside transport activity is performed by the *i*ENTP. The nucleoside transport  
25 activity of the cell is evaluated. A potential drug is selected as a drug when a decrease in the nucleoside transport activity is determined relative to that determined when the evaluating was performed in the absence of the potential drug. The nucleoside transport activity of the transfected or transduced cell can be evaluated from any number of ways including: as a function of the determination of the trans-stimulation of a permeant; as a function of cell  
30 toxicity; as a function of the determination of the direct transport of a permeant, as a function of the determination of the countertransport of a permeant; as a function of the toxicity of a

nucleoside analog which is a permeant of the *i*ENTP, such as tubercidin, 2-chloro-2'-deoxyadenosine or Ara-C (wherein a two-fold change or greater is considered significant); or as a function of two or more of these determinations.

5 A drug can also be selected using the *i*ENTP-transfected or transduced cell described above by detecting the mutual inhibition (*i.e.* competition) of nucleoside transport in the transfected or transduced cell between a potential drug and a known permeant of the *i*ENTP (such as adenosine). A potential drug is selected as a drug when mutual inhibition is detected. The inhibition may be measured by any known means including those described above.

#### Transgenic Vectors and Gene Therapy

10 The functional activity of *i*ENTP can be evaluated transgenically. In this respect, a transgenic animal model can be used [Archibald *et al.*, Int. Pat. Publ. WO90/05188; Hurwitz *et al.*, Int. Pat. Publ. WO93/03164; Bleck *et al.*, U.S. Patent 5,530,177 issued June 25, 1996; Drohan *et al.* U.S. Patent 5,589,604]. The *i*ENTP gene can be used in complementation studies employing a transgenic mouse for example. Transgenic vectors, including viral  
15 vectors, or cosmid clones (or phage clones) corresponding to the wild type locus of candidate gene, can be constructed using the isolated *i*ENTP gene. Cosmids may be introduced into transgenic mice using published procedures [Jaenisch, *Science*, **240**:1468-1474 (1988)]. In a genetic sense, the transgene acts as a suppressor mutation.

Alternatively, a transgenic animal model can be prepared in which expression of the *i*ENTP  
20 gene is disrupted. Gene expression is disrupted, according to the invention, when no functional protein is expressed. One such method for preparing a such a "knockout mouse" is detailed by Capecchi *et al.*, in U.S. Patent 5,464,764. A standard procedure for evaluating the phenotypic effect of a gene product is to employ knock-out technology to delete the gene. Alternatively, recombinant techniques can be used to introduce mutations, such as nonsense  
25 and amber mutations, or mutations that lead to expression of an inactive protein.

The present invention also extends to the preparation of antisense nucleotides and ribozymes that may be used to interfere with the expression of the *i*ENTPs at the translational level. This approach utilizes antisense nucleic acid and ribozymes to block translation of a specific mRNA, either by masking that mRNA with an antisense nucleic acid or cleaving it with a  
30 ribozyme.

Antisense nucleic acids are DNA or RNA molecules that are complementary to at least a portion of a specific mRNA molecule [see Marcus-Sekura, *Anal. Biochem.* 172:298 (1988)]. In the cell, they hybridize to that mRNA, forming a double stranded molecule. The cell does not translate an mRNA in this double-stranded form. Therefore, antisense nucleic acids

5 interfere with the expression of mRNA into protein. Oligomers of about fifteen nucleotides and molecules that hybridize to the AUG initiation codon will be particularly efficient, since they are easy to synthesize and are likely to pose fewer problems than larger molecules when introducing them into organ cells. Antisense methods have been used to inhibit the expression of many genes *in vitro* [Marcus-Sekura, 1988, *supra*; Hambor *et al.*, *J. Exp. Med.*

10 168:1237 (1988)]. Preferably synthetic antisense nucleotides contain phosphoester analogs, such as phosphorothiolates, or thioesters, rather than natural phosphoester bonds. Such phosphoester bond analogs are more resistant to degradation, increasing the stability, and therefore the efficacy, of the antisense nucleic acids.

15 Ribozymes are RNA molecules possessing the ability to specifically cleave other single stranded RNA molecules in a manner somewhat analogous to DNA restriction endonucleases. Ribozymes were discovered from the observation that certain mRNAs have the ability to excise their own introns. By modifying the nucleotide sequence of these RNAs, researchers have been able to engineer molecules that recognize specific nucleotide

20 sequences in an RNA molecule and cleave it [Cech, *J. Am. Med. Assoc.* 260:3030 (1988)]. Because they are sequence-specific, only mRNAs with particular sequences are inactivated.

Investigators have identified two types of ribozymes, *Tetrahymena*-type and "hammerhead"-type. *Tetrahymena*-type ribozymes recognize four-base sequences, while "hammerhead"-type recognize eleven- to eighteen-base sequences. The longer the

25 recognition sequence, the more likely it is to occur exclusively in the target mRNA species. Therefore, hammerhead-type ribozymes are preferable to *Tetrahymena*-type ribozymes for inactivating a specific mRNA species, and eighteen base recognition sequences are preferable to shorter recognition sequences.

The DNA sequences encoding the *i*ENTPs described and enabled herein may thus be used to

30 prepare antisense molecules against and ribozymes that cleave mRNAs for the *i*ENTPs, thus inhibiting a cell from expressing the gene encoding the *i*ENTP, thereby hindering or curtailing the nucleoside transport of a specific nucleoside or nucleoside analog into the cell.

In one embodiment, a gene encoding an iENTP or active fragment thereof is introduced *in vivo* in a viral vector. Such vectors include an attenuated or defective DNA virus, such as but not limited to herpes simplex virus (HSV), papillomavirus, Epstein Barr virus (EBV), adenovirus, adeno-associated virus (AAV), and the like. Defective viruses, which entirely or almost entirely lack viral genes, are preferred. Defective virus is not infective after introduction into a cell. Use of defective viral vectors allows for administration to cells in a specific, localized area, without concern that the vector can infect other cells. Examples of particular vectors include, but are not limited to, a defective herpes virus 1 (HSV1) vector [Kaplitt *et al.*, *Molec. Cell. Neurosci.* 2:320-330 (1991)], an attenuated adenovirus vector, such as the vector described by Stratford-Perricaudet *et al.* [*J. Clin. Invest.* 90:626-630 (1992)], and a defective adeno-associated virus vector [Samulski *et al.*, *J. Virol.* 61:3096-3101 (1987); Samulski *et al.*, *J. Virol.* 63:3822-3828 (1989)].

Preferably, for *in vitro* administration, an appropriate immunosuppressive treatment is employed in conjunction with the viral vector, *e.g.*, adenovirus vector, to avoid immunodeactivation of the viral vector and transduced cells. For example, immunosuppressive cytokines, such as interleukin-12 (IL-12), interferon- $\gamma$  (IFN- $\gamma$ ), or anti-CD4 antibody, can be administered to block humoral or cellular immune responses to the viral vectors [see, *e.g.*, Wilson, *Nature Medicine* (1995)]. In addition, it is advantageous to employ a viral vector that is engineered to express a minimal number of antigens.

In another embodiment the gene can be introduced in a retroviral vector, *e.g.*, as described in Anderson *et al.*, U.S. Patent No. 5,399,346; Mann *et al.*, 1983, *Cell* 33:153; Temin *et al.*, U.S. Patent No. 4,650,764; Temin *et al.*, U.S. Patent No. 4,980,289; Markowitz *et al.*, 1988, *J. Virol.* 62:1120; Temin *et al.*, U.S. Patent No. 5,124,263; International Patent Publication No. WO 95/07358, published March 16, 1995, by Dougherty *et al.*; and Kuo *et al.*, 1993, *Blood* 82:845.

Targeted gene delivery is described in International Patent Publication WO 95/28494, published October 1995.

Alternatively, the vector can be introduced *in vivo* by lipofection. For the past decade, there has been increasing use of liposomes for encapsulation and transfection of nucleic acids *in vitro*. Synthetic cationic lipids designed to limit the difficulties and dangers encountered

with liposome mediated transfection can be used to prepare liposomes for *in vivo* transfection of a gene encoding a marker [Felgner, et. al., *Proc. Natl. Acad. Sci. U.S.A.* 84:7413-7417 (1987); see Mackey, et al., *Proc. Natl. Acad. Sci. U.S.A.* 85:8027-8031 (1988)]. The use of cationic lipids may promote encapsulation of negatively charged nucleic acids, and also

5 promote fusion with negatively charged cell membranes [Felgner and Ringold, *Science* 337:387-388 (1989)]. The use of lipofection to introduce exogenous genes into the specific organs *in vivo* has certain practical advantages. Molecular targeting of liposomes to specific cells represents one area of benefit. It is clear that directing transfection to particular cell

10 types would be particularly advantageous in a tissue with cellular heterogeneity, such as pancreas, liver, kidney, and the brain. Lipids may be chemically coupled to other molecules for the purpose of targeting [see Mackey, et. al., *supra*]. Targeted peptides, e.g., hormones or neurotransmitters, and proteins such as antibodies, or non-peptide molecules could be coupled to liposomes chemically.

It is also possible to introduce the vector *in vivo* as a naked DNA plasmid. Naked DNA

15 vectors for gene therapy can be introduced into the desired host cells by methods known in the art, e.g., transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun, or use of a DNA vector transporter [see, e.g., Wu et al., *J. Biol. Chem.* 267:963-967 (1992); Wu and Wu, *J. Biol. Chem.* 263:14621-14624 (1988); Hartmut et al., Canadian Patent Application No. 2,012,311,

20 filed March 15, 1990].

In a preferred embodiment of the present invention, a gene therapy vector as described above employs a transcription control sequence operably associated with the sequence for the *iENTP* inserted in the vector. That is, a specific expression vector of the present invention can be used in gene therapy.

25 Such an expression vector is particularly useful to regulate expression of a therapeutic *iENTP* gene. In one embodiment, the present invention contemplates constitutive expression of the *iENTP* gene, even if at low levels.

The present invention provides a method of using such expression vectors in cancer chemotherapy. Transducing normal hematopoietic stem cells *ex vivo*, with cDNA encoding

30 the NBMPR-insensitive equilibrative nucleoside transport protein, would offer protection to

- the transduced cells *in vivo*, during antimetabolite therapy that is coupled with the administration of NBMPR, a potent inhibitor of the es nucleoside transporter. The transduced cells, which express the *i*ENTP, would survive the NBMPR and antimetabolite therapy through the *i*ENTP-dependent salvage of nucleosides from exogenous pools. In contrast, untransduced cells and tumor cells which do not express the *i*ENTP, would be selectively diminished as the antimetabolite blocks *de novo* nucleoside biosynthesis, and NBMPR prevents nucleoside salvage *via* the es transporter.

- The dosage of NBMPR to be administered can be empirically determined with initial studies in mouse models, and then in higher mammals. These are the type of studies that have become routine for those having skill in the art of chemotherapy. For example, normal mice can be treated by intraperitoneal administration with varying doses of methotrexate (MTX; 20 mg/kg- 200 mg/kg) for five consecutive days, to determine cytotoxic effects on both normal myeloid progenitor cells and hematopoietic stem cells with this antimetabolite. Other nucleoside antimetabolites such as PALA, 5-fluorouracil, AraC, and AZT, can be similarly tested (as required) at clinically relevant dosages. The marrow from drug treated and untreated mice are examined for myeloid progenitor cell numbers to determine the degree of cytotoxic effects.

- NBMPR (0.1  $\mu$ M to 10  $\mu$ M) and draflazine (0.1  $\mu$ M to 10  $\mu$ M) can be added in conjunction with the antimetabolite (at concentrations found to be cytotoxic in the above study) to murine bone marrow cells in an *in vitro* culture system optimized using medium supplemented with hematopoietic growth factors (IL-3 at 20 ng/ml, human IL-6 at 50 ng/ml, rat SCF at 50 ng/ml) and fetal bovine serum. The effect of NBMPR or draflazine on potentiating the activity of the antimetabolites are assessed by cell count measurements over a 24 hour period after treatment.

- Hematopoietic stem cells can be transduced with either viral constructs (*e.g.*, retrovirus, adeno-associated virus or lenti virus) containing a nucleic acid encoding an *i*ENTP (*e.g.*, hENT2) or a control nucleic acid, *e.g.*, encoding MDR1 [Pastan *et al.*, *Proc. Nat. Acad. Sci.* **85**:4486 (1988)]. Mice can then be transplanted with either hENT2 or MDR1 transduced cells *e.g.*, the cells may be used as donors for bone marrow transplantation [Torok-Storb *et al.*, *Bone Marrow Transplant.* **14**: Suppl 4: S71-S73 (1994); Allay *et al.*, *Blood* **88**:645a (1996); PCT Application, US/96/17660, filed November 4, 1996 designating the United



States, entitled "*In Vivo* Selection of Primitive Hematopoietic Cells" having Sorrentino *et al.* as the Inventors, incorporated herein by reference in its entirety.] The mice are next subjected to antimetabolite treatment in the presence or absence of a nucleoside transport inhibitor (*e.g.*, NBMPR or draflazine) over a period of about 10 or more days, and at the concentrations determined above. The *in vivo* enrichment of myeloid progenitors is assessed by comparing marrow cellularities between untreated control mice, transduced mice treated with the nucleoside transport inhibitor, and transduced mice not treated with nucleoside transport inhibitor.

In a related aspect, the present invention provides a method of overcoming a major limitation to successful hematopoietic cell-directed gene therapy. This major limitation is inefficient gene transfer into repopulating stem cells. The method is based on the selection of cells that express a desired heterologous gene due to linkage of the heterologous gene to a gene that encodes an *i*ENTP.

Effective *in vivo* enrichment of transduced cells requires the elimination of unmodified hematopoietic cells. This can be effected by the administration of an antimetabolite such as trimetrexate (TMTX) in the presence of an *es* transporter inhibitor that preferentially inhibits the *es* transporter relative to the *i*ENTP, (*e.g.*, NBMPR). In the absence of expression of an *i*ENTP, such a regimen has been shown to be toxic to hematopoietic progenitor cells both *in vitro* and *in vivo* [Allay *et al.*, *Blood* 88:Supp.1, 645a (1996)]. In contrast, cells expressing *i*ENTP can rely on the *i*ENTP-dependent nucleoside salvage pathway in the presence of the inhibitors to *de novo* nucleoside synthesis and the *es* transporter-dependent nucleoside salvage pathway as described above. Therefore, linking the heterologous gene with the expression of the *i*ENTP will ensure that surviving hematopoietic cells contain the desired heterologous gene when the cells are treated with drugs such as TMTX and NBMPR as described above.

Various therapeutic heterologous genes can also be inserted in a gene therapy vector of the invention such as but not limited to adenosine deaminase (ADA) to treat severe combined immunodeficiency (SCID); marker genes or lymphokine genes into tumor infiltrating (TIL) T cells [Kasis *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 87:473 (1990); Culver *et al.*, *ibid.* 88:3155 (1991)]; genes for clotting factors such as Factor VIII and Factor IX for treating hemophilia [Dwarki *et al.* *Proc. Natl. Acad. Sci. USA*, 92:1023-1027 (1995); Thompson, *Thromb. and*

*Haemostatis*, 66:119-122 (1991)]; and various other well known therapeutic genes such as, but not limited to,  $\beta$ -globin, dystrophin, insulin, erythropoietin, growth hormone, glucocerebrosidase,  $\beta$ -glucuronidase,  $\alpha$ -antitrypsin, phenylalanine hydroxylase, tyrosine hydroxylase, ornithine transcarbamylase, apolipoproteins, and the like. In general, see U.S. Patent No. 5,399,346 to Anderson *et al.*

In another aspect, the present invention provides for regulated expression of the heterologous gene in concert with the expression of the *i*ENTP. The present invention provides for co-expression of *i*ENTP and a therapeutic heterologous gene under control of a specific DNA recognition sequence by providing a gene therapy expression vector comprising both a  
10 *i*ENTP coding gene and a gene under control of, *inter alia*, the *i*ENTP regulatory sequence. Concerted control of such heterologous genes may be particularly useful in the context of treatment for proliferative disorders, such as tumors and cancers, when the heterologous gene encodes a targeting marker or immunomodulatory cytokine that enhances targeting of the tumor cell by host immune system mechanisms. Examples of such heterologous genes for  
15 immunomodulatory (or immuno-effector) molecules include, but are not limited to, interferon- $\alpha$ , interferon- $\gamma$ , interferon- $\beta$ , interferon- $\omega$ , interferon- $\tau$ , tumor necrosis factor- $\alpha$ , tumor necrosis factor- $\beta$ , interleukin-2, interleukin-7, interleukin-12, interleukin-15, B7-1 T cell co-stimulatory molecule, B7-2 T cell co-stimulatory molecule, immune cell adhesion molecule (ICAM) -1 T cell co-stimulatory molecule, granulocyte colony stimulatory factor,  
20 granulocyte-macrophage colony stimulatory factor, and combinations thereof.

The present invention may be better understood by reference to the following non-limiting Examples, which are provided as exemplary of the invention. These examples are presented in order to more fully illustrate the preferred embodiments of the invention. They should in no way be construed, however, as limiting the broad scope of the invention.

25

#### EXAMPLE I

Molecular Cloning of the Equilibrative, Nitrobenzylmercaptapurineriboside (NBMPR)-  
Insensitive Nucleoside Transporter *ei*: a Delayed Early Response Gene

#### Introduction

Mammalian cells obtain nucleic acid precursors through the *de novo* synthesis of nucleotides  
30 and the salvage of exogenous nucleobases and nucleosides. The first step in the salvage of

nucleosides is their transport across the plasma membrane. Several nucleoside transport activities, including both equilibrative and concentrative mechanisms, have been identified by their functional properties. Until recently, however, little has been known about the proteins that mediate these transport processes. Two of the concentrative transporters have now been cloned, and just recently the equilibrative NBMPR-sensitive transporter *es* was cloned (Griffiths *et al.*, *Nature Med.* 3:89-93, 1997). The protein mediating equilibrative NBMPR-insensitive transport (*ei*), however, has remained elusive. The cloning of a 2522 basepair (bp) cDNA from HeLa cells that encodes a functional *ei* transport protein is disclosed in this example. This cDNA was cloned by complementation of a defect in nucleoside transport in subline of CEM human leukemia cells. The cDNA encodes a 456-residue protein with 10 to 11 predicted membrane-spanning regions. Stable expression of this cDNA in nucleoside transport-deficient CEM cells, as well as transient expression in COS cells, conferred equilibrative, NBMPR-insensitive transport activity to the cells.

The predicted protein is highly homologous (50% identity, 69% similarity) to the recently cloned human NBMPR-sensitive equilibrative nucleoside transporter hENT1, and thus has been designated hENT2. Surprisingly, the carboxy terminal portion of the predicted hENT2 protein is nearly identical to a 326 residue predicted peptide (hHNP36) in the Genbank database that has been identified as a growth factor-induced "delayed early response" gene of unknown function.

The transient transfection studies with full length hENT2 and a 5' truncated construct that lacks the first start codon (predicted protein 99% identical to hHP36) demonstrated that a functional nucleoside transport protein is not produced from the second start codon. These data suggest that the hHNP36 protein is a truncated, non-functional form of hENT2. Since the hHNP36 cDNA was originally cloned as a delayed early response gene (der12), hENT2 may be a delayed early response gene, and nucleoside transport may play an important role in the proliferative response when quiescent cells are stimulated into cycle by growth factors.

#### Materials and Methods

*Cells and Growth Conditions.* HeLa S3 cells and COS-1 cells from the American Type Culture Collection were grown at 37°C in a humidified air and 5% CO<sub>2</sub> atmosphere in Dulbecco's Modified Eagle Medium (D-MEM). For HeLa S3 cells the medium was supplemented with 10% heat-inactivated fetal calf serum and for COS-1 cells with 5% heat-

inactivated fetal calf serum *plus* 5% NuSerum IV (Collaborative Research Products). The CEM cell lines were grown as stationary suspension cultures at 37°C in a humidified air and 5% CO<sub>2</sub> atmosphere in RPMI 1640 medium supplemented with 10% heat-inactivated horse serum and the following additions: CEM/AraC-8C, 0.25 µM tubercidin [4-amino-7-β-D-ribofuranosylpyrolo[2,3-d|pyrimidine] /0.5 µM AraC [1-β-D-arabinofuranosylcytosine]; CEM/C-19 cells, 0.25 µM tubercidin/0.5 µM AraC/50 µg/ml G418; N-1-7, 20 µM DUP-785 [6-fluoro-2(2'-fluoro-1, 1'-biphenyl-4-yl)-3-methyl-4-quinoline carboxylic acid sodium salt]/100 µM uridine [Dexter *et al.* Cancer Res. 45:5563 (1985)]. The nucleoside transport deficient cell line CEM/AraC-8C [Ullman *et al.*, *J. Biol. Chem.* 263:12391-12396 (1988)] was provided by Dr. Buddy Ullman, Oregon Health Sciences University, Portland Or. DUP-785 was provided by the National Cancer Institute.

*Isolation of C-19 cells.* A mixture containing CEM/AraC-8C cells (2x10<sup>7</sup>) and 10 µg of a plasmid mixture consisting of Sca I-restricted pCMVEBNA (Clontech) and Sca I-restricted pRSVneo at a 20:1 molar ratio was electroporated at 190 V at a capacitance of 960 µF utilizing a Gene Pulsar obtained from BioRad. After a 48 hour of recovery, the cells were selected in medium containing 200 µg/ml of G418 (Geneticin, obtained from Life Technologies) for 25 days. Surviving cells were cloned by plating in soft agarose (0.35%) containing 200 µg/ml G418. After 21 days colonies were transferred to liquid culture and grown for characterization.

*Expression cloning.* A Clontech HeLa S3 cell c-DNA library in the pDR2 vector was transfected into C-19 cells (2x10<sup>8</sup>) by electroporation as described above. In bulk culture, the electroporated cells were sequentially selected in medium containing 200 µg/ml hygromycin B (14 days), 20 µM DUP-785/100 µM uridine (27 days) and finally 20 µM DUP-785/100 µM uridine/1 µM NBMPR [(nitrobenzylmercaptapurineriboside), 6-[(4-nitrobenzyl)thio-9-β-D-ribofuranosyl purine] (14 days). Plasmids were extracted (utilizing a QIA-prep Spin Plasmid Miniprep Kit, Qiagen) from cells surviving selection and, subsequently used to transform electrocompetent WM 1100 E. coli cells (obtained from BioRad). Plasmids from individual E. coli colonies were analyzed by restriction digestion with BamHI plus XbaI. Plasmids containing inserts were individually reintroduced into CEM/C19 cells which were then selected as before.

*Sequencing of the pDR2/N171 insert.* Both strands of the insert were sequenced to a level of 3 to 7-fold redundancy by Taq DyeDeoxy terminator cycle sequencing on an automated Model 373A DNA Sequencer, (obtained from Applied Biosystems).

*Northern analysis.* PolyA<sup>+</sup>-RNA was isolated from the indicated cell lines using the FastTrack 2.0 kit from Invitrogen. The RNA (2 µg/lane) was separated on a formaldehyde reducing 1% agarose gel and transferred to charged nylon membranes (obtained from Hybond-N, Amersham Corp.). A BamHI/NheI cDNA fragment (1.8 kb) encompassing nucleotides 393-2183 was gel purified and labeled with <sup>32</sup>P-dCTP using the PrimeIt kit from Strategene. Hybridization was carried out for 16 hours at 42° C in 50% formamide containing 10% dextran sulfate. The blot was washed at high stringency (0.2 X SSPE at 65° C) and analyzed using a PhosphorImager and ImageQuant software. A multiple human tissue blot (obtained from Clontech) with 2 µg of polyA<sup>+</sup> RNA/lane was also probed under identical conditions.

*Transient Expression in COS-1 cells:* The N1-71 clone contained a 1368 bp open reading frame with two potential start codons. The full orf plus the 3'-untranslated region were excised from pDR2/N1-71 in a BglII/XbaI fragment (bp 233-2605) and directionally cloned into the multicloning site of pcDNA3 (Invitrogen) to give pcDNA3/N171orf1. Likewise, the second start site and 3'-untranslated region were excised in a BglII/XbaI fragment (bp 1104-2605) and ligated into pcDNA3 to give pcDNA3/N171orf2. These constructs were transfected into COS-1 cells by the DEAE-dextran method and uptake of uridine determined as described by Fang *et al.* [Biochem. J. 317:457-465 (1996)].

## Results

*Cloning Strategy.* Since an NBMPR-insensitive equilibrative nucleoside transport protein had not previously been identified, and there were no antibodies or affinity probes available, a cloning strategy based on the functional expression of *ei* transport activity in a nucleoside transport deficient cell line was devised. A nucleoside transport deficient subline of the human T-cell leukemia CEM [Ullman *et al.*, J.Biol.Chem. 263:12391-12396 (1988)] was transfected with an EBNA-1 (Epstein-Barr Nuclear Antigen 1) expression cassette to produce a transport deficient cell line capable of supporting the episomal replication of the EBV-based mammalian expression vector pDR2. This cell line, designated CEM/C19, had a stable transfection frequency with pDR2 of approximately 10<sup>-2</sup>, which was four orders of magnitude

- greater than that of the parental EBNA-negative cell line. CEM/C19 cells were sensitive to the *de novo* uridylate synthesis inhibitor DUP-785, but could not be rescued from DUP-785 toxicity by uridine because of their transport defect. In contrast, transport competent CEM cells were readily rescued from DUP-785 toxicity by 100  $\mu$ M uridine. CEM/C19 cells were
- 5 transfected with a pDR2 human cDNA library from HeLa cells, which express *es* and *ei* transport activities [Dahlig-Harley *et al.*, *Biochem J.* **200**:295-305 (1981)] but do not have any detectable sodium-dependent nucleoside transport activity. Since CEM/C19 cells do not clone well in soft agar, batch cultures of transfected cells were subjected to sequential selection as follows: (1) hygromycin to select for transfected cells, (2) DUP-785 plus uridine
- 10 to select for cells expressing any nucleoside transporter (all known transporters accept uridine as a permeant), and (3) DUP-785 plus uridine and NBMPR to select for cells expressing NBMPR-insensitive uridine transport activity. Surviving cell cultures were screened for NBMPR-insensitive uridine uptake, and plasmids extracted from positive cultures and rescued back into *E. coli*. Plasmids isolated from individual *E. coli* colonies
- 15 were analyzed for the presence of inserts and reintroduced into CEM/C-19 cells. The cells were then selected for expression of NBMPR-insensitive uridine transport activity as before. A plasmid (pDR2/N1-7) containing a 2.6 Kb insert was identified that permitted cell survival upon reintroduction and selection. The cell line was designated CEM/N1-7 and used for further functional characterization of the plasmid.
- 20 *Uridine Transport in CEM/N1-7 Cells.* To confirm the presence of uridine transport activity in the transfected cells, uridine influx was compared in CEM/N1-7 and CEM/C19 cells (Figure 1A). CEM/N1-7 cells displayed a large component of uridine influx that was at least 10-fold greater than that of the CEM/C19 cells. Addition of a large excess of unlabeled uridine blocked uridine transport in the transfected cells, indicating the presence of a
- 25 saturable carrier mediated process; but had no effect on uridine uptake in CEM/C19 cells, suggesting that the slow rate of uptake was due to simple diffusion. Removal of sodium from the buffer had no effect on transport in CEM/N1-7 indicating the presence of an equilibrative type transporter. Addition of NBMPR at a concentration of 0.1  $\mu$ M, which is sufficient to block *es* mediated transport, had no effect on transport in CEM/N1-7 cells
- 30 (Figure 1B) suggesting that the cDNA insert encoded the NBMPR-insensitive equilibrative nucleoside transporter *ei*. Partial inhibition of transport at higher concentrations of NBMPR (Figure 1B) was also consistent with the described properties of the human *ei* transporter in HeLa cells where the  $IC_{50}$  values (concentration producing a 50% inhibition) for inhibition of

- uridine transport *via es* and *ei* are 1 nM and 6  $\mu$ M, respectively [Dahlig-Harley *et al.*, (1981), *supra*]. Also consistent with the *ei* transporter of HeLa cells [Dahlig-Harley *et al.*, (1981), *supra*], transport in CEM/N1-7 cells was completely blocked by 10  $\mu$ M DIP [dipyridamole, or bis(diethanolamino)-4,8-dipiperidinopyrimido-[5,4-d]-2,6-pyrimidine] (Figure 1B). As
- 5 expected from the permeant selectivity observed for *ei* activity in several cell lines [Plagemann *et al.*, *Biochim. Biophys. Acta*, 947:405-444; Cass, Nucleoside Transport in N.H. Gergopapadakou (ed.), Drug Transport in Antimicrobial Therapy and Anticancer Therapy, pp. 403-451, New York: Marcel Dekker (1995); Griffith and Jarvis, 1996, *supra*], uridine
- 10 influx in CEM/N1-7 cells was inhibited by both purine and pyrimidine nucleosides (Figure 1C), but not by the corresponding nucleotides. Interestingly, uridine transport in CEM/N1-7 cells was inhibited by the nucleobase hypoxanthine, but not by the other nucleobases tested (Figure 1C). While *ei* activity is generally considered a nucleoside transporter, previous
- studies have suggested that it may also transport hypoxanthine (reviewed in [Griffith and Jarvis, 1996, *supra*]). This was recently confirmed by Jarvis and colleagues [Osses *et al.*,
- 15 *Biochem. J.*, 317:843-848 (1996)] by direct measurements of hypoxanthine in human vascular endothelial cells. In summary, the uridine transport activity demonstrated in CEM/N1-7 cells was Na<sup>+</sup>-independent, inhibited by physiological nucleosides, such as hypoxanthine and dipyridamole, but relatively insensitive to inhibition by NBMPR. All these features are consistent with those of an *ei* transporter, *i.e.*, an iENTP.
- 20 *Rescue and analysis of the plasmid.* Plasmids were extracted from CEM/N1-7 cells and rescued back into *E. coli*. Restriction analysis of the plasmids from individual *E. coli* colonies demonstrated the presence of a single plasmid containing a 2.6 Kb insert which appeared to be identical to the plasmid initially introduced into CEM/C19 cells to create the CEM/N1-7 cell line. The insert from one of the recovered cloned plasmids (designated N1-
- 25 71) was sequenced. The N1-71 cDNA was 2522 basepairs and contained a 1368 basepair open reading frame that encodes a 456 residue protein with 10 to 11 predicted membrane spanning regions (Figure 2).
- The N1-71 protein exhibits 50% identity (69% similarity) to the recently cloned human NBMPR sensitive nucleoside transport protein hENT1, Figure 2 [Griffiths *et al. Nature Med.*
- 30 3:89-93 (1997)], and thus has been designated hENT2, as a member of this family of proteins. As noted previously members of this family can also be found in yeast and nematodes [Griffiths *et al.* (1997), *supra*]. Analysis of the aligned sequences shown in

Figure 2 predict 10 transmembrane domains for this family of proteins, although analysis of either hENT1 [Griffiths *et al.* (1997), *supra*] or hENT2 alone predict 11 transmembrane domains. As seen with other membrane transporter families, the most highly conserved regions of the ENT proteins fall in the transmembrane domains. All members of the family have an extracellular loop, with an N-glycosylation site between transmembrane domains 1 and 2 in nine of the ten reported family members. The length of the extracellular loop is variable, and there is very little conservation of sequence within the loop except for the N-glycosylation site.

Surprisingly, the carboxy terminal portion of the predicted hENT2 protein is also nearly identical to a 326 amino acid residue predicted peptide (hHNP36) in the Genbank database that has been identified as a growth factor-induced "delayed early response" gene of unknown function [Williams *et al.*, *Biochem. Biophys. Res. Comm.*, **213**:325-333 (1995)]. Inspection of the hHNP36 nucleotide sequence revealed two potential open reading frames with hHNP36 translated from the second start codon. While hENT2 also has two potential start codons, they are within the same open reading frame. The full length cDNA of hHNP36 (2281 bp) is nearly identical to hENT2, but contains a 68 bp deletion beginning at position 338. This deletion shifts initial reading frames relative to hENT2 and would result in a truncated 22 Kd protein with only 51% identity to the hENT2 protein. Transient transfection studies with full length hENT2 and a 5'-truncated construct that lacks the first start codon (predicted protein 99% identical to hHNP36 (Figure 3)) demonstrated that a functional nucleoside transport protein is not produced from the second start codon. These data suggest that the hHNP36 protein is a truncated, non-functional form of hENT2.

*Expression of hENT2 in human cell lines and tissues.* Northern blots of polyA<sup>+</sup> RNA from HeLa, parental CEM cells, the transport deficient recipient cell line CEM/C19, and the stable transfectant CEM/N1-7 were probed at high stringency using a <sup>32</sup>P labeled BamHI/NheI fragment of N1-71 that encompasses 90% of the coding region of hENT2. As shown in Figure 4A, a single transcript of approximately 2.6 Kb was identified in HeLa cells, the cell line from which the cDNA library was derived. A slightly larger transcript (approximately 3.0 Kb) was observed in the stable transfectant CEM/N1-7. The larger size of the message in CEM/N1-7 cells can be accounted for by the fact that in these cells the message is derived from transcriptional start and termination sites of the pDR2 vector, which adds approximately 460 nucleotides to the insert. These data indicate that N1-71 represents the



full length cDNA for the *ei* transporter. As shown in Figure 4A, no message was detected in the transport deficient recipient cell line CFM/C19.

The tissue distribution of the *ei* transporter was examined using human multiple tissue blots from CLONTECH (Fig. 4B). As expected from previous functional studies of *ei* transport activity in cultured cell lines, ENT2 was found to be expressed in a number of tissues, and the level of expression was variable among tissues. A message of about 2.6 kbp was detected in most tissues, but a larger transcript ( $\approx 4$  kbp) was also observed in thymus, prostate, heart, brain, lung, skeletal muscle, and pancreas. The highest level of ENT2 expression was in skeletal muscle, with the 2.6-kbp message predominating. The high level of expression in skeletal muscle was unexpected, as this tissue is composed of nondividing, terminally differentiated cells. It is possible, however, that the ENT2 transporter plays a role in the efflux of inosine and hypoxanthine from muscle cells during the net degradation of purine nucleotides that occurs during strenuous exercise and/or in the re-uptake of these purines during the recovery process [Arabadjis *et al.*, *Am. J. Physiol.*, **264**:C1246-C1251 (1993); Norman *et al.*, *Clin. Physiol.*, **7**:503-510 (1987)].

## EXAMPLE 2

### Protection of hematopoietic stem cells with a cDNA encoding a NBMPR-insensitive equilibrative nucleoside transport (*i*ENTP) for use in Chemotherapy:

#### Introduction

Antimetabolites such as trimetrexate, methotrexate, PALA and 5-fluorouracil are commonly used in the clinical treatment neoplastic disorders, including cancers. These drugs were designed to block *de novo* nucleotide synthesis, and thereby prevent the proliferation of the otherwise rapidly replicating tumor cells. One common problem associated with such treatments arises when the targeted tumor cells circumvent the cytotoxic effects of the *de novo* synthesis inhibitor by acquiring purine and pyrimidine nucleosides from exogenous pools through a nucleoside salvage pathway. In fact, tumor cells commonly express significant levels of nucleoside transporters.

Furthermore, nucleoside analogs such as cytosine arabinoside (Ara-C), 2-Chloro-2'-deoxyadenosine, AZT, and ddI are commonly used to treat viral and neoplastic disorders

including AIDS and cancers. Nucleoside transporters are involved in the uptake and efflux of these drugs by cells. Thus the administration of NBMPR following the cytotoxic nucleoside may enhance the activity of these drugs by blocking their exit from the cell and prolonging the exposure of the cellular targets to the drug and its active metabolites.

- 5 The major form of nucleoside transport seen in 9/9 leukemia, 4/4 rhabdomyosarcoma and 4/4 colon carcinoma cell lines is performed by an NBMPR-sensitive, equilibrative (es) transporter [Belt *et al. Advan. Enzyme Regul.*, 33:235-252 (1993)]. Therefore, supplementing the antimetabolite regimen with NBMPR serves to potentiate the desired cytotoxic effects in the tumor cells. Unfortunately, the es transporter is also the major  
10 nucleoside transporter in normal bone marrow cells [Belt *et al. Advan. Enzyme Regul.*, 33:235-252 (1993)], and thus administering NBMPR with the antimetabolites also potentiates an undesired cytotoxic effect in normal myeloid progenitors in bone marrow cells. Described herein, is a method of clinically treating viral and neoplastic disorders, including cancers and AIDS, which allows for the potentiation of the desired cytotoxic  
15 effects of antimetabolites in tumor cells by co-administering NBMPR, which also protects the hematopoietic stem cells from the undesired cytotoxic effects of such treatment.

#### Materials and Methods

*Treatment of normal myeloid progenitor cells with antimetabolites to determine resistance.*

- Normal mice are treated by intraperitoneal administration with varying doses of methotrexate  
20 (MTX; 20 mg/kg- 200 mg/kg) for five consecutive days, to determine cytotoxic effects on normal myeloid progenitor cells and hematopoietic stem cells with this antimetabolite. Other nucleoside antimetabolites such as trimetrexate, PALA, 5-fluorouracil, AraC, and AZT, are similarly tested (as required) at clinically relevant dosages. The marrow from drug treated and untreated mice are examined for myeloid progenitor cell numbers to determine the  
25 degree of cytotoxic effects.

*The use of NBMPR or draflazine to potentiate the activity of antimetabolite in vitro.* NBMPR (0.1  $\mu$ M to 10  $\mu$ M) and/or draflazine (0.1  $\mu$ M to 10  $\mu$ M) are added in conjunction with (or directly before or after) an antimetabolite to murine bone marrow cells in an *in vitro* culture system optimized using medium supplemented with hematopoietic growth factors (IL-3 at 20  
30 ng/ml, human IL-6 at 50 ng/ml, rat SCF at 50 ng/ml) and fetal bovine serum. The concentration of antimetabolite used is that found to be cytotoxic in the above study. The

effect of NBMPR or draflazine on potentiating the activity of the antimetabolites are assessed by cell count measurements over a 24 hour period after treatment.

*In vivo selection of myeloid progenitor cells using hENT2 cDNA.* Hematopoietic stem cells are transduced with either viral constructs (retrovirus, adeno-associated virus or lenti virus) containing a nucleic acid encoding an *i*ENTP (e.g., hENT2) or a control nucleic acid (e.g., encoding MDR1). Mice are then transplanted with either hENT2 or MDR1 transduced cells e.g., the cells may be used as donors for bone marrow transplantation [Torok-Storb *et al.*, *Bone Marrow Transplant.* 14: Suppl 4: S71-S73 (1994); Allay *et al.*, *Blood* 88:645a (1996); PCT Application, US/96/17660, filed November 4, 1996 designating the United States, entitled "*In Vivo* Selection of Primitive Hematopoietic Cells" having Sorrentino *et al.* as the Inventors, incorporated herein by reference in its entirety]. The mice are next subjected to antimetabolite treatment in the presence of a nucleoside transport inhibitor (the antimetabolite and the nucleoside transport inhibitor also may be administered separately) or in the absence of a nucleoside transport inhibitor, e.g., NBMPR or draflazine, over a period of about 10 days or more, and at the concentrations determined above. The *in vivo* enrichment of myeloid progenitors is assessed by comparing marrow cellularities between untreated control mice, transduced mice treated with the nucleoside transport inhibitor, and transduced mice not treated with nucleoside transporter inhibitor.

#### Results

The solution presented herein relies on the transduction of normal hematopoietic stem cells *ex vivo* with a cDNA encoding an *i*ENTP. Such a transduced cell when transplanted expresses *i*ENTP *in vivo* and is thereby protected from the antimetabolite/NBMPR treatment by the *i*ENTP-dependent nucleoside salvage pathway. In contrast, untransduced cells and tumor cells which do not express *i*ENTP are selected against, due to the blockage of both their *de novo* nucleoside biosynthesis and their NBMPR-sensitive nucleoside salvage pathway by the nucleoside antimetabolite/NBMPR treatment. In the case of the nucleoside analogs, the transduced hematopoietic stem cells are protected by the efflux of the nucleoside analogs, *via* the *i*ENTP-dependent transport pathway. Untransduced cells and tumor cells are selected against due to the retention of the nucleoside analog and its active metabolites in the cells when the NBMPR-sensitive transport pathway is blocked by NBMPR.

The dosage of NBMPR to be administered is empirically determined by studies in a murine models first, as described Materials and Methods, and subsequently in higher mammals and humans. The use of a nucleoside transporter to provide protection in hematopoietic stem cells provides for the use of any antimetabolite, and in particular, methotrexate, trimetrexate, 5-PALA, 2CDA, ddC, and 5-fluorouracil which have already been used in the clinic for the treatment of neoplastic and viral disorders.

Figure 5 is a schematic depicting the *in vivo* results following the *ex vivo* transduction of normal CD34 positive hematopoietic stem cells with viral vectors containing a nucleic acid encoding hENT2. Re-transplantation of the transduced cells is followed by intraperitoneally administering an antimetabolite (MTX, trimetrexate, 5-FU or PALA) together with a nucleoside transport inhibitor (e.g., NBMPR or draflazine). The combination of the antimetabolite and the nucleoside transport inhibitor selectively enriches for the hENT2 transduced cells which are resistant to both NBMPR and draflazine. These transduced cells are thereby protected from the antimetabolite/NBMPR regimen by the NBMPR-insensitive hENT2-dependent nucleoside salvage pathway which transports purine and pyrimidine nucleosides from exogenous pools through the plasma membrane.

### EXAMPLE 3

#### Isolation of a BAC containing the *i*ENTP gene

An *i*ENTP cDNA was used to screen a BAC library (Genome Systems, Inc.). Of the three clones identified, one clone contained both the 5' and 3' - UTR (SEQ ID NO:5 and SEQ ID NO:10) as determined by Southern Analysis and PCR.

PCR sequencing of the BAC using *i*ENTP primers identified 11 introns from the 5' UTR to 3' UTR nucleic acid. A BAC-specific primer for *i*ENTP was used to identify a 2.4 kilobase sequence 5 prime to the cDNA (SEQ ID NO:6). In all, the *i*ENTP gene was found to have at least 11 kilobases with 12 exons and 11 introns (Figure 6).

EXAMPLE 4Alternative splice sites

An alternative splice variant was identified in Thymus cells. A nucleic acid was identified having the nucleotide sequence of SEQ ID NO:9. A nucleotide sequence of SEQ ID NO:7  
5 was then deduced which has the amino acid sequence of SEQ ID NO:8. A schematic drawing of the alternatively spliced nucleic acid is shown in Figure 7. The identification of this alternative splice site indicates that there is tissue specific regulation of iENTP expression with alternative splicing.

10 While the invention has been described and illustrated herein by references to the specific embodiments, various specific material, procedures and examples, it is understood that the invention is not restricted to the particular material combinations of material, and procedures selected for that purpose. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

It is further to be understood that all base sizes or amino acid sizes, and all molecular weight or molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided for description.

Various publications, patent applications and patents are cited herein, the disclosures of which are incorporated by reference in their entireties.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Belt, Judith A.  
Crawford, Charles R.  
Patel, Divyen
- (ii) TITLE OF INVENTION: A NITROBENZYL MERCAPTOPYRIMIDINE NUCLEOSIDE  
(NBMPR)-INSENSITIVE, EQUILIBRATIVE, NUCLEOSIDE TRANSPORT  
PROTEIN, NUCLEIC ACIDS ENCODING THE SAME AND METHODS OF  
USE
- (iii) NUMBER OF SEQUENCES: 22
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: David A. Jackson, Esq.
  - (B) STREET: 411 Hackensack Ave, Continental Plaza, 4th  
Floor
  - (C) CITY: Hackensack
  - (D) STATE: New Jersey
  - (E) COUNTRY: USA
  - (F) ZIP: 07601
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER: US
  - (B) FILING DATE:
  - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Jackson Esq., David A.
  - (B) REGISTRATION NUMBER: 26,742
  - (C) REFERENCE/DOCKET NUMBER: 1340-1-013 PCT
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: 201-487-5800
  - (B) TELEFAX: 201-343-1684

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 2522 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GGATCCGCGG TGGCGCGACC CTCTGTCCCC GCCTCGGGGC GGAGCCCAGG TCCCAGCCTG	60
CGGAGCGCGA GACACGCCGA AATCCGCCCC AGGCTACCTG TGC GACTCCA GCCGCCCTGC	120
ACCGGAATCT GGGGAGACCC GCCCCCGGCC CCACCGGTCT GCGGCCCTCC GCCCCAGCGC	180
AGGTGCAGGT GCGGCTTCTC TGCCCCCTTC ACCCCAGGCG CATCCGCCGC GGCGGCCATG	240
GCGCGAGGAG ACGCCCCGCG GGACAGCTAC CACCTGGTCG GGATCAGCTT CTTTCATCCTG	300
GGGCTGGGCA CCCTCCTTCC CTGGAAGTTC TTCATCACCG CCATCCCGTA CTTCCAGGCG	360
CGACTGGCCG GGGCCGGCAA CAGCACAGCC AGGATCCTGA GCACCAACCA CACGGGTCCC	420
GAGGATGCCT TCAACTTCAA CAATTGGGTG ACGCTGCTGT CCCAGCTGCC CTTGCTGCTC	480
TTCACCTCC TCAACTCCTT CCTGTACCAG TCGTCCCGG AGACGGTGCG CATTCTGGGC	540
AGCCTGCTGG CCATACTGCT GCTCTTTGCC CTGACAGCAG CGCTGGTCAA GGTGGACATG	600
AGCCCCGGAC CTTTCTTCTC CATCACCATG GCCTCCGTCT GCTTCATCAA CTCCTTCAGT	660
GCAGTCCTAC AGGGCAGCCT CTTGCGGCAG CTGGGCACCA TGCCCTCCAC CTACAGCACC	720
CTCTTCTCA GCGGCCAGGG CCTGGCTGGG ATCTTTGCTG CCCTTGCCAT GCTCCTGTCC	780
ATGGCCAGTG GCGTGGACGC CGAGACCTCT GCCCTGGGGT ACTTTATCAC GCCCTGTGTG	840
GGCATCCTCA TGTCCATCGT GTGTTACCTG AGCCTGCCTC ACCTGAAGTT TGCCCGCTAC	900
TACCTGGCCA ATAAATCATC CCAGGCCCAA GCTCAGGAGC TGGAGACCAA AGCTGAGCTC	960
CTCCAGTCTG ATGAGAACGG GATTCCCAGT AGTCCCAGA AAGTAGCTCT GACCCTGGAT	1020
CTTGACCTGG AGAAGGAGCC GGAATCAGAG CCAGATGAGC CCCAGAAGCC AGGAAAACCT	1080
TCAGTCTTCA CTGTCTTCCA GAAGATCTGG CTGACAGCGC TGTGCCTTGT GTTGGTCTTC	1140
ACAGTCACCC TGTCCGTCTT CCCC GCCATC ACAGCCATGG TGACCAGCTC CACCAGTCCT	1200
GGGAAGTGGA GTCAGTTCTT CAACCCCATC TGCTGCTTCC TCCTCTTCAA CATCATGGAC	1260
TGGCTGGGAC GGAGCCTGAC CTCTTACTTC CTGTGGCCAG ACGAGGACAG CCGGCTGCTG	1320
CCCCTGCTGG TCTGCCTGCG GTTCCTGTTC GTGCCCTCT TCATGCTGTG CCACTGCCCC	1380
CAGAGGTCCC GGCTGCCCAT CCTCTTCCCA CAGGATGCCT ACTTCATCAC CTTTCATGCTG	1440

CTCTTTGCCG TTTCTAATGG CTACCTGGTG TCCCTCACCA TGTGCCTGGC GCCCAGGCAG	1500
GTGCTGCCAC ACGAGAGGGA GGTGGCCGGC GCCCTCATGA CCTTCTTCCT GGCCCTGGGA	1560
CTTTCCTGTG GAGCCTCCCT CTCCTTCCTC TTCAAGGCGC TGCTCTGAAG TGGCCCCCTCC	1620
AGGCTCTTTG GCAGCCTCTT CTCGACGTCT CCTTCCGGAG CTGAGATCCA GCCCAGGGCG	1680
AATGGCGAGC TTGGCTCAGG CCTCTGCGGG GTGGAGGCCC CTGGGCCTGA GGCTGCCAGC	1740
AGCGGGCAGG AGCTGCTCTT CATCCACTTG GAGTGCTGCG GGGAAGAAAT CACCACCGGT	1800
CATTCTAACC CTCACCCAGG AATGGGGGTG ACTCGACAA GACCTCATGG AAAGGGTGAT	1860
GACTAGGGAA AAGAGGGTGC AGGGCACGGC TGCTCCCCAC CACCAGGTCT GCATTTGTTC	1920
ATCATCATCA GGAGCAGAGG TGACCAGAGG GTTCAGAGTG GGAGGCAGGG CCAGCCCAGG	1980
CCAGGAGCGC CTCATCTTCC CAGGCCTCAG CCACCCAGGG TAAAAGGTGC CAGGGAAGTT	2040
GTGGGCACCT GAGAGGAGGA ACAGATGTGG AGGACCTGAG GGTGCTCAA GGGCCAGGCT	2100
CAGCCTCAAG CAGTGTTTTT ATTGCCAACA CTTACTGTAC CCACTCCGCA GAGCCCCGCT	2160
GGGCCTGGGC CCCAGGGCCA CAGCTAGCCT GCATGTGTGT ACTGCACTTT ACAGTTTGCA	2220
AAGCTCTTCC ATACCCACTC TCTCACCGAA GCCTAATTGA GGCTCTTGA AGGAGTCAGG	2280
CAAGGATTGT GCTTCCCCCA TTATACAGGT GACAAAAGTG AGTCCTGGGG AAAGTGACTG	2340
GTCCGTGGTA GAGCCGGGAC CCAATCCCCT CTCTCTCCTC CCTGTTGGTG CTGTTCTTCC	2400
TGCCAACAC CTGTTTCTCT TTTCTCAAG GGGTTTGGGG CAGGAGCCTG GGCATTACT	2460
CCCCGTTTTT GCTGTTTCTC CTTCTGACCC TGCTCTTGGG TCTAATAACC CCATTTATTT	2520
GT	2522

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 456 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

- (A) DESCRIPTION: hENT2

## (iii) HYPOTHETICAL: NO

## (v) FRAGMENT TYPE:

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens



(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

Met Ala Arg Gly Asp Ala Pro Arg Asp Ser Tyr His Leu Val Gly Ile
1           5           10           15

Ser Phe Phe Ile Leu Gly Leu Gly Thr Leu Leu Pro Trp Asn Phe Phe
20           25           30

Ile Thr Ala Ile Pro Tyr Phe Gln Ala Arg Leu Ala Gly Ala Gly Asn
35           40           45

Ser Thr Ala Arg Ile Leu Ser Thr Asn His Thr Gly Pro Glu Asp Ala
50           55           60

Phe Asn Phe Asn Asn Trp Val Thr Leu Leu Ser Gln Leu Pro Leu Leu
65           70           75           80

Leu Phe Thr Leu Leu Asn Ser Phe Leu Tyr Gln Cys Val Pro Glu Thr
85           90           95

Val Arg Ile Leu Gly Ser Leu Leu Ala Ile Leu Leu Leu Phe Ala Leu
100          105          110

Thr Ala Ala Leu Val Lys Val Asp Met Ser Pro Gly Pro Phe Phe Ser
115          120          125

Ile Thr Met Ala Ser Val Cys Phe Ile Asn Ser Phe Ser Ala Val Leu
130          135          140

Gln Gly Ser Leu Phe Gly Gln Leu Gly Thr Met Pro Ser Thr Tyr Ser
145          150          155          160

Thr Leu Phe Leu Ser Gly Gln Gly Leu Ala Gly Ile Phe Ala Ala Leu
165          170          175

Ala Met Leu Leu Ser Met Ala Ser Gly Val Asp Ala Glu Thr Ser Ala
180          185          190

Leu Gly Tyr Phe Ile Thr Pro Cys Val Gly Ile Leu Met Ser Ile Val
195          200          205

Cys Tyr Leu Ser Leu Pro His Leu Lys Phe Ala Arg Tyr Tyr Leu Ala
210          215          220

Asn Lys Ser Ser Gln Ala Gln Ala Gln Glu Leu Glu Thr Lys Ala Glu
225          230          235          240

Leu Leu Gln Ser Asp Glu Asn Gly Ile Pro Ser Ser Pro Gln Lys Val
245          250          255

Ala Leu Thr Leu Asp Leu Asp Leu Glu Lys Glu Pro Glu Ser Glu Pro
260          265          270

Asp Glu Pro Gln Lys Pro Gly Lys Pro Ser Val Phe Thr Val Phe Gln
275          280          285

```

Lys Ile Trp Leu Thr Ala Leu Cys Leu Val Leu Val Phe Thr Val Thr  
 290 295 300  
 Leu Ser Val Phe Pro Ala Ile Thr Ala Met Val Thr Ser Ser Thr Ser  
 305 310 315 320  
 Pro Gly Lys Trp Ser Gln Phe Phe Asn Pro Ile Cys Cys Phe Leu Leu  
 325 330 335  
 Phe Asn Ile Met Asp Trp Leu Gly Arg Ser Leu Thr Ser Tyr Phe Leu  
 340 345 350  
 Trp Pro Asp Glu Asp Ser Arg Leu Leu Pro Leu Leu Val Cys Leu Arg  
 355 360 365  
 Phe Leu Phe Val Pro Leu Phe Met Leu Cys His Val Pro Gln Arg Ser  
 370 375 380  
 Arg Leu Pro Ile Leu Phe Pro Gln Asp Ala Tyr Phe Ile Thr Phe Met  
 385 390 395 400  
 Leu Leu Phe Ala Val Ser Asn Gly Tyr Leu Val Ser Leu Thr Met Cys  
 405 410 415  
 Leu Ala Pro Arg Gln Val Leu Pro His Glu Arg Glu Val Ala Gly Ala  
 420 425 430  
 Leu Met Thr Phe Phe Leu Ala Leu Gly Leu Ser Cys Gly Ala Ser Leu  
 435 440 445  
 Ser Phe Leu Phe Lys Ala Leu Leu  
 450 455

## (2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 326 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein
- (A) DESCRIPTION: hHNP36

(iii) HYPOTHETICAL: NO

(v) FRAGMENT TYPE:

- (vi) ORIGINAL SOURCE:
- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met Ala Ser Val Cys Phe Ile Asn Ser Phe Ser Ala Val Leu Gln Gly

1	5	10	15
Ser Leu Phe Gly Gln Leu Gly Thr Met Pro Ser Thr Tyr Ser Thr Leu	20	25	30
Phe Leu Ser Gly Gln Gly Leu Ala Gly Ile Phe Ala Ala Leu Ala Met	35	40	45
Leu Leu Ser Met Ala Ser Gly Val Asp Ala Glu Thr Ser Ala Leu Gly	50	55	60
Tyr Phe Ile Thr Pro Tyr Val Gly Ile Leu Met Ser Ile Val Cys Tyr	65	70	75
Leu Ser Leu Pro His Leu Lys Phe Ala Arg Tyr Tyr Leu Ala Asn Lys	85	90	95
Ser Ser Gln Ala Gln Ala Gln Glu Leu Glu Thr Lys Ala Glu Leu Leu	100	105	110
Gln Ser Asp Glu Asn Gly Ile Pro Ser Ser Pro Gln Lys Val Ala Leu	115	120	125
Thr Leu Asp Leu Asp Leu Glu Lys Glu Pro Glu Ser Glu Pro Asp Glu	130	135	140
Pro Gln Lys Pro Gly Lys Pro Ser Val Phe Thr Val Phe Gln Lys Ile	145	150	155
Trp Leu Thr Ala Leu Cys Leu Val Leu Val Phe Thr Val Thr Leu Ser	165	170	175
Val Phe Pro Ala Ile Thr Ala Met Val Thr Ser Ser Thr Ser Pro Gly	180	185	190
Lys Trp Ser Gln Phe Phe Asn Pro Ile Cys Cys Phe Leu Leu Phe Asn	195	200	205
Ile Met Asp Trp Leu Gly Arg Ser Leu Thr Ser Tyr Phe Leu Trp Pro	210	215	220
Asp Glu Asp Ser Arg Leu Leu Pro Leu Leu Val Cys Leu Arg Phe Leu	225	230	235
Phe Val Pro Leu Phe Met Leu Cys His Val Pro Gln Arg Ser Arg Leu	245	250	255
Pro Ile Leu Phe Pro Gln Asp Ala Tyr Phe Ile Thr Phe Met Leu Leu	260	265	270
Phe Ala Val Ser Asn Gly Tyr Leu Val Ser Leu Thr Met Cys Leu Ala	275	280	285
Pro Arg Gln Val Leu Pro His Glu Arg Glu Val Ala Gly Ala Leu Met	290	295	300

Thr Phe Phe Leu Ala Leu Gly Leu Ser Cys Gly Ala Ser Leu Ser Phe  
 305 310 315 320

Leu Phe Lys Ala Leu Leu  
 325

## (2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 456 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

(A) DESCRIPTION: hENT1

## (iii) HYPOTHETICAL: NO

## (v) FRAGMENT TYPE:

## (vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Thr Thr Ser His Gln Pro Gln Asp Arg Tyr Lys Ala Val Trp Leu  
 1 5 10 15

Ile Phe Phe Met Leu Gly Leu Gly Thr Leu Leu Pro Trp Asn Phe Phe  
 20 25 30

Met Thr Ala Thr Gln Tyr Phe Thr Asn Arg Leu Asp Met Ser Gln Asn  
 35 40 45

Val Ser Leu Val Thr Ala Glu Leu Ser Lys Asp Ala Gln Ala Ser Ala  
 50 55 60

Ala Pro Ala Ala Pro Leu Pro Glu Arg Asn Ser Leu Ser Ala Ile Phe  
 65 70 75 80

Asn Asn Val Met Thr Leu Cys Ala Met Leu Pro Leu Leu Leu Phe Thr  
 85 90 95

Tyr Leu Asn Ser Phe Leu His Gln Arg Ile Pro Gln Ser Val Arg Ile  
 100 105 110

Leu Gly Ser Leu Val Ala Ile Leu Leu Val Phe Leu Ile Thr Ala Ile  
 115 120 125

Leu Val Lys Val Gln Leu Asp Ala Leu Pro Phe Phe Val Ile Thr Met  
 130 135 140

Ile Lys Ile Val Leu Ile Asn Ser Phe Gly Ala Ile Leu Gln Gly Ser

145	150	155	160
Leu Phe Gly Leu Ala Gly Leu Leu Pro Ala Ser Tyr Thr Ala Pro Ile	165	170	175
Met Ser Gly Gln Gly Leu Ala Gly Phe Phe Ala Ser Val Ala Met Ile	180	185	190
Cys Ala Ile Ala Ser Gly Ser Glu Leu Ser Glu Ser Ala Phe Gly Tyr	195	200	205
Phe Ile Thr Ala Cys Ala Val Ile Ile Leu Thr Ile Ile Cys Tyr Leu	210	215	220
Gly Leu Pro Arg Leu Glu Phe Tyr Arg Tyr Tyr Gln Gln Leu Lys Leu	225	230	235
Glu Gly Pro Gly Glu Gln Glu Thr Lys Leu Asp Leu Ile Ser Lys Gly	245	250	255
Glu Glu Pro Arg Ala Gly Lys Glu Glu Ser Gly Val Ser Val Ser Asn	260	265	270
Ser Gln Pro Thr Asn Glu Ser His Ser Ile Lys Ala Ile Leu Lys Asn	275	280	285
Ile Ser Val Leu Ala Phe Ser Val Cys Phe Ile Phe Thr Ile Thr Ile	290	295	300
Gly Met Phe Pro Ala Val Thr Val Glu Val Lys Ser Ser Ile Ala Gly	305	310	315
Ser Ser Thr Trp Glu Arg Tyr Phe Ile Pro Val Ser Cys Phe Leu Thr	325	330	335
Phe Asn Ile Phe Asp Trp Leu Gly Arg Ser Leu Thr Ala Val Phe Met	340	345	350
Trp Pro Gly Lys Asp Ser Arg Trp Leu Pro Ser Leu Val Leu Ala Arg	355	360	365
Leu Val Phe Val Pro Leu Leu Leu Leu Cys Asn Ile Lys Pro Arg Arg	370	375	380
Tyr Leu Thr Val Val Phe Glu His Asp Ala Trp Phe Ile Phe Phe Met	385	390	395
Ala Ala Phe Ala Phe Ser Asn Gly Tyr Leu Ala Ser Leu Cys Met Cys	405	410	415
Phe Gly Pro Lys Lys Val Lys Pro Ala Glu Ala Glu Thr Ala Gly Ala	420	425	430
Ile Met Ala Phe Phe Leu Cys Leu Gly Leu Ala Leu Gly Ala Val Phe	435	440	445

Ser Phe Leu Phe Arg Ala Ile Val  
450 455

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GGATCCGCGG TGGCGCGACC CTCTGTCCCC GCCTCGGGGC GGAGCCCAGG TCCCAGCCTG	60
CGGAGCGCGA GACACGCCGA AATCCGCCCG AGGCTACCTG TGCCTACTCA GCCGCCCTGC	120
ACCGGAATCT GGGGAGACCC GCGCCCGCC CCACCGGTCT GCGGCCCTCC GCGCCAGCGC	180
AGGTGCAGGT GCGGCTTCTC TGCCCCCTTC ACCCCAGGCG CATCCGCCGC GGCGGCCATG	240
GCGCGAGGAG ACGCCCCGCG GGACAGGTGA GTGGGCCCCG GTGCGTTGCA AGTGCCCGG	300
GGCGTTGCAG ACCCGCTCCC TGAAGGCGCT CCGAGGCTCA GAGAAGACCG GATCGAACTA	360
CAATTCCCAT CAGCCGACTC CCTCGGCCGC CGGAACCGGG GTGATGGGGG TTGTAGTCCG	420
CTCCGGAGGG GGTGGCCTGG GAGGCGGGAG GGCCTGCGGA GGCGGGTGCG TCCTCGGGGT	480
GACCTTCCCA CCGATCCCA CAGCTACCAC CTGGTCGGGA TCAGCTTCTT CATCCTGGGG	540
CTGGGCACCC TCCTTCCCTG GAACTTCTTC ATCACCGCCA TCCCGGTGAG ACTCCTGGCG	600
GCGTGGCAGC CTCGTGGCCA CAGCCAGCAC CCCTCCCTCC AGCCCTTTGG ATGAAGCTTA	660
GCGGGCGCTT CCTCACCGCG CACCTGTGAC CCCTCGTTGA GCTCATTATG GGCTGAAGCT	720
CGGAGAGGGG AATGCTTCCC CCGTGGCTAG GAAAGTAGAA CTTAGCAAT GCCACATCT	780
CAGAGGGGCA AGGCCACCAG CCCACAGGGT CTGGAATGAG CAAAGGCGCT GCCACCCCTC	840
TCTGTGTGTC GTTATTCCTG AGTCAGTCAC CCAAAAGTC GGTATCGAA CGTTTGATTT	900
TCTTTGAAAT ACCATGAATT TCATTATTC ACTCATTCAT TCAACAACT TTTTTTTTTT	960
TTTTTTTTTT GAGACAGAGT CTGGCTCTTT CGCCAGGCT GGAGTGCAGT GGCGCCATCT	1020
CGGCTCACTG CAAGCTCCGC CTCCCGGGTT CACGCCATTC TCCTGCCTCA CCCTCCCGAG	1080
TAGCTGGGAC TACAGGCGCC CGCCGCCACG CGCGGCTATT TTTTTTTGTA TTTTAGTAG	1140
AGACGGGGTT TCACCGTGTG AGCCAGGATG GTCTCGATCT CCTGACCTCG TGATCCTCCC	1200
GCCTCGGCCT CCCAAAGTGC TGGGATTACA GCGTGAGCC ACCGTGCCCA GCCTCATTCA	1260
ACAACTTTT AGTGTGCATC TACTGTGGAG CAGGCACTGG GGACACAGGA GGAAACAGCA	1320
GGGAGGCTCT TCAGGGAAGG CAGAAATGTG GGGTTTGCAT TGTCTTTGGG ACCGGGTAT	1380
TCATCTGTAT TCACTGCAAC AACTTTGCAA ATGCTTCTTG GGTACTGGCT CTGTGCTGGG	1440
CCCTGGAAAC CCAGAGATGA ATCAGCCCTT GGGCTTGAGA GCAAGAAGGG GCCAAAGAGC	1500
TATTAATAAT GTAACATGAT GCGTGACATT CCAGGCTTGG AGCAGAGTGC AGTGGGTCCC	1560

CAGGGAAGGA	GAAAGTTCCT	TCTGCTTCAT	GGAAGAGGAG	ATTTGTAAAT	TGGGAGTAGG	1620
GTAGGCAAAG	TGCGTGTGGA	GGGGTGTGGT	CAGTAGGGCA	TTCCAAGCCG	AGGCGACAGC	1680
CATGCCAAAG	GCAGGCAGGC	AAGAGACGAT	CAGCCTGTTT	AGAGGGAGAT	TCCACAGCCA	1740
GGGCTGCCTG	GAGCTTAGCA	GGATGGAGCA	GAAGATGGGG	CACAAAGGGA	GACTAGGATC	1800
TGATTCTGAA	GAGCTGTTCC	ATTTGGGGCT	TTGCCCTGCA	GGCAATAGGG	AGGCATGAAT	1860
CGGGGTGTTG	AGGAGTGAGG	AGGTTAAGCA	GAGGAGTGGC	AGGCTATGTG	CTCTAGAGAG	1920
AATGCAGTTG	TTCAGCACTT	AGGCCAAAGC	CTGGCTTGAC	AGTAGGCGCT	CAATAAATAC	1980
CCGTGGAATG	AATGAATGTA	GCAGCTGCTG	CAGGAGTGGG	GATGGGGGCT	GGAACCAGGG	2040
CACTGAAGAG	GAGGGGCCGT	CCAAGGCTGG	ATCGAGGCTC	TTGCTGGGGG	CTCTTAATGC	2100
TTAGGCTGTG	TCCCAGACTT	CAGCCATTTA	ACTCAGCACA	CATTCATGGA	GCTCCGACTG	2160
TGTGCCGGCT	GCTGGGAACA	GAACAAGGGC	AAGGCAGACA	AGTCCCCACA	GACATTAGAA	2220
AGCAATCACA	AGTGAGGGGG	AAGGCAGCGG	GGGAAGGCTG	AGAGGTGCTG	ACCCTCCACC	2280
ACCTCCCTAC	CTGGCAGTAC	TTCCAGGCGC	GACTGGCCGG	GGCCGGCAAC	AGCACAGCCA	2340
GGATCCTGAG	CACCAACCAC	ACGGGTCCCG	AGGATGCCTT	CAACTTCAAC	AATTGGGTGA	2400
CGTGCTGTG	CCAGCTGCCC	CTGCTGCTCT	TCACCCTCCT	CAACTCCTTC	CTGTACCAGT	2460
GGTGAGAGGC	CTGCCCTGGC	TCCTGCGCCC	TCTGCCGAGG	CAGCTTCATT	GAGGCCCTCC	2520
CCTGCGCCCC	CTGCCCTCCA	GCCCTACTGC	CCAGCCCCAG	GTGTCGAGCC	TCCTTCCCCA	2580
GCCCCCTCTG	GCCTGGGCCC	CACCTGATGCA	CTCTGCCTGC	TTCTGAGCAA	GCGTCCCGGA	2640
GACGGTGCGC	ATTCTGGGCA	GCCTGCTGGC	CATACTGCTG	CTCTTTGCCC	TGACAGCAGC	2700
GCTGGTCAAG	GTGGACATGA	GCCCCGGACC	CTTCTTCTCC	ATCACCATGG	CCTCCGTCTG	2760
CTTCATCAAC	TGTGAGCACC	TCCACCCCCT	CTCCAGCCAG	CCTATGCAGG	GCTTCAGCCT	2820
GGCCTCATCA	TTGAAAGGGC	CCAGCATATC	CGAGAAGGGC	AGACAGCATC	ATGGTCGCTC	2880
ATATCCCTGG	TGAAGAAACT	GAGGCCACCA	GGGAGGGGAA	GAGTCACTTG	TCCGGTGACC	2940
TAGGAGCAGG	CCTCCTGGTC	AACAGCCCCA	CAGACCAATG	GCTGCACCTC	AGAAGAGGAC	3000
TGAATAGCGG	GTGTTGCCCC	CGAGTGCTCA	GAGTCCCTAG	GGAAGCTCAC	ACCTGCGCAA	3060
CCTGTGCCAG	AGTCCCCTGT	GTATCCTGCC	GGCACCTCCT	CCAGGGAGCC	TCTGAGTCTT	3120
GCCTAGTTGA	GCAGCAGCCC	CCATCCCTGT	CCTCCACAGC	CTTCAGTGCA	GTCCCTACAGG	3180
GCAGCCTCTT	CGGGCAGCTG	GGCACCATGC	CCTCCACCTA	CAGCACCTC	TTCCTCAGCG	3240

GCCAGGGCCT	GGCTGGGATC	TTTGCTGCCC	TGCCATGCT	CCTGTCCATG	GCCAGTGAGT	3300
GCACTTGGGT	GGCTGGGAGG	GCTGGGGTGG	CCTCTGAGGT	TTGGGGAAGA	GAGAGGGCAT	3360
GTGAGAGCAA	GACACATGGG	TTCTGGGTGA	AGATGGAGGT	AAGCGGGTGA	TATGGAAATG	3420
GGGATTGGTC	TGGGGCTAGG	GAATGGGGCT	CATGGGCCCT	GCAGTGAGGA	GTAATAACCA	3480
AGTGAGGACT	GGGTTAACTC	AGGGACAGGG	GCAGGATTCC	TGGGGCTAAT	ACTGGCATGT	3540
GGCAGCAGGT	TGAAGTTGAA	GGATAAGGGG	ATGGGTTTGG	GATTCAAGATA	GTCTTGGGTT	3600
TGAATCTGCT	TCACCGCTTA	CCAGCTAGGG	GTGTTGGACA	AGGCTTGTC	CCTCTCTGTG	3660
CTAGCTTCCC	CACCGATGTG	ATTGGTACAG	CTCCCTGCTC	AGATTGTAAT	GAGCATGCAA	3720
TGAGAGAAGG	CTACTGGCAC	ATAGTACGTG	CTCAACAAAA	ATGACACATG	GGGAAAGTGA	3780
GAGAAGTGCA	GGGCTGCTCT	GGGGCCCTGT	ACAAGATTCC	CATTTGTCAG	TGAAGGGAGG	3840
AGCGGAAGAG	GCTGGGAGTG	GCTCTGAGAA	GTACACAATG	GGAAGTGGGA	CAAGAGTTGG	3900
AAGCCCCGTG	GGAGCCGGCG	GGACCAGGTG	CCTCTCTTCT	GCAGCTGAAG	TTCCTCCGCA	3960
GGTGGCGTGG	ACGCCGAGAC	CTCTGCCCTG	GGGTACTTTA	TCACGCCCTG	TGTGGGCATC	4020
CTCATGTCCA	TCGTGTGTTA	CCTGAGCCTG	CCTCACCTGG	TGAGCCTGCT	GTTGGGCTCG	4080
AGGCCCCACC	TCAAAGCATC	TTGGATAGAG	TCCTGAGCCT	GAAGCCCTGA	GAGAGGCCAG	4140
GGGAGGTGGA	GGAGACCTGG	TCTCAGCCCT	GACCCCCAGA	GAAGACACTG	AGGGGGCCCCA	4200
GCCTCCAGGC	CAATGGTATG	GGGAGGGATC	CAGACACCTC	AGGCAAGCCA	GGCAGGCCCA	4260
ACACTTTCTCT	GTCTTTCTGC	AGAAGTTTGC	CCGCTACTAC	CTGGCCAATA	AATCATCCCA	4320
GGCCCCAAGCT	CAGGAGCTGG	AGACCAAAGC	TGAGCTCCTC	CAGTCTGGTA	AGCCCTGAGA	4380
CCCTCCTGGG	GAGGTGGGAG	ATGCAGAGGA	AGCTAGAGCC	ACCTCCCCTG	GGAAGCTGTT	4440
CCATCTGTTC	CCAGCCAGAG	CCCACCCCTA	GTAGCCTTGT	GCAAACAGGA	AGATCATGAA	4500
GGGAAGTTGG	TAGGATTAAA	GTCATCCCTG	CTGTTGTTTG	GGCCTCAGTT	TCCACCTCTA	4560
TAAAAATGGGG	AGGCGACAGA	AGTTCCATGC	ATGCAAACTT	TGGATCGAAG	ACCTCTGAAT	4620
TGGAATACTA	GTTTCACAAC	ATCCCRGCTG	TGTGGCCTGA	GACAAACCAC	TTAGCCACTG	4680
CACCCCTCTG	AACCTCAATG	TGTCATTTGT	AAAGCAATGG	TAATGAGATA	ATCCATCTAA	4740
GGTGCTTCGC	TCATCACCCG	ACCCATGCAC	GCGCTTCTGG	TAGCTATGCA	TATTTCCATC	4800
ATGAATTCCC	TTGCGCTGCA	GCCTCAGCTT	AGGCTGGAGG	AAGATCACCT	TTTTTTGTTT	4860
TGGGGTGAGG	GGGTTGTTGT	TATTTTGAGT	CAGGATCTCA	CTCTGTCACC	TAGGCTGCAC	4920



TGCAGTGCTA	TCACAACCTCA	ACTGCAGCTT	CGACCTTCTG	GGCTCAAGTG	AGCCACCTCA	4980
GTCTCCCGAG	TAGCTGGGAC	TATAGGTGCA	GGCTGCCATG	CCCGGCTAAT	TTTTTTATTT	5040
TTGTAGAGAT	GGTGATTCAC	CATGTTGCCC	AGGCTGGTCT	CGAACTCCTG	GGCTCAAGCA	5100
ATATGCCCCG	TTCGGCCTTC	CAAAATGTTG	GGATTACAGG	CGTGAGCCAC	CATGCCGAGC	5160
TGAGGATCAC	TTGTTTTAAC	TGCTGGGAAT	CTCCCTTCGT	TGGGCCTGGC	TGTCGGGAAA	5220
CCTGGGTCAC	AAGCATGACC	CTTCCCCGTC	CCCCCTCACC	CCAGATGAGA	ACGGGATTCC	5280
CAGTAGTCCC	CAGAAAGTAG	CTCTGACCCT	GGATCTTGAC	CTGGAGAAGG	AGCCGGAATC	5340
AGAGCCAGAT	GAGCCCCAGA	AGCCAGGAAA	ACCTTCAGTC	TTCACTGTCT	TCCAGAAGGT	5400
TTGGCTTGGA	TACAGCCCCC	AACCACCATC	TTTGGGGAAG	AATGGGGCTC	ACATTGACTC	5460
CAAGGTCATA	GGGTCACAGT	GGGTCAGGGA	CACAGCTGGG	CCAGGCCCCA	AGTGTCTTGC	5520
TCCCACATGG	GGCTTGGGCA	AGAGGGTGGG	GCCCTGGGAC	TGCCCTGCCT	GCTCACACCC	5580
CTGCCTCYGG	CTCCCAGATC	TGGCTGACAG	CGCTGTGCCT	TGTGTTGGTC	TTCACAGTCA	5640
CCCTGTCCGT	CTTCCCCGCC	ATCACAGCCA	TGGTGACCAG	CTCCACCAGT	CCTGGGAAGT	5700
GGAGTGAGTG	TCAGGGTGGA	GAAGACGGCA	GGGCAGGGGG	TACAAAGGGG	AGAGGACGGG	5760
AGAGGGGAGT	TGGAGACCAG	TATGAGCTGC	AGCCGTTTCC	CTCCCAGGTC	AGTTCTTCAA	5820
CCCCATCTGC	TGCTTCCTCC	TCTTCAACAT	CATGGACTGG	CTGGGACGGA	GCCTGACCTC	5880
TTACTTCCTG	TGGGTAAGCA	CACCAGGGCT	GGGTGATCCG	ATGTTTTAGG	AAGCAGTTTG	5940
GGATCCGAGG	GCTTGAAAGA	GCACGGAGGT	GATTTTCTGG	TAGTCCAAGT	GGCCTGGTAA	6000
TGCAACCACT	GGCCAAGCAG	CAGGGAGCAC	TTGGGCCCTG	GAGGCGTGCA	AGGCCAGGGC	6060
TTGCACTGTG	AGCTCCCTGA	AAGCAAAAAT	CATGTCCAGC	TGACCTCTGT	GTCCCCAGCA	6120
TCCAGCCTTT	GCTGCTCAGA	GAATGTTACA	TGGAGGTTCC	TGCACCAGGT	GAGGGACTGA	6180
GCAAGATCTT	AGTTTGGGG	TTGGTTTTAG	CCATGGTGCT	GTATCTTTAA	ATGAAATCTT	6240
CCAAAGAGAC	AATACATAAC	GCAGGTGAAA	GANGANCTGG	TCTCATCCAA	GTCAGGACAN	6300
NGAGCTGATC	TACAGCTTCC	AATCCCACTC	AGAAACCCTC	TGCCCCCAAN	GGGG	6354

## (2) INFORMATION FOR SEQ ID NO:6:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2140 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CATAGGGACC TAGTAAACA AATTAAAGTG GTAGTTATTT GGATCAGTGA TAACTAATTC	60
TTATAATTTT TGCAGATGGA ATTGGCTGCT CTAGAAAAAA TTAAATCTAC TTGGATTAAA	120
AACCAAGATG ACAGCTTGAC TGAACAGAC ACTCTGGTAT GTATGGGTCA GTTTCCTGTT	180
TCAGCTGTTT CAAATAGTGT TTGTCCCTTT AGAAATAACG GCAGAAGGAC CCTCAGGACC	240
ACCATAGAAA TTTCACCTAA ATCTGCAGGC TTATGAATGT CCTGCACTCT CNTTCTCCTG	300
AAATCCTTAC CCCGTGGAAT GCAACCTACT ACCTGGGTGT AGACACCAAG TTGCTCTCAA	360
ACTTAGTATA CCAGAAATGT CCTCATTCTG CCCTTTAATA AGAGCTGACC AAATGCTAGC	420
TGGGGAAACT TCTCACCATC TGTCAACAGC GTTCTCCCTG GAAAACATCC CTTCTCAAT	480
TGGGATGTTG CTGTTTCCCG TGGGCCAAGG CAACCCACAA CATTCAAGTC TCGACTGGTA	540
CTGGTCCGTG TTCTTAAGAG GTGCTGGAGC TGCCCAAGGA GTGCAGGCTT AARCCCAGT	600
GAAGTGGAAT TGAGTTGGTT GGGATGCCCA GTTTTTTTAC AGGGTCGAAT TGCACAAACA	660
TTTACTGTGC CCCTGCTTGT GTTGGGCACT GAAGATGCRA ACATGAGTGA GCCACAGTTT	720
GCATCCCCTG TACCTCCGGC CCCAGGGAGG TACAGGGGAT GCAAACTGGA GAAGCGACAT	780
CTGAGCTGGG CTTTGCGGGT TACGTCAAAG TTCATCCCGT GGGACCAGAG GCAGGACCCT	840
TGTGGGGAAG GAGCATAGAA CTTTACAGAA TGCCATCTAG GGATGAGCCT CACGGTGGGA	900
CCTGCTGGGA GTTGACTAGA ATCTGTGAAA GAATTATTTT AAGCCTTATG TTTTCTATAG	960
TAAATAAGAC TACATTTAAA GATCTTATGT ATTTAGGCTT GATTCAAGAT TAATTTGAAA	1020
CTCACTACCC TAACTTACAT TTTCTAGTTC ACCAGGTAAT CTGAATAATC CTACTTCCAC	1080
CGTGGCCCCA CTGTAGTCCG TACTGCACGT GGCAAGTACA GTGTGSCCTT TTCAAAATTA	1140
AATTCCAATT GTGTCACTTC CTGATTAAAA CTCTTCAGTG ATTGGCCAAA TCTCAGCAAT	1200
TTAATGTTGA GTGAGTAAAA AGAAGCCGGA ATGCCAAAAA ATGCACGCCA TAGGATTCCA	1260
GTTCTGTGAA ACTCACAAAC AGGCAAAACT AATCCATGAG GGTGACGTCA GCATACCTTG	1320
TTACCCAGG GGGAGAGGGA GGGGCATCGG GAGGCCTCAG GAATGCTGGA ACGTTCTGTC	1380
TTGATCTGGT TAATGGTCAC CTGGGGGCAT ATTTGCATAA AAATTCAAGT TGACTATTNT	1440

AGATTTGTGC TTCTTACTTT ATAGAAGTTA TTCCCTCAGT AAACATTTTG AAAACATAAA 1500  
GACCAGGCAG AGGCAGGGAA GTAGGCAGGT GTGCGGCCTG TATTGGTAGC AGAGTCCTCC 1560  
CTGAGGGCTG GATCATTAGG GAGGTAGTGG GCCCAGGGAG GAGGCACGGG AGGTTAATTT 1620  
AGAAAGGTGG CCCAGGCTGG GTCATGGTGG CCTCAGAGGC CCCACTAAAG AATCAGACTT 1680  
GGCCAGGTGT GGTGGCTCAC ACCTGTAATC CCAGTACTTT TGGGAGGCTG AGGCAGGCAC 1740  
ATTGTTTGAG CCTGGGGATT CAAGACCAGC CCGGGCAACA TGGGAAAAAC CCSGTCTCTA 1800  
CAAAAAAAAA AAAAAAAAAA AATAGTAATA CAAAAAATT AGCCAGGCAT GCTGACATGC 1860  
ACCTGTACTT GGAAGGCTGA GGTAAGATAA CCACTTGAGC CCAGGAGTTC AAGGCTGCAG 1920  
TGAGCTGAGA CCATGCCACT GCACTNCAGG CTGTGCAAGA GAGCAAGACC CTGTCTAAAA 1980  
AAAATTTAAA AGGATGTCAG GAATTAGGCT GGGGGCGGTG GTTCATGCCT GTAATCCCAG 2040  
CACTTTGGGA GGCCGAGGCG GCGGGTTCC GCAGGCCCT AGGTGGGGCG GGGCCGAGC 2100  
CAGAGTCGAG TCCCTGAGGC GGGTGGGGGA AGGAGAGACG 2140

## (2) INFORMATION FOR SEQ ID NO:7:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1272 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (iii) HYPOTHETICAL: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CTAGAATTCA GCGGCCGCTG AATTCTAGGG CATCCTCATG TCCATCGTGT GTTACCTGAG 60  
CCTGCCTCAC CTGAAGTTTG CCCGCTACTA CCTGGCCAAT AAATCATCCC AGGCCCAAGC 120  
TCAGGAGCTG GAGACCAAAG CTGAGCTCCT CCAGTCTGGT AAGCCCTGAG ACCCTCCTGG 180  
GGAGGTGGGA GATGCAGAGG AAGCTAGAGC CACCTCCCCT GGGAAGCTGT TCCATCTGTT 240  
CCCAGCCAGA GCCCACCCCT AGTAGCCTTG TGCAAACAGG AAGATCATGA AGGGAAGTTG 300  
GTAGGATTAAG AGTCATCCCT GCTGTTGTTT GGGCCTCAGT TTCCACCTCT ATAAAATGGG 360  
GAGGCGACAG AAGTTCCATG CATGCAAACCT TTGGATCGAA GACCTCTGAA TTGGAATACT 420  
AGTTTCACAA CATCCCRGCT GTGTGGCCTG AGACAAACCA CTTAGCCACT GCACCCCTCT 480

```

GAACCTCAAT GTGTCATTTG TAAAGCAATG GTAATGAGAT AATCCATCTA AGGTGCTTCG      540
CTCATCACCC GACCCATGCA CGCGCTTCTG GTAGCTATGC ATATTTCCAT CATGAATTCC      600
CTTCGCCTGC AGCCTCAGCT TAGGCTGGAG GAAGATCACC TTTTTTGT TTTGGGTGAG      660
GGGGTTGTTG TTATTTTGAG TCAGGATCTC ACTCTGTCAC CTAGGCTGCA CTGCAGTGCT      720
ATCACAACTC AACTGCAGCT TCGACCTTCT GGGCTCAAGT GAGCCACCTC AGTCTCCCGA      780
GTAGCTGGGA CTATAGGTGC AGGCTGCCAT GCCCGGCTAA TTTTTTATT TTTGTAGAGA      840
TGGTGATTCA CCATGTTGCC CAGGCTGGTC TCGAACTCCT GGGCTCAAGC AATATGCCCC      900
CTTCGGCCTT CCAAATGTT GGGATTACAG GCGTGAGCCA CCATGCCGAG CTGAGGATCA      960
CTTGTTTAA CTGCTGGGAA TCTCCCTTCG TTGGGCCTGG CTGTCGGGAA ACCTGGGTCA     1020
CAAGCATGAC CCTTCCCCGT CCCCCCTCAC CCCAGATGAG AACGGGATTC CCAGTAGTCC     1080
CCAGAAAGTA GCTCTGACCC TGGATCTTGA CCTGGAGAAG GAGCCGGAAT CAGAGCCAGA     1140
TGAGCCCCAG AAGCCAGGAA AACCTTCAGT CTTCACTGTC TTCCAGAAGA TCTGGCTGAC     1200
AGCGCTGTGC CTTGTGTTGG TCTTCACAGT CACCCTGTCC GTCTTCCCCG CCATCACAGC     1260
CATGGTGACC AG                                                    1272

```

## (2) INFORMATION FOR SEQ ID NO:8:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 247 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (iii) HYPOTHETICAL: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

```

Met Ala Arg Gly Asp Ala Pro Arg Asp Ser Tyr His Leu Val Gly Ile
1           5           10           15

Ser Phe Phe Ile Leu Gly Leu Gly Thr Leu Leu Pro Trp Asn Phe Phe
20          25          30

Ile Thr Ala Ile Pro Tyr Phe Gln Ala Arg Leu Ala Gly Ala Gly Asn
35          40          45

Ser Thr Ala Arg Ile Leu Ser Thr Asn His Thr Gly Pro Glu Asp Ala
50          55          60

```

Phe Asn Phe Asn Asn Trp Val Thr Leu Leu Ser Gln Leu Pro Leu Leu  
 65 70 75 80  
 Leu Phe Thr Leu Leu Asn Ser Phe Leu Tyr Gln Cys Val Pro Glu Thr  
 85 90 95  
 Val Arg Ile Leu Gly Ser Leu Leu Ala Ile Leu Leu Leu Phe Ala Leu  
 100 105 110  
 Thr Ala Ala Leu Val Lys Val Asp Met Ser Pro Gly Pro Phe Phe Ser  
 115 120 125  
 Ile Thr Met Ala Ser Val Cys Phe Ile Asn Ser Phe Ser Ala Val Leu  
 130 135 140  
 Gln Gly Ser Leu Phe Gly Gln Leu Gly Thr Met Pro Ser Thr Tyr Ser  
 145 150 155 160  
 Thr Leu Phe Leu Ser Gly Gln Gly Leu Ala Gly Ile Phe Ala Ala Leu  
 165 170 175  
 Ala Met Leu Leu Ser Met Ala Ser Gly Val Asp Ala Glu Thr Ser Ala  
 180 185 190  
 Leu Gly Tyr Phe Ile Thr Pro Cys Val Gly Ile Leu Met Ser Ile Val  
 195 200 205  
 Cys Tyr Leu Ser Leu Pro His Leu Lys Phe Ala Arg Tyr Tyr Leu Ala  
 210 215 220  
 Asn Lys Ser Ser Gln Ala Gln Ala Gln Glu Leu Glu Thr Lys Ala Glu  
 225 230 235 240  
 Leu Leu Gln Ser Gly Lys Pro  
 245

## (2) INFORMATION FOR SEQ ID NO:9:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1847 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (iii) HYPOTHETICAL: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

ATGGCGCGAG GAGACGCCCC GCGGGACAGC TACCACCTGG TCGGGATCAG CTTCTTCATC 60  
 CTGGGGCTGG GCACCCTCCT TCCCTGGAAC TTCTTCATCA CCGCCATCCC GTACTTCCAG 120

GCGCGACTGG	CCGGGGCCGG	CAACAGCACA	GCCAGGATCC	TGAGCACCAA	CCACACGGGT	180
CCCGAGGATG	CCTTCAACTT	CAACAATTGG	GTGACGCTGC	TGTCCCAGCT	GCCCCTGCTG	240
CTCTTCACCC	TCCTCAACTC	CTTCCTGTAC	CAGTGCGTCC	CGGAGACGGT	GCGCATTCTG	300
GGCAGCCTGC	TGGCCATACT	GCTGCTCTTT	GCCCTGACAG	CAGCGCTGGT	CAAGGTGGAC	360
ATGAGCCCCG	GACCCTTCTT	CTCCATCACC	ATGGCCTCCG	TCTGCTTCAT	CAACTCCTTC	420
AGTGCAGTCC	TACAGGGCAG	CCTCTTCGGG	CAGCTGGGCA	CCATGCCCTC	CACCTACAGC	480
ACCCTCTTCC	TCAGCGGCCA	GGGCCTGGCT	GGGATCTTTG	CTGCCCTTGC	CATGCTCCTG	540
TCCATGGCCA	GTGGCGTGGA	CGCCGAGACC	TCTGCCCTGG	GGTACTTTAT	CACGCCCTGT	600
GTGGGCATCC	TCATGTCCAT	CGTGTGTTAC	CTGAGCCTGC	CTCACCTGAA	GTTTGCCCGC	660
TACTACCTGG	CCAATAAATC	ATCCCAGGCC	CAAGCTCAGG	AGCTGGAGAC	CAAAGCTGAG	720
CTCCTCCAGT	CTGSTAAGCC	CTGAGACCCT	CCTGGGGAGG	TGGGAGATGC	AGAGGAAGCT	780
AGAGCCACCT	CCCCTGGGAA	GCTGTTCCAT	CTGTTCCAG	CCAGAGCCCA	CCCCTAGTAG	840
CCTTGTGCAA	ACAGGAAGAT	CATGAAGGGA	AGTTGGTAGG	ATTAAAGTCA	TCCCTGCTGT	900
TGTTTGGGCC	TCAGTTTCCA	CCTCTATAAA	ATGGGGAGGC	GACAGAAGTT	CCATGCATGC	960
AAACTTTGGA	TCGAAGACCT	CTGAATTGGA	ATACTAGTTT	CACAACATCC	CRGCTGTGTG	1020
GCCTGAGACA	AACCACTTAG	CCACTGCACC	CCTCTGAACC	TCAATGTGTC	ATTTGTAAAG	1080
CAATGGTAAT	GAGATAATCC	ATCTAAGGTG	CTTCGCTCAT	CACCCGACCC	ATGCACGCGC	1140
TTCTGGTAGC	TATGCATATT	TCCATCATGA	ATTCCCTTCG	CCTGCAGCCT	CAGCTTAGGC	1200
TGGAGGAAGA	TCACCTTTTT	TTGTTTTGGG	GTGAGGGGGT	TGTTGTTATT	TTGAGTCAGG	1260
ATCTCACTCT	GTACCTTAGG	CTGCACTGCA	GTGCTATCAC	AACTCAACTG	CAGCTTCGAC	1320
CTTCTGGGCT	CAAGTGAGCC	ACCTCAGTCT	CCCAGTAGC	TGGGACTATA	GGTGCAGGCT	1380
GCCATGCCCC	GCTAATTTTT	TTATTTTTGT	AGAGATGGTG	ATTCACCATG	TTGCCCAGGC	1440
TGGTCTCGAA	CTCCTGGGCT	CAAGCAATAT	GCCCGCTTCG	GCCTTCCAAA	ATGTTGGGAT	1500
TACAGGCGTG	AGCCACCATG	CCGAGCTGAG	GATCACTTGT	TTTAACTGCT	GGGAATCTCC	1560
CTTCGTTGGG	CCTGGCTGTC	GGGAAACCTG	GGTCACAAGC	ATGACCCTTC	CCCGTCCCCC	1620
CTCACCCAG	ATGAGAACGG	GATTCCCAGT	AGTCCCCAGA	AAGTAGCTCT	GACCCTGGAT	1680
CTTGACCTGG	AGAAGGAGCC	GGAATCAGAG	CCAGATGAGC	CCCAGAAGCC	AGGAAAACCT	1740
TCAGTCTTCA	CTGTCTTCCA	GAAGATCTGG	CTGACAGCGC	TGTGCCTTGT	GTTGGTCTTC	1800

ACAGTCACCC TGTCCGTCTT CCCC GCCATC ACAGCCATGG TGACCAG

1847

## (2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 2396 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: double
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GCAC TTTTGG GAGGCCAAGG GCAAGAGAAT CGCTTGAGCT CAGGAGTTCA AAACCAGCCT	60
TGGGCAACAC AGTGAGACTT TGTCTGTACA CACACACACA CACACAAATT TTTAATGAAG	120
AAAATAGAGG CCGGGTATGG TGGCTCACGC CTGTAATCCC AGCACTTTGG GAGGCTGAGG	180
CAGGTGGATC ACTCGAGGTC AGAAGTTCGA GACCAGCCTG GCCAACATGA TGAAACCTGG	240
CTCTACTAAA AATACAAAAA TTATCTGGGC ATGGTGGTGG CGGGCGCCTA TAGTCCCAGC	300
TACTCAGGAG GCTGAAGCAG GAGGATTTCT TGAACCCAGG AGGTGGAGGT TGCAGTGAGC	360
TGAGATCAGG GCCACTGCAC TCCAGCCTGG GCAACAGAGC GAGACTCCAT CTAAAAAAAA	420
AAAAAAAAAAG TACTCTATGG GTGTCCTGAG ATGCCCTGGA GCAGAGACCT GGCTCCAGGG	480
ACCATGCTGA CTTACGCCTC TACCACAGCC AGACGAGGAC AGCCGGCTGC TGCCCCTGCT	540
GGTCTGCCTG CGGTTCTGT TCGTGCCCTT CTTCATGCTG TGCCACGTGC CCCAGAGGTC	600
CCGGCTGCCC ATCCTCTTCC CACAGGATGC CTACTTCATC ACCTTCATGC TGCTCTTTGC	660
CGTTTCTAAT GGCTACCTGG TGTCCCTCAC CATGTGCCTG GCGCCCAGGT CCGGGCAATG	720
GGTGGSTGGG GGGCTGGATT AGGAGGTGGT TTATCTTNGG GAAGGACCGC TGCAATGGAG	780
GGACGGCCAT CCTGTTCTGG CCAGCCCAAC CTAGCTGTCT GCAGCCTTGC TGGCGCCCN	840
TACTGGCCAA GCTTAACTGC AGGGGAGAGA ACTGGGTAGG GAGGTACCCG CCCAACCAAG	900
TAGCCCAGGC ACTGGTTCTG GGCCGCCTCA ATGTGCNTCA GTTTCCCAT CTGTAAAAAA	960
AAAAATGGGT TGAAGTGTCA TCCCTCAGGG CCCATCTAAC TGTAATAATC TCAGTTGAAG	1020
GAGAGCTAAG GTTTTGACCA AAAACAAGGT CATGGGCTAT TTCCTCAAGG GGCAATGGAG	1080
TGGAGAATCC AGAGAGAATG AAGCTGGCAG GGCAGACAGG CTGAGAGCAC TGTGGAAAGG	1140

GCAGGCTGTG GAATCTGGAA TCCCATCATG TTAGACTCAG AGGCCCTGAG AGACATCCTT	1200
ATCCAGCAGC CTCATTTACA GACCAGGAAA CTGAGGCCCA GAAAGAAGGG GCCAGTTATG	1260
GTGACAGAGG GGTGGGTCA GAGCCCAGAC TGGATGGGCA GAGGGCAGTG GAGCTGGGTC	1320
CAGATTTAGA CCCAGCATTT TCTAAGAGCT CCTGTTCCCG GGTGTTTTAG GCAGGTGCTG	1380
CCACACGAGA GGGAGGTGGC CGGCGCCCTC ATGACCTTCT TCCTGGCCCT GGGACTTTC	1440
TGTGGAGCCT CCCTCTCCTT CCTCTTCAAG GCGCTGCTCT GAAGTGGCCC CTCCAGGCTC	1500
TTTGGCAGCC TCTTCTCGAC GTCTCCTTCC GGAGCTGAGA TCCAGCCCAG GGCGAATGGC	1560
GAGCTTGGCT CAGGCCTCTG CGGGGTGGAG GCCCCTGGGC CTGAGGCTGC CAGCAGCGGG	1620
CAGGAGCTGC TCTTCATCCA CTTGGAGTGC TGCGGGGAAG AAATCACCAC CGGTCATTCT	1680
AACCCCTACC CAGGAATGGG GGTGACTCGC ACAAGACCTC ATGGAAAGGG TGATGACTAG	1740
GGAAAAGAGG GTGCAGGGCA CGGCTGCTCC CCACCACCAG GTCTGCATTT GTTCATCATC	1800
ATCAGGAGCA GAGGTGACCA GAGGGTTCAG AGTGGGAGGC AGGGCCAGCC CAGGCCAGGA	1860
GCGCCTCATC TTCCAGGCC TCAGCCACCC AGGGTAAAG GTGCCAGGGA AGTTGTGGGC	1920
ACCTGAGAGG AGGAACAGAT GTGGAGGACC TGAGGGTGCT CAAAGGGCCA GGCTCAGCCT	1980
CAAGCAGTGT TTTCATTGCC AACACTTACT GTACCCACTC CGCAGAGCCC CGCTGGGCCT	2040
GGGCCCCAGG GCCACAGCTA GCCTGCATGT GTGTACTGCA CTTTACAGTT TGCAAAGCTC	2100
TTCCATACCC ACTCTCTCAC CGAAGCCTAA TTGAGGCTCT TGAAGGAGT CAGGCAAGGA	2160
TTGTGCTTCC CCCATTATAC AGGTGACAAA ACTGAGTCCT GGGGAAAGTG ACTGGTCCGT	2220
GGTAGAGCCG GGACCCAATC CCCTCTCTCT CCTCCCTGTT GGTGCTGTTC TTCCTGCCCA	2280
ACACCTGTTT CTCTTTTCCT CAAGGGGTTT GGGGCAGGAG CCTGGGCACT TACTCCCCGT	2340
TTTGTGCTGT TCTCCTTCTG ACCCTGCTCT TGGGTCTAAT AACCCCATTT ATTTGT	2396

## (2) INFORMATION FOR SEQ ID NO:11:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 237 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "intron 1"

## (iii) HYPOTHETICAL: NO



## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GTGAGTGGGC CCGGGTGCCT TGCAAGTGGC CGGGGGCGTT GCAGACCCGC TCCCTGAAGG	60
CGCTCCGAGG CTCAGAGAAG ACCGGATCGA ACTACAATTC CCATCAGCCG ACTCCCTCGG	120
CCGCCGGAAC CGGGGTGATG GGGGTTGTAG TCCGCTCCGG AGGGGGTGGC CTGGGAGGCG	180
GGAGGGCCTG CGGAGGCGGG TGCCTCCTCG GGGTGACCTT CCCACCGATC CCCACAG	237

## (2) INFORMATION FOR SEQ ID NO:12:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1712 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "intron 2"

## (iii) HYPOTHETICAL: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GTGAGACTCC TGGCGGCGTG GCAGCCTCGT GGCCACAGCC AGCACCCTC CCTCCAGCCC	60
TTTGATGAA GCTTAGCGGG CGCTTCCTCA CCGCGCACCT GTGACCCTC GTTGAGCTCA	120
TTATGGGCTG AAGCTCGGAG AGGGGAATGC TCCCCCGTG GCTAGGAAAG TAGAACTCA	180
GCAATGCCCA CATCTCAGAG GGGCAAGGCC ACCAGCCCAC AGGGTCTGGA ATGAGCAAAG	240
GCGCTGCCAC CCCTCTCTGT GTGTCGTTAT TCCTGAGTCA GTCACCCCA AAGTCGGTTA	300
TCGAACGTTT GATTTCTTT GAAATACCAT GAATTTCAAT CATTCACTCA TTCATTCAAC	360
AAACTTTTTT TTTTTTTTTT TTTTGTAGAC AGAGTCTGGC TCTTTCGCCC AGGCTGGAGT	420
GCAGTGGCGC CATCTCGGCT CACTGCAAGC TCCGCCTCCC GGGTTCACGC CATTCTCCTG	480
CCTCACCTC CCGAGTAGCT GGGACTACAG GCGCCCGCCG CCACGCGCGG CTATTTTTTT	540
TTGTATTTTT AGTAGAGACG GGGTTTCACC GTGTTAGCCA GGATGGTCTC GATCTCCTGA	600
CCTCGTGATC CTCCCGCCTC GGCCTCCCAA AGTGCTGGGA TTACAGGCGT GAGCCACCGT	660
GCCCAGCCTC ATTCAACAAA CTTTTAGTGT GCATCTACTG TGGAGCAGGC ACTGGGGACA	720
CAGGAGGAAA CAGCAGGGAG GCTCTTCAGG GAAGGCAGAA ATGTGGGGTT TGCATTGTCT	780
TTGGGACCGG GTTATTCATC TGTATTCAT GCAACAACCT TGCAAATGCT TCTTGGGTAC	840

TGGCTCTGTG CTGGGCCCTG GAAACCCAGA GATGAATCAG CCCCTGGGCT TGAGAGCAAG 900  
AAGGGGCCAA AGAGCTATTA ATAATGTAAC ATGATGCGTG ACATTCCAGG CTTGCAGCAG 960  
AGTGCACTGG GTCCCCAGGG AAGGAGAAAG TTCCTTCTGC TTCATGGAAG AGGAGATTTG 1020  
TAAATTGGGA GTAGGGTAGG CAAAGTGCCT GTGGAGGGGT GTGGTCAGTA GGGCATTCCA 1080  
AGCCGAGGCG ACAGCCATGC CAAAGGCAGG CAGGCAAGAG ACGATCAGCC TGTTTAGAGG 1140  
GAGATTCCAC AGCCAGGGCT GCCTGGAGCT TAGCAGGATG GAGCAGAAGA TGGGGCACAA 1200  
AGGGAGACTA GGATCTGATT CTGAAGAGCT GTTCCATTTG GGGCTTTGCC CTGCAGGCAA 1260  
TAGGGAGGCA TGAATCGGGG TGTGAGGAG TGAGGAGGTT AAGCAGAGGA GTGGCAGGCT 1320  
ATGTGCTCTA GAGAGAATGC AGTTGTTCAG CACTTAGGCC AAAGCCTGGC TTGACAGTAG 1380  
GCGCTCAATA AATACCCGTG GAATGAATGA ATGTAGCAGC TGCTGCAGGA GTGGGGATGG 1440  
GGGCTGGAAC CAGGGCACTG AAGAGGAGGG GCCGTCCAAG GCTGGATCGA GGCTCTTGCT 1500  
GGGGGCTCTT AATGCTTAGG CTGTGTCCCA GACTTCAGCC ATTTAACTCA GCACACATTC 1560  
ATGGAGCTCC GACTGTGTGC CGGCTGCTGG GAACAGAAAC AGGGCAAGGC AGACAAGTCC 1620  
CCACAGACAT TAGAAAGCAA TCACAAGTGA GGGGGAAGGC AGCGGGGGAA GGCTGAGAGG 1680  
TGCTGACCCCT CCACCACCTC CCTACCTGGC AG 1712

## (2) INFORMATION FOR SEQ ID NO:13:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 170 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "intron 3"

## (iii) HYPOTHETICAL: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GTGAGAGGCC TGCCCTGGCT CCTGCGCCCT CTGCCGAGGC AGCTTCATTG AGGCCCTCCC 60  
CTGCGCCCCC TGCCCTCCAG CCCTACTGCC CAGCCCCAGG TGTCGAGCCT CCTTCCCCAG 120  
CCCCCTCTGG CCTGGGCCCC ACTGATGCAC TCTGCCTGCT TCTGAGCAAG 170

## (2) INFORMATION FOR SEQ ID NO:14:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 388 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "intron 4"

## (iii) HYPOTHETICAL: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GTGAGCACCT CCACCCCTC TCCAGCCAGC CTATGCAGGG CTTCAGCCTG GCCTCATCAT	60
TGAAAGGGCC CAGCATATCC GAGAAGGGCA GACAGCATCA TGGTCGCTCA TATCCCTGGT	120
GAAGAACTG AGGCCACAG GGAGGGGAAG AGTCACTTGT CCGGTGACCT AGGAGCAGGC	180
CTCCTGGTCA ACAGCCCCAC AGACCAATGG CTGCACCTCA GAAGAGGACT GAATAGCGGG	240
TGTTGCCCCC GAGTGCTCAG AGTCCCTAGG GAAGCTCACA CCTGCGCAAC CTTGTCCAGA	300
GTCCCCTGTG TATCCTGCCG GCACCTCCTC CAGGGAGCCT CTGAGTCTTG CCTAGTTGAG	360
CAGCAGCCCC CATCCCTGTC CTCCACAG	388

## (2) INFORMATION FOR SEQ ID NO:15:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 667 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "intron 5"

## (iii) HYPOTHETICAL: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

GTGAGTGCAC TTGGGTGGCT GGGAGGGCTG GGGTGGCCTC TGAGGTTTGG GGAAGAGAGA	60
GGGCATGTGA GAGCAAGACA CATGGGTTCT GGGTGAAGAT GGAGGTAAGC GGGTGATATG	120
GAAATGGGGA TTGGTCTGGG GCTAGGGAAT GGGGCTCATG GGCCCTGCAG TGAGGAGTAA	180
TAACCAAGTG AGGACTGGGT TAACTCAGGG ACAGGGGCAG GATTCCTGGG GCTAATACTG	240

GCATGTGGCA GCAGGTTGAA GTTGAAGGAT AAGGGGATGG GTTGGGATT CAGATAGTCT 300  
TGGGTTTGAA TCTGCTTCAC CGCTTACCAG CTAGGGGTGT TGGACAAGGC TTGTCACCTC 360  
TCTGTGCTAG CTTCCCCACC GATGTGATTG GTACAGCTCC CTGCTCAGAT TGTAAATGAGC 420  
ATGCAATGAG AGAAGGCTAC TGGCACATAG TACGTGCTCA ACAAAAATGA CACATGGGGA 480  
AAGTGAGAGA AGTGCAGGGC TGCTCTGGGG CCCTGTACAA GATTCCCATT TGTCAGTGAA 540  
GGGAGGAGCG GAAGAGGCTG GGAGTGGGTC TGAGAAGTAC ACAATGGGAA GTGGGACAAG 600  
AGTTGGAAGC CCCGTGGGAG CCGGCGGGAC CAGGTGCCTC TCTTCTGCAG CTGAAGTTCC 660  
TCCGCAG 667

## (2) INFORMATION FOR SEQ ID NO:16:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 223 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "intron 6"

## (iii) HYPOTHETICAL: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GTGAGCCTGC TGTTGGGCTC GAGGCCCCAC CTCAAAGCAT CTTGGATAGA GTCCTGAGCC 60  
TGAAGCCCTG AGAGAGGCCA GGGGAGGTGG AGGAGACCTG GTCTCAGCCC TGACCCCCAG 120  
AGAAGACACT GAGGGGCCCC AGCCTECAGG CCAATGGTAT GGGGAGGGAT CCAGACACCT 180  
CAGGCAAGCC AGGCAGGCC AACACTTTCC TGTCTTCTG CAG 223

## (2) INFORMATION FOR SEQ ID NO:17:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 897 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "intron 7"

## (iii) HYPOTHETICAL: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GTAAGCCCTG AGACCCTCCT GGGGAGGTGG GAGATGCAGA GGAAGCTAGA GCCACCTCCC	60
CTGGGAAGCT GTTCCATCTG TCCCCAGCCA GAGCCCACCC CTAGTAGCCT TGTGCAAACA	120
GGAAGATCAT GAAGGGAAGT TGGTAGGATT AAAGTCATCC CTGCTGTTGT TTGGGCCTCA	180
GTTTCCACCT CTATAAAATG GGGAGGCGAC AGAAGTTCCA TGCATGCAAA CTTTGGATCG	240
AAGACCTCTG AATTGGAATA CTAGTTTCAC AACATCCCRG CTGTGTGGCC TGAGACAAAC	300
CACCTAGCCA CTGCACCCCT CTGAACCTCA ATGTGTCATT TGTAAGCAA TGGTAATGAG	360
ATAATCCATC TAAGGTGCTT CGCTCATCAC CCGACCCATG CACGCGCTTC TGGTAGCTAT	420
GCATATTTCC ATCATGAATT CCCTTCGCCT GCAGCCTCAG CTTAGGCTGG AGGAAGATCA	480
CCTTTTTTTG TTTTGGGGTG AGGGGGTTGT TGTATTTTG AGTCAGGATC TCACTCTGTC	540
ACCTAGGCTG CACTGCAGTG CTATCACAAC TCAACTGCAG CTTGACCTT CTGGGCTCAA	600
GTGAGCCACC TCAGTCTCCC GAGTAGCTGG GACTATAGGT GCAGGCTGCC ATGCCCGGCT	660
AATTTTTTTA TTTTGTAGA GATGGTGATT CACCATGTTG CCCAGGCTGG TCTCGAACTC	720
CTGGGCTCAA GCAATATGCC CGCTTCGGCC TTCCAAAATG TTGGGATTAC AGGCGTGAGC	780
CACCATGCCG AGCTGAGGAT CACTGTGTTT AACTGCTGGG AATCTCCCTT CGTTGGGCCT	840
GGCTGTGCGG AAACCTGGGT CACAAGCATG ACCCTTCCCC GTCCCCCTC ACCCCAG	897

## (2) INFORMATION FOR SEQ ID NO:18:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 199 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "intron 8"

## (iii) HYPOTHETICAL: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

GTTTGGCTTG GATACAGCCC CCAACCACCA TCTTTGGGGA AGAATGGGGC TCACATTGAC	60
TCCAAGGTCA TAGGGTCACA GTGGGTCAGG GACACAGCTG GGCCAGGCCC CAAGTGTCTT	120
GCTCCACAT GGGGCTTGGG CAAGAGGGTG GGGCCCTGGG ACTGCCCTGC CTGCTCACAC	180

CCCTGCCTCY GGCTCCCAG

199

## (2) INFORMATION FOR SEQ ID NO:19:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 104 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "intron 9"

## (iii) HYPOTHETICAL: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

GTGAGTGTCA GGGTGGAGAA GACGGCAGGG CAGGGGGTAC AAAGGGGAGA GGACGGGAGA 60

GGGGAGTTGG AGACCAATAT GAGCTGCAGC CGTTTCCCTC CCAG 104

## (2) INFORMATION FOR SEQ ID NO:20:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 461 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "intron 10(5)'"

## (iii) HYPOTHETICAL: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

GTAAGCACAC CAGGGCTGGG TGATCCGATG TTTTAGGAAG CAGTTTGGGA TCCGAGGGCT 60

TGAAAGAGCA CGGAGGTGAT TTTCTGCTAG TCCAAGTGGC CTGGTAATGC AACCCTGGC 120

CAAGCAGCAG GGAGCACTTG GGCCCTGGAG GCGTGCAAGG CCAGGGCTTG CACTGTGAGC 180

TCCCTGAAAG CAAAAATCAT GTCCAGCTGA CCTCTGTGTC CCCAGCATCC AGCCTTTGCT 240

GCTCAGAGAA TGTTACATGG AGGTTCTGTC ACCAGGTGAG GGAAGTACCA AGATCTTAGT 300

TTTGGGGTTG GTTTTAGCCA TGGTGCTGTA TCTTTAAATG AAATCTTCCA AAGAGACAAT 360

ACATAACGCA GGTGAAAGAN GANCTGGTCT CATCCAAGTC AGGACANNGA GCTGATCTAC 420

AGCTTCCAAT CCCACTCAGA AACCCCTCTGC CCCCANGGG G

461

## (2) INFORMATION FOR SEQ ID NO:21:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 508 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "intron 10(3')"

## (iii) HYPOTHETICAL: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

GCACTTTTGG GAGGCCAAGG GCAAGAGAAT CGCTTGAGCT CAGGAGTTCA AAACCAGCCT	60
TGGGCAACAC AGTGAGACTT TGTCTGTACA CACACACACA CACACAAATT TTTAATGAAG	120
AAAATAGAGG CCGGGTATGG TGGCTCACGC CTGTAATCCC AGCACTTTGG GAGGCTGAGG	180
CAGGTGGATC ACTCGAGGTC AGAAGTTCGA GACCAGCCTG GCCAACATGA TGAAACCTGG	240
CTCTACTAAA AATACAAAAA TTATCTGGGC ATGGTGGTGG CGGGCGCCTA TAGTCCCAGC	300
TACTCAGGAG GCTGAAGCAG GAGGATTTCT TGAACCCAGG AGGTGGAGGT TGCAGTGAGC	360
TGAGATCAGG GCCACTGCAC TCCAGCCTGG GCAACAGAGC GAGACTCCAT CTAAAAA	420
AAAAAAG TACTCTATGG GTGTCCTGAG ATGCCCTGGA GCAGAGACCT GGCTCCAGGG	480
ACCATGCTGA CTTCAGCCTC TACCACAG	508

## (2) INFORMATION FOR SEQ ID NO:22:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 662 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "intron 11"

## (iii) HYPOTHETICAL: NO

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

GTCCGGGCAA TGGGTGGGTG GGGGGCTGGA TTAGGAGGTG GTTTATCTTN GGGAAGGACC 60  
GCTGCAATGG AGGGACGGCC ATCCTGTTCT GGCCAGCCCA ACCTAGCTGT CTGCAGCCTT 120  
GCTGGCGCCC CNTACTGGCC AAGCTTAACT GCAGGGGAGA GAACTGGGTA GGGAGGTACC 180  
CGCCCAACCA AGTAGCCCAG GCACTGGTTC TGGGCCGCCT CAATGTGCNT CAGTTTCCCC 240  
ATCTGTAAAA AAAAAAATGG GTTGAATGT CATCCCTCAG GGCCCATCTA ACTGTAAAT 300  
TCTCAGTTGA AGGAGAGCTA AGGTTTTGAC CAAAAACAAG GTCATGGGCT ATTCCTCAA 360  
GGGGCAATGG AGTGGAGAAT CCAGAGAGAA TGAAGCTGGC AGGGCAGACA GGCTGAGAGC 420  
ACTGTGGAAA GGGCAGGCTG TGAATCTGG AATCCCATCA TGTTAGACTC AGAGGCCCTG 480  
AGAGACATCC TTATCCAGCA GCCTCATTTA CAGACCAGGA AACTGAGGCC CAGAAAGAAG 540  
GGGCCAGTTA TGGTGACAGA GGGGTTGGGT CAGAGCCCAG ACTGGATGGG CAGAGGGCAG 600  
TGGAGCTGGG TCCAGATTTA GACCCAGCAT TTTCTAAGAG CTCTGTTC CGGGTGTTTT 660  
AG 662



WHAT IS CLAIMED IS:

- 1 1. An isolated nucleic acid encoding a nitrobenzylmercaptapurineriboside (NBMPR)  
2 insensitive, equilibrative nucleoside transport protein (*i*ENTP) or active fragment thereof,  
3 wherein the *i*ENTP:
  - 4 (a) functions as an equilibrative nucleoside transport protein;
  - 5 (b) is insensitive to NBMPR; and
  - 6 (c) is a protein containing approximately 450 amino acid residues.
- 1 2. The isolated nucleic acid of Claim 1 having a nucleotide sequence with at least 80%  
2 identity with the coding sequence of SEQ ID NO:1.
- 1 3. The isolated nucleic acid of Claim 2 having the nucleotide sequence of nucleotides  
2 238-1605 of SEQ ID NO:1.
- 1 4. The isolated nucleic acid of Claim 1 wherein the *i*ENTP has an amino acid sequence  
2 selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:2 comprising a  
3 conservative substitution thereof.
- 1 5. The isolated nucleic acid of Claim 1 which is a DNA.
- 1 6. A DNA construct comprising the DNA of Claim 5 that is operatively linked to an  
2 expression control sequence.
- 1 7. A cell which is transfected or transduced with the DNA construct of Claim 6.
- 1 8. The transfected or transduced cell of Claim 7 that is a prokaryotic cell.
- 1 9. The transfected or transduced cell of Claim 7 that is a eukaryotic cell.
- 1 10. The eukaryotic cell of Claim 9 that is a COS cell.
- 1 11. The eukaryotic cell of Claim 9 that is a human T-cell leukemia CEM cell.

- 1 12. An isolated NBMPR insensitive, equilibrative nucleoside transport protein (*i*ENTP)  
2 or active fragment thereof, wherein the *i*ENTP:
  - 3 (a) functions as an equilibrative nucleoside transport protein;
  - 4 (b) is insensitive to NBMPR; and
  - 5 (c) is a protein containing approximately 450 amino acid residues.
- 1 13. The isolated *i*ENTP of Claim 12 having an amino acid sequence selected from the  
2 group consisting of SEQ ID NO:2 and SEQ ID NO:2 comprising a conservative substitution  
3 thereof.
- 1 14. The isolated *i*ENTP of Claim 12 having an amino acid sequence encoded by a  
2 nucleotide sequence with at least 80% identity with the coding sequence of SEQ ID NO:1.
- 1 15. A fusion protein comprising a NBMPR insensitive, equilibrative nucleoside transport  
2 protein (*i*ENTP), wherein the *i*ENTP:
  - 3 (a) functions as an equilibrative nucleoside transport protein;
  - 4 (b) is insensitive to NBMPR; and
  - 5 (c) is a protein containing approximately 450 amino acid residues.
- 1 16. The fusion protein of Claim 15 wherein the nucleoside transport protein has an  
2 amino acid sequence selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:2  
3 comprising a conservative substitution thereof.
- 1 17. An antibody to an NBMPR insensitive, equilibrative nucleoside transport protein  
2 (*i*ENTP) wherein the *i*ENTP:
  - 3 (a) functions as an equilibrative nucleoside transport protein;
  - 4 (b) is insensitive to NBMPR; and
  - 5 (c) is a protein containing approximately 450 amino acid residues.
- 1 18. The antibody of Claim 17 that is a monoclonal antibody.
- 1 19. The antibody of Claim 18 that is a chimeric antibody.
- 1 20. An immortal cell line that produces a monoclonal antibody according to Claim 18.

- 1 21. The transfected or transduced cell of Claim 7 in which all detectable nucleoside  
2 transport activity is performed by the *iENTP* encoded by the DNA.
- 1 22. The transfected or transduced cell of Claim 21 which is a human cell.
- 1 23. A nucleoside transport deficient subline of a human T-cell leukemia cell line CEM,  
2 transfected with an Epstein-Barr Nuclear Antigen 1 expression cassette, wherein the cell line  
3 is capable of supporting the episomal replication of the Epstein-Barr virus-based mammalian  
4 expression vector pDR2; and wherein the cell line has a stable transfection frequency with  
5 pDR2 of approximately  $10^{-2}$ .
- 1 24. A knockout mouse comprising a first and a second allele which naturally encode and  
2 express the *iENTP* of Claim 12;  
3 wherein the first allele and the second allele each contain a defect which prevents the  
4 knockout mouse from expressing the *iENTP*; and  
5 wherein the knockout mouse has a functional phenotype of being particularly  
6 susceptible to drugs such as NBMPR.
- 1 25. A method of isolating a cDNA encoding an NBMPR insensitive, equilibrative  
2 nucleoside transport protein (*iENTP* cDNA) comprising:  
3 (a) transfecting a nucleoside transport protein deficient cell with an expression  
4 vector from an expression vector library; wherein a cDNA library encoding an *iENTP* is  
5 represented in the expression vector library; and wherein the *iENTP* cDNA is expressed in a  
6 transfected cell;  
7 (b) selecting for an expression vector containing the *iENTP* cDNA by culturing  
8 the transfected cell under conditions in which the cell growth is dependent on the expression  
9 of the *iENTP* and its corresponding transport activity; and wherein the selected expression  
10 vector contains the *iENTP* cDNA;  
11 (c) extracting the selected expression vector from the transfected cell;  
12 (d) transfecting a host cell with the selected expression vector; and  
13 (e) isolating the cDNA encoding the NBMPR insensitive, equilibrative,  
14 nucleoside transport protein.

- 1 26. A method of making an *i*ENTP by culturing the transfected or transduced cell of  
2 Claim 7, wherein the *i*ENTP is expressed.
- 1 27. The method of Claim 26 wherein the *i*ENTP has an amino acid sequence selected  
2 from the group consisting of SEQ ID NO:2, and SEQ ID NO:2 comprising a conservative  
3 substitution thereof.
- 1 28. A method of obtaining a purified NBMPR insensitive, equilibrative nucleoside  
2 transport protein (*i*ENTP) from a cell that expresses the *i*ENTP comprising lysing the cell,  
3 and purifying the NBMPR insensitive, equilibrative nucleoside transport protein.
- 1 29. The method of Claim 28, wherein the *i*ENTP has an amino acid sequence selected  
2 from the group consisting of SEQ ID NO:2, and SEQ ID NO:2 comprising a conservative  
3 substitution thereof.
- 1 30. A method of identifying a ligand of an equilibrative, NBMPR insensitive nucleoside  
2 transport protein (*i*ENTP) comprising:  
3 (a) contacting a potential ligand with the *i*ENTP of Claim 12 under  
4 physiological conditions; and  
5 (b) detecting whether the potential ligand binds to the *i*ENTP wherein a potential  
6 ligand is selected as a ligand if it binds to the *i*ENTP.
- 1 31. The method of identifying a ligand of an *i*ENTP of Claim 30, wherein said detecting  
2 includes determining the dissociation constant between the potential ligand and the *i*ENTP,  
3 and wherein a potential ligand is selected as a ligand when the dissociation constant is less  
4 than  $10^{-5}$  M.
- 1 32. A method of identifying a permeant of an NBMPR insensitive, equilibrative  
2 nucleoside transport protein (*i*ENTP) comprising:  
3 (a) contacting a nucleoside or nucleoside analog with the transfected or  
4 transduced cell of Claim 21;  
5 (b) evaluating whether the nucleoside transport of the nucleoside or nucleoside  
6 analog by the transfected or transduced cell follows a facilitated diffusion process; wherein  
7 the nucleoside or nucleoside analog is identified as a permeant when the transport of the

8 nucleoside or nucleoside analog into the transfected or transduced cell is determined to  
9 follow a facilitated diffusion process.

1 33. The method of Claim 32 wherein the nucleoside or nucleoside analog is selected  
2 from the group consisting of an antiviral nucleoside analog and an antitumor nucleoside  
3 analog.

1 34. A method of selecting a drug that inhibits an NBMPR insensitive, equilibrative  
2 nucleoside transport protein (*i*ENTP) comprising:  
3 (a) contacting a potential drug with the transfected or transduced cell of Claim  
4 21; and  
5 (b) evaluating a nucleoside transport activity of the transfected or transduced  
6 cell; wherein a potential drug is selected as a drug when a decrease in the nucleoside  
7 transport activity is determined by said evaluating, relative to the determination in the  
8 absence of the potential drug.

1 35. The method of Claim 34 wherein the nucleoside transport activity of the transfected  
2 or transduced cell is selected from the group consisting of the trans-stimulation of a  
3 permeant, direct transport of a permeant, countertransport of a permeant, and the toxicity of a  
4 toxic nucleoside analog which is a permeant of the *i*ENTP.

1/11




Figure 1A




Figure 1B




Figure 1C



```

hENT2      : MARGDARRESYHLVGTISRFLEGLGTHPEWNRSSRAIP : 39
hHNP36     : ----- : -
hENT1      : MTTSHQEQDRYKAYWHIESELEGLGTHPEWNRSEETHTQ : 39
              <=====TM1=====>

          *****
hENT2      : QARFAGFCNSTARILSTNHTGPEDEFN----- : 66
hHNP36     : ----- : -
hENT1      : TNKEDMSQNVSLVTAELSKDAQASAPAAPLPERNLSLA : 78

hENT2      : -FNNWVPELSQIPDHNELLENSEHYQCVPEYVQREES : 104
hHNP36     : ----- : -
hENT1      : IFNNVMTLCAMPEPDLLEHYINSEPHORDEOSVREES : 117
              <=====TM2=====>

          #
hENT2      : ATELEFADFAALVKKVDMSPGPERSTHMASVGFINSF : 143
hHNP36     : ----- : 13
hENT1      : ATELEFADFAALVKKVQDAPPEFVTHMIKIVLINSFGAI : 156
              TM3===== TM4=====

hENT2      : LQGSIFCGEGIMPSTYSTELSGQGLAGIFAALAML : 182
hHNP36     : LQGSIFCGEGIMPSTYSTELSGQGLAGIFAALAML : 52
hENT1      : LQGSIFCGEGILPASYTAPIMSGQGLAGIFASVAMICAI : 195
              > <=====TM5=====

hENT2      : ASGVDAETSALGYFITPGVCIILMSIVCYLSLPHLKFAFY : 221
hHNP36     : ASGVDAETSALGYFITPGVCIILMSIVCYLSLPHLKFAFY : 91
hENT1      : ASGSELSASALGYFITAGAVITLTICYLCLPRLEFYRY : 234
              == > <=====TM6=====

hENT2      : YLANKSSOAGAGQETETKAEILQSPENGDESSPQKWA : 260
hHNP36     : YLANKSSOAGAGQETETKAEILQSPENGDESSPQKWA : 130
hENT1      : YQQLK--LEGPGCEETKLDLISKGEPRAGK----- : 263

hENT2      : DDEDEKEPESEPEDEPKPKPKPSVETVEQKIWLTAPEGL : 299
hHNP36     : DDEDEKEPESEPEDEPKPKPKPSVETVEQKIWLTAPEGL : 169
hENT1      : -----EESGVSVSNSOPTNESHHSIKAILKNLSVLAFSVCF : 298
              <=====

```

Figure 2A

```

hENT2      : VFTVTLLVFPAITLVSS-TS-FFNPILCFE : 337
hHNP36     : VFTVTLLVFPAITLVSS-TS-FFNPILCFE : 207
hENT1      : IFTITICMFPAVTVEVKSSIAGSSIWERYFIPVSCFLIF : 337
            ==TM7===== <=====TM8=====

hENT2      : NIDWLGRSLTSFLWPFDSRLLP:LV:K:LFVPL : 376
hHNP36     : NIDWLGRSLTSFLWPFDSRLLP:LV:K:LFVPL : 246
hENT1      : NIDWLGRSLTAVFMWPGKDSRWLPSLV:AR:VFVPL : 376
            ===== <=====TM9=====

hENT2      : LCHVFRSRLEILFEQDAFFIFMFAFNSGYL:SL : 415
hHNP36     : LCHVFRSRLEILFEQDAFFIFMFAFNSGYL:SL : 285
hENT1      : LCNIKPRRYLTIVVEBHDWFIFFMAAFNSGYLASLCV : 415
            => <=====TM10=====

hENT2      : CLEAPROVIFPHEREVAGALMTFFLALGLSCGASFSFLFKA : 454
hHNP36     : CLEAPROVIFPHEREVAGALMTFFLALGLSCGASFSFLFKA : 324
hENT1      : CLEAPROVIFPHEREVAGALMTFFLALGLSCGASFSFLFKA : 454
            <=====TM11=====

hENT2      : LL : 456
hHNP36     : LL : 326
hENT1      : IV : 456

```

Figure 2B

6/11




Figure 3




Figure 4A




Figure 4B


**Nucleoside transport inhibitor plus antimetabolite therapy**

Figure 5




Figure 6




Figure 7



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 98/07283

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C12N15/62 C12N5/10 C12N5/20 C07K14/705  
C07K16/18 G01N33/68 G01N33/50 A01K67/027

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K G01N A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>GRIFFITHS M ET AL: "Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and therapeutic drugs"</p> <p>NATURE MEDICINE, vol. 3, no. 1, January 1997, pages 89-93, XP002071071</p> <p>cited in the application</p> <p>See from line 25, right column of page 89 to line 6 of page 90.</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	<p>1-3,5-9, 12,14, 17-20, 24,26,28</p>

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*A\* document member of the same patent family

Date of the actual completion of the international search

12 August 1998

Date of mailing of the international search report

03/09/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Lonnoy, 0

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 98/07283

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CRAWFORD C ET AL : "Isolation of a human cDNA that confers equilibrative, nitrobenzylmercaptapurine riboside-insensitive nucleoside transport activity (ei) to a transport deficient human leukemia cell line" PROC. ANNU. MEET. AM. ASSOC. CANCER RES., vol. 38, March 1997, page 60 XP002073989 see the whole document ----	25
E	WO 98 29437 A (YOUNG JAMES D ;CASS CAROL E (CA); UNIV TORONTO (CA); BALDWIN STEPH) 9 July 1998 see the whole document ----	1-22, 24-35
P,X	CRAWFORD C R ET AL: "Cloning of the human equilibrative, nitrobenzylmercaptapurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 9, 27 February 1998, pages 5288-5293, XP002073990 see the whole document ----	1-22, 24-35
P,X	GRIFFITHS M ET AL: "Molecular cloning and characterisation of a nitrobenzylthioinosine insensitive (ei) equilibrative nucleoside transporter from human placenta" BIOCHEMICAL J., vol. 328, 1997, pages 739-743, XP002071072 see the whole document ----	1-22,24, 26-35
A	WILLIAMS J ET AL: "A mammalian delayed-early response gene encodes HNP36, a novel, conserved nucleolar protein " BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 213, no. 1, 4 August 1995, pages 325-333, XP002071067 cited in the application -----	

# INTERNATIONAL SEARCH REPORT

Information on patent family members

national Application No

PCT/US 98/07283

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9829437 A	09-07-1998	NONE	

**PThis Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: \_\_\_\_\_**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**